Fused bicyclic compounds and their use as pest control agents

Abstract

The present invention provides novel bicyclic compounds of Formula (I) or salts, stereo-isomers, tautomers, polymorphs, metal complexes or N-oxides thereof, Formula (I) wherein, the definition of A1, Q, Z, R3, R4 and R5 is described in the detailed description, which are demonstrating high pesticidal efficacy. The present invention also relates to methods for the preparation of the compounds of Formula (I). The present invention further relates to compositions, combinations, uses and methods of application of the compounds of Formula (I).

Description

[0001] PI External Title: FUSED BICYCLIC COMPOUNDS AND THEIR USE AS PEST CONTROL AGENTS FIELD OF THE INVENTION: The present invention described herein relates to novel bicyclic compounds; in particular, the present invention relates to the compounds of Formula (I), compositions containing these compounds and their 5 use as pest control agents. Further, the present invention also relates to the preparation of these novel bicyclic compounds, and to useful intermediates thereof. BACKGROUND: It is known from prior art, for example, from WO2018011111, WO2016071499, WO2015038503, 10 WO2016087363, WO2016087368, WO2016087421, and WO2016087422 that certain substituted bicyclic compounds exhibit pest control properties. The active compounds reported in the prior art mentioned above have disadvantages in certain aspects. For example, they exhibit a narrow spectrum of pesticidal activity only, do not have satisfactory pest control efficacy at lower application rates, or do not exhibit the desired quick action or a long-lasting 15 efficacy. Therefore, there is a constant need for new pest control agents with improved pesticidal activity, broader spectrum of efficacy, longer lasting activity, increased plant compatibility, better environmental safety, and improved formulation properties as well as a low risk of resistance development. 20 SUMMARY: The present invention relates to novel bicyclic compounds that have been found to have advantageous effects over similar compounds reported in the literature, either in terms of improved pest control activity, more favorable biological or environmental properties, a broader spectrum of application, or enhanced plant compatibility. 25 The novel bicyclic compounds of the present invention can also be used in combination with other biologically active compounds, by this improving the efficacy particularly against insects that are difficult to control. Accordingly, the present invention provides novel bicyclic compounds of Formula (I), 30 wherein, A1represents C or N; PI External Q is selected from 8- or 9- membered fused heterobicyclic ring system selected from Q-a to Q-t; Z is selected from a direct bond, O, N, a substituted or unsubstituted 5-6 membered heterocyclic ring or a substituted or unsubstituted 6-10 membered aryl ring; wherein said heterocyclic ring and aryl ring can be substituted by one to three substituents independently selected from halogen, cyano, C1-C6-alkyl, 5 C2-C6-alkenyl, C2-C6-alkynyl, C1-C6haloalkyl, C3-C8-cycloalkyl, C1-C6-alkoxy, -NH(C1-C6alkyl), - N(C1-C6alkyl)2, or -S(O)0-2C1-C6-alkyl; G represents O or S; R1and R2are independently selected from the group consisting of hydrogen, halogen, cyano, C1-C4- alkyl, and C1-C4-haloalkyl; 10 R3is selected from the group consisting of hydrogen, halogen, cyano, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6-cycloalkyl, C1-C6-alkoxy, and C1-C6 haloalkyl; R4is selected from the group consisting of C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6-alkoxy, C2-C6 haloalkenyl, C3-C8 cycloalkyl, C3-C8 cycloalkyl-C1-C6 alkyl, C2-C6 heterocyclyl, phenyl, phenoxy, phenylthio, and -NRcRd; 15 Rcis selected from the group consisting of hydrogen, C1-C6 alkyl, C3-C8 cycloalkyl-C1-C6 alkyl, and C3-C8 cycloalkyl; Rdis selected from the group consisting of hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C2-C6 haloalkenyl, C3-C8 cycloalkyl, C3-C6-cycloalkyl-C1-C4-alkyl; or 20 Rcand Rdsubstituents together with the atom to which they are attached or together with further atoms selected from the group consisting of C, N, O, C(=O), C(=S), and S(O)0-2 may form a 3- to 6-membered ring, which may optionally be substituted by one or more substituents selected from the group consisting of halogen, CN, and C1-C6 alkyl; R5is selected from the group consisting of C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, 25 C1-C6-alkoxy, C3-C8 cycloalkyl, C3-C8 cycloalkyl-C1-C6 alkyl, C2-C6 alkenyl, C2-C6 haloalkenyl, phenyl, phenoxy, phenylthio, benzyl, and C2-C6 heterocyclyl; R4and R5substituents together with the atom to which they are attached or together with further atoms selected from the group consisting of C, N, O, C(=O), C(=S), and S(O)0-2 may form a 3- to 6-membered ring, which may optionally be substituted by one or more substituents selected from 30 the group consisting of halogen, CN, and C1-C6 alkyl; wherein each aliphatic group of R1, R2, R4, and R5, may be optionally substituted with one or more groups of Ra; and cyclic groups of R1, R2, R4, and R5, may optionally be substituted with one or more groups of Rb, wherein, Rais selected from the group consisting of halogen, cyano, C1-C6alkyl, C1-C6haloalkyl, 35 C3-C8cycloalkyl, C1-C6alkoxy, C3-C8cycloalkyloxy, C1-C6alkylthio, phenyl and C2-C6heterocyclyl; PI External Rbis selected from the group consisting of halogen, cyano, C1-C6alkyl, C2-C6alkenyl, C2- C6alkynyl, C1-C6haloalkyl, C2-C6haloalkenyl, C3-C8cycloalkyl, C1-C6alkylthio, C1-C6haloalkylthio, C1-C6alkoxy, and C1-C6haloalkoxy; or salts, stereo-isomers, tautomers, polymorphs, metal complexes or N-oxides thereof. 5 In another embodiment, the present invention provides a composition comprising the compound of Formula (I), its salts, metal complexes, stereo-isomers, tautomers, polymorphs or N-oxides thereof, and at least one additional component selected from the group consisting of surfactants and auxiliaries. In yet another embodiment, the present invention provides a composition, wherein the said composition additionally comprises at least one biological active compatible compound selected from fungicides, 10 insecticides, nematicides, acaricides, biopesticides, herbicides, plant growth regulators, biostimulants, antibiotics, fertilizers or nutrients. In yet another embodiment, the present invention provides a method for the preparation of compounds of Formula (I). The present invention will now be described in detail. 15 DETAILED DESCRIPTION OF THE INVENTION: DEFINITIONS: The definitions provided herein for the terminologies used in the present disclosure are for illustrative purpose only and in no manner limit the scope of the present invention disclosed in the present 20 disclosure. As used herein, the terms “comprise”, “comprising”, “include”, “including”, “has”, “having”, “contain”, “containing”, “characterized by” or any other variation thereof, are intended to cover a non- exclusive inclusion, subject to any limitation explicitly indicated. For example, a composition, mixture, process or method that comprises a list of elements is not necessarily limited to only those elements but 25 may include other elements not expressly listed or inherent to such composition, mixture, process or method. The transitional phrase “consisting of” excludes any element, step or ingredient not specified. If in the claim, such would close the claim to the inclusion of materials other than those recited except for impurities ordinarily associated therewith. When the phrase “consisting of” appears in a clause of the 30 body of a claim, rather than immediately following the preamble, it limits only the element set forth in that clause; other elements are not excluded from the claim as a whole. The transitional phrase “consisting essentially of” is used to define a composition or method that includes materials, steps, features, components or elements, in addition to those literally disclosed, provided that these additional materials, steps, features, components or elements do not materially affect PI External the basic and novel characteristic(s) of the claimed invention. The term “consisting essentially of” occupies a middle ground between “comprising” and “consisting of”. Further, unless expressly stated to the contrary, “or” refers to an inclusive “or” and not to an exclusive “or”. For example, a condition A “or” B is satisfied by any one of the following: A is true (or present) 5 and B is false (or not present), A is false (or not present) and B is true (or present), and both A and B are true (or present). Also, the indefinite articles “a” and “an” preceding an element or component of the present invention are intended to be nonrestrictive regarding the number of instances (i.e. occurrences) of the element or component. Therefore “a” or “an” should be read to include one or at least one, and the singular word 10 form of the element or component also includes the plural unless the number is obviously meant to be singular. As referred to in this disclosure, the term “invertebrate pest” or “invertebrates” includes arthropods, gastropods, and nematodes of economic importance as pests. The term “arthropod” includes insects, mites, spiders, scorpions, centipedes, millipedes, pill bugs, and symphylans. The term “gastropod” 15 includes snails, slugs, and other Stylommatophora. The term “nematode” refers to a living organism of the Phylum Nematoda. The term “helminths” includes roundworms, heartworms, phytophagous nematodes (Nematoda), flukes (Tematoda), acanthocephala, and tapeworms (Cestoda). In the context of this disclosure “invertebrate pest control” means inhibition of invertebrate pest development (including mortality, feeding reduction, and / or mating disruption), and related expressions 20 are defined analogously. The term “agronomic” refers to the production of field crops such as for food, feed and fiber and includes the growth of corn, soybeans and other legumes, rice, cereal (e.g., wheat, oats, barley, rye, rice, maize), leafy vegetables (e.g., lettuce, cabbage, and other vegetable crops), fruiting vegetables (e.g., tomatoes, pepper, eggplant, crucifers, and cucurbits), potatoes, sweet potatoes, grapes, cotton, tree fruits 25 (e.g., pome, stone, and citrus), small fruit (berries, cherries) and other specialty crops (e.g., canola, sunflower, olives). The term “non-agronomic” refers to other than field crops such as horticultural crops (e.g., greenhouse, nursery or ornamental plants not grown in a field), residential, agricultural, commercial and industrial structures, turf (e.g., sod farm, pasture, golf course, lawn, sports field, etc.), wood products, stored 30 product, agro-forestry and vegetation management, public health (i.e. human) and animal health (e.g., domesticated animals such as pets, livestock and poultry, undomesticated animals such as wildlife) applications. Non-agronomic applications include protecting an animal from an invertebrate parasitic pest by administering a parasiticidally effective (i.e. biologically effective) amount of a compound of the 35 present invention, typically in the form of a composition formulated for veterinary use, to the animal to be protected. As referred to in the present disclosure and claims, the terms “parasiticidal” and PI External “parasiticidally” refers to observable effects on an invertebrate parasite pest to provide protection of an animal from the pest. Parasiticidal effects typically relate to diminishing the occurrence or activity of the target invertebrate parasitic pest. Such effects on the pest include death, retarded growth, diminished mobility or lessened ability to remain on or in the host animal, reduced feeding and inhibition of 5 reproduction. These effects on invertebrate parasite pests provide control (including prevention, reduction or elimination) of a parasitic infestation or infection of the animal. Compounds of the present disclosure may be present either in a pure form or as mixtures of different possible isomeric forms such as stereoisomers or constitutional isomers. The various stereoisomers include enantiomers, diastereomers, chiral isomers, atropisomers, conformers, rotamers, tautomers, 10 optical isomers, polymorphs, and geometric isomers. Any desired mixtures of these isomers fall within the scope of the claims of the present disclosure. One skilled in the art will appreciate that one stereoisomer may be more active and / or may exhibit beneficial effects when enriched relative to the other isomer(s) or when separated from the other isomer(s). Additionally, the person skilled in the art knows processes or methods or technologies to separate, enrich, and / or to selectively prepare said 15 isomers. The meaning of various terms used in the description shall now be illustrated. The term “alkyl”, used either alone or in compound words such as “alkylthio” or “haloalkyl” or - 20 N(alkyl) or alkylcarbonylalkyl or alkylsufonylamino includes straight-chain or branched C1 to C12 alkyl, preferably C1 to C8 alkyl, more preferably C1 to C6 alkyl. Representative examples of alkyl include methyl, ethyl, propyl, 1-methylethyl, butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1,1- dimethylpropyl, 1,2-dimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-1-methylpropyl, and l-ethyl-2- 25 methylpropyl or the different isomers. If the alkyl is at the end of a composite substituent, as, for example, in alkylcycloalkyl, the part of the composite substituent at the start, for example the cycloalkyl, may be mono- or polysubstituted identically or differently and independently by alkyl. The same also applies to composite substituents in which other radicals, for example alkenyl, alkynyl, hydroxyl, halogen, carbonyl, carbonyloxy and the like, are at the end. 30 The term “alkenyl”, used either alone or in compound words includes straight-chain or branched C2 to C12alkenes, preferably C2to C8alkenes, more preferably C2to C6alkenes. Representative examples of alkenes include ethenyl, 1-propenyl, 2-propenyl, 1-methylethenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1- methyl-1-propenyl, 2-methyl-l-propenyl, l-methyl-2 -propenyl, 2-methyl-2-propenyl, 1-pentenyl, 2- pentenyl, 3-pentenyl, 4-pentenyl, 1-methyl-1-butenyl, 2-methyl-1-butenyl, 3-methyl-1-butenyl, l-35 methyl-2-butenyl, 2-methyl-2-butenyl, 3-methyl-2-butenyl, l-methyl-3-butenyl, 2-methyl-3-butenyl, 3- methyl-3-butenyl, 1,1-dimethyl-2-propenyl, 1,2-dimethyl-1-propenyl, 1,2-dimethyl-2 -propenyl, 1- PI External ethyl-1-propenyl, l-ethyl-2-propenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 1- methyl-1-pentenyl, 2-methyl-1-pentenyll,l,2-trimethyl-2-propenyl, 1-ethyl-l-methyl-2-propenyl, l- ethyl-2-methyl-l-propenyl and l-ethyl-2-methyl-2-propenyl and the different isomers. “Alkenyl” also includes polyenes such as 1,2-propadienyl and 2,4-hexadienyl. This definition also applies to alkenyl 5 as a part of a composite substituent, for example haloalkenyl and the like, unless defined specifically elsewhere. Non-limiting examples of alkynes include ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3- butynyl, 1-methyl-2-propynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, l-methyl-2-butynyl, l- methyl-3-butynyl, 2-methyl-3-butynyl, 3-methyl-l-butynyl, 1,1-dimethyl-2-propynyl, 1-ethyl -2-10 propynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl, 1-methyl-2-pentynyl, l-methyl-3- pentynyl, 1-methyl-4-pentynyl, 2-methyl-3-pentynyl, 2-methyl-4-pentynyl, 3-methyl-l-pentynyl, 3- methyl-4-pentynyl, 4-methyl-l-pentynyl, 4-methyl-2-pentynyl, 1,1-dimethyl-2-butynyl, l,l-dimethyl-3- butynyl, l,2-dimethyl-3-butynyl, 2,2-dimethyl-3-butynyl, 3,3-dimethyl-l-butynyl, l-ethyl-2-butynyl, l- ethyl-3-butynyl, 2-ethyl-3-butynyl and 1-ethyl-l-methyl-2-propynyl and the different isomers. This 15 definition also applies to alkynyl as a part of a composite substituent, for example haloalkynyl etc., unless specifically defined elsewhere. The term “alkynyl” can also include moieties comprised of multiple triple bonds such as 2,5-hexadiynyl. The term “cycloalkyl” means alkyl closed to form a ring. Non-limiting examples include cyclopropyl, cyclobutyl cyclopentyl cyclohexyl, and cycloheptyl. This definition also applies to cycloalkyl as a part 20 of a composite substituent, for example cycloalkylalkyl etc., unless specifically defined elsewhere. The term “cycloalkoxy”, “cycloalkenyloxy” and the like are defined analogously. Non-limiting examples of cycloalkoxy include cyclopropyloxy, cyclopentyloxy, and cyclohexyloxy. This definition also applies to cycloalkoxy as a part of a composite substituent, for example cycloalkoxy alkyl etc., unless specifically defined elsewhere. 25 The term “halogen”, either alone or in compound words such as “haloalkyl”, includes fluorine, chlorine, bromine or iodine. Further, when used in compound words such as “haloalkyl”, said alkyl may be partially or fully substituted with halogen atoms which may be the same or different. Non-limiting examples of “haloalkyl” include chloromethyl, bromomethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chlorofluoromethyl, dichlorofluoromethyl, 30 chlorodifluoromethyl, 1-chloroethyl, 1-bromoethyl, 1-fluoroethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-chloro-2-fluoroethyl, 2-chloro-2,2-difluoroethyl, 2,2-dichloro-2-fluoroethyl, 2,2,2-trichloroethyl, pentafluoroethyl, 1,1-dichloro-2,2,2-trifluoroethyl, and 1,1,1-trifluoroprop-2-yl. This definition also applies to haloalkyl as a part of a composite substituent, for example haloalkylaminoalkyl etc., unless specifically defined elsewhere. PI External The terms “haloalkenyl”, “haloalkynyl” are defined analogously except that, instead of alkyl groups, alkenyl and alkynyl groups are present as a part of the substituent. The term “haloalkoxy” means straight-chain or branched alkoxy groups where some or all of the hydrogen atoms in these groups may be replaced by halogen atoms as specified above. Non-limiting 5 examples of haloalkoxy include chloromethoxy, bromomethoxy, dichloromethoxy, trichloromethoxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy, chlorofluoromethoxy, dichlorofluoromethoxy, chlorodifluoromethoxy, 1-chloroethoxy, 1-bromoethoxy, 1-fluoroethoxy, 2-fluoroethoxy, 2,2- difluoroethoxy, 2,2,2-trifluoroethoxy, 2-chloro-2-fluoroethoxy, 2-chloro-2,2-difluoroethoxy, 2,2- dichloro-2-fluoroethoxy, 2,2,2-trichloroethoxy, pentafluoroethoxy, and l,l,l-trifluoroprop-2-oxy. This 10 definition also applies to haloalkoxy as a part of a composite substituent, for example haloalkoxyalkyl etc., unless specifically defined elsewhere. The term “haloalkylthio” means straight-chain or branched alkylthio groups where some or all of the hydrogen atoms in these groups may be replaced by halogen atoms as specified above. Non-limiting examples of haloalkylthio include chloromethylthio, bromomethylthio, dichloromethylthio, 15 trichloromethylthio, fluoromethylthio, difluoromethylthio, trifluoromethylthio, chlorofluoromethylthio, dichlorofluoromethylthio, chlorodifluoromethylthio, 1-chloroethylthio, 1- bromoethylthio, 1- fluoroethylthio, 2-fluoroethylthio, 2,2-difluoroethylthio, 2,2,2-trifluoroethylthio, 2- chloro-2- fluoroethylthio, 2-chloro-2,2-difluoroethylthio, 2,2-dichloro-2-fluoroethylthio, 2,2,2- trichloroethylthio, pentafluoroethylthio, and l,l,l-trifluoroprop-2-ylthio. This definition also applies to 20 haloalkylthio as a part of a composite substituent, for example haloalkylthioalkyl etc., unless specifically defined elsewhere. The term “hydroxy” means –OH, amino means –NRR, wherein R can be H or any possible substituent such as alkyl. Carbonyl means -C(O)-, carbonyloxy means -OC(O)-, sulfinyl means SO, sulfonyl means S(O)2. 25 The term “alkoxy” used either alone or in compound words includes C1 to C12 alkoxy, preferably C1 to C8 alkoxy, more preferably C1 to C6 alkoxy. Examples of alkoxy include methoxy, ethoxy, propoxy, 1- methylethoxy, butoxy, 1-methylpropoxy, 2-methylpropoxy, 1,1-dimethylethoxy, pentoxy, 1- methylbutoxy, 2-methylbutoxy, 3-methylbutoxy, 2,2-dimethylpropoxy, 1-ethylpropoxy, hexoxy, 1,1- dimethylpropoxy, 1,2-dimethylpropoxy, 1-methylpentoxy, 2-methylpentoxy, 3-methylpentoxy, 4- 30 methylpentoxy, 1,1-dimethylbutoxy, 1,2-dimethylbutoxy, 1,3-dimethylbutoxy, 2,2-dimethylbutoxy, 2,3-dimethylbutoxy, 3,3-dimethylbutoxy, 1-ethylbutoxy, 2-ethylbutoxy, 1,1,2-trimethylpropoxy, 1,2,2- trimethylpropoxy, 1-ethyl-1-methylpropoxy, and l-ethyl-2-methylpropoxy and the different isomers. This definition also applies to alkoxy as a part of a composite substituent, for example haloalkoxy, alkynylalkoxy, etc., unless specifically defined elsewhere. PI External The term “Alkoxyalkyl” denotes alkoxy substitution on alkyl. Non-limiting examples of “alkoxyalkyl” include CH3OCH2, CH3OCH2CH2, CH3CH2OCH2, CH3CH2CH2CH2OCH2, and CH3CH2OCH2CH2. The term “alkylthio” includes branched or straight-chain alkylthio moieties such as methylthio, ethylthio, propylthio, 1-methylethylthio, butylthio, 1-methylpropylthio, 2-methylpropylthio, 1,1- 5 dimethylethylthio, pentylthio, 1-methylbutylthio, 2-methylbutylthio, 3-methylbutylthio, 2,2- dimethylpropylthio, 1-ethylpropylthio, hexylthio, 1,1-dimethylpropylthio, 1,2-dimethylpropylthio, 1- methylpentylthio, 2-methylpentylthio, 3-methylpentylthio, 4-methylpentylthio, 1,1-dimethylbutylthio, 1,2-dimethylbutylthio, 1,3-dimethylbutylthio, 2,2-dimethylbutylthio, 2,3-dimethylbutylthio, 3,3- dimethylbutylthio, 1-ethylbutylthio, 2-ethylbutylthio, 1,1,2-trimethylpropylthio, 1,2,2- 10 trimethylpropylthio, 1-ethyl-1-methylpropylthio, and l-ethyl-2-methylpropylthio and the different isomers. Halocycloalkyl, halocycloalkenyl, alkylcycloalkyl, cycloalkylalkyl, cycloalkoxyalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, haloalkylcarbonyl, cycloalkylcarbonyl, haloalkoxylalkyl, and the like, are defined analogously to the above examples. 15 “Alkylamino”, “dialkylamino”, and the like, are defined analogously to the above examples. The term “carbocycle” includes an “aromatic carbocyclic ring system” and a “nonaromatic carbocyclic ring system” or polycyclic or bicyclic (spiro, fused, bridged, nonfused) ring compounds in which the ring may be aromatic or non-aromatic (where aromatic indicates that the Hückel rule is satisfied and non-aromatic indicates that the Hueckel rule is not satisfied). 20 The term “hetero” in connection with rings refers to a ring in which at least one ring atom is not carbon and which can contain 1 to 4 heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur, provided that each ring contains no more than 4 nitrogens, no more than 2 oxygens and no more than 2 sulfurs. The term “heterocyclyl” or “heterocyclic” includes an “aromatic heterocycle” or a “heteroaryl ring 25 system” and a “nonaromatic heterocycle ring system” or polycyclic or bicyclic (spiro, fused, bridged, non-fused) ring compounds in which the ring may be aromatic or non-aromatic, wherein the heterocycle ring contains at least one heteroatom selected from N, O, S(O)0-2, or one of the C ring member of the heterocycle may be replaced by a heteroatom and optionally with C(=O), C(=S), C(=CR*R*) and C=NR*, * indicates integers. C2-C6-heterocyclyl can be construed accordingly. Non-limiting examples 30 of C2-C6-heterocyclyl include tetrahydrofuranyl, tetrahydrothiophenyl, pyrrolidinyl, piperidinyl, pyrazolyl, thiophenyl, furanyl, thiazolyl, pyridinyl or pyrmidinyl. The term “non-aromatic heterocycle” or “non-aromatic heterocyclic” means a three- to fifteen- membered, preferably three- to ten-membered, saturated or partially unsaturated heterocycle containing one to four heteroatoms from the group of oxygen, nitrogen and sulfur: mono, bi- or tricyclic PI External heterocycles which contain, in addition to carbon ring members, one to three nitrogen atoms and / or one oxygen or sulfur atom or one or two oxygen and / or sulfur atoms; if the ring contains more than one oxygen atom, they are not directly adjacent; for example (but not limited to) oxetanyl, oxiranyl, aziridinyl, thietanyl, tetrahydrofuranyl, tetrahydrothienyl, pyrrolidinyl, isoxazolidinyl, isothiazolidinyl, 5 pyrazolidinyl, oxazolidinyl, thiazolidinyl, imidazolidinyl, 1,2,4-oxadiazolidinyl, l,2,4-thiadiazolidinyl, l,2,4-triazolidin-1-yl, l,2,4-triazolidin-3-yl, l,2,3-triazolidinyl, l,3,4-oxadiazolidinyl, l,3,4- thiadiazolidinyl, 1,3,4-triazolidinyl, dihydrofuryl, dihydrothienyl, pyrrolinyl, isoxazolinyl, isothiazolinyl, dihydropyrazolyl, dihydrooxazolyl, dihydrothiazolyl,piperidinyl, pyrazynyl, morpholinyl, thiomorphlinyl, l,3-dioxan-5-yl, tetrahydropyranyl, tetrahydrothienyl, 10 hexahydropyridazinyl, hexahydropyrimidinyl, piperazinyl, and cycloserines. This definition also applies to heterocyclyl as a part of a composite substituent, for example heterocyclylalkyl etc., unless specifically defined elsewhere. The term “heteroaryl” or “aromatic heterocyclic” means 5 or 6-membered, fully unsaturated monocyclic ring systems containing one to four heteroatoms from the group of oxygen, nitrogen, and 15 sulfur; if the ring contains more than one oxygen atom, they are not directly adjacent; 5-membered heteroaryl containing one to four nitrogen atoms or one to three nitrogen atoms and one sulfur or oxygen atom: 5-membered heteroaryl groups which, in addition to carbon atoms, may contain one to four nitrogen atoms or one to three nitrogen atoms and one sulfur or oxygen atom as ring members, for example (but not limited thereto) furyl, thienyl, pyrrolyl, isoxazolyl, isothiazolyl, pyrazolyl, oxazolyl,20 thiazolyl, imidazolyl, l,2,4-oxadiazolyl, l,2,4-thiadiazolyl, l,2,4-triazolyl, l,3,4-oxadiazolyl, l,3,4- thiadiazolyl, l,3,4-triazolyl, tetrazolyl; nitrogen-bonded 5-membered heteroaryl containing one to four nitrogen atoms, or benzo fused nitrogen-bonded 5-membered heteroaryl containing one to three nitrogen atoms: 5-membered heteroaryl groups which, in addition to carbon atoms, may contain one to four nitrogen atoms or one to three nitrogen atoms as ring members and in which two adjacent carbon25 ring members or one nitrogen and one adjacent carbon ring member may be bridged by a buta-l,3-diene- l,4-diyl group in which one or two carbon atoms may be replaced by nitrogen atoms, where these rings are attached to the skeleton via one of the nitrogen ring members, for example (but not limited to) 1- pyrrolyl, 1-pyrazolyl, 1,2,4-triazol-l- yl, 1-imidazolyl, 1,2,3-triazol-l-yl, and 1,3,4-triazol-l-yl. 6-membered heteroaryl which contains one to four nitrogen atoms: 6-membered heteroaryl groups 30 which, in addition to carbon atoms, may contain, respectively, one to three and one to four nitrogen atoms as ring members, for example (but not limited thereto) pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, l,3,5-triazin-2-yl, l,2,4-triazin-3-yl, and l,2,4,5-tetrazin-3-yl; benzofused 5-membered heteroaryl containing one to three nitrogen atoms or one nitrogen atom and one oxygen or sulfur atom: for example (but not limited to) indolyl, benzimidazolyl, indazolyl, benzofuranyl, benzothiophenyl, 35 benzothiazolyl, and benzoxazolyl; benzofused 6-membered heteroaryl which contains one to three nitrogen atoms: for example (but not limited to) quinolinyl, isoquinolinyl, quinoxalinyl, phthalazinyl, quinazolinyl and cinnolinyl. PI External The term “partially / fully saturated or unsaturated heterocycles” include partially / fully saturated heterocycles or partially / fully unsaturated heterocycles. This definition also applies to heteroaryl as a part of a composite substituent, for example heteroarylalkyl etc., unless specifically defined elsewhere. 5 Non-limiting examples of “alkylcarbonyl” include C(O)CH3, C(O)CH2CH2CH3, and C(O)CH(CH3)2. Non-limiting examples of “alkoxycarbonyl” include CH3OC(=O), CH3CH2OC(=O), CH3CH2CH2OC(=O), (CH3)2CHOC(=O), and the different butoxy -or pentoxycarbonyl isomers. The term “amide” means A-R'C=ONR''-B, wherein R' and R'' indicate substituents and A and B indicate any group. 10 The term “thioamide” means A-R'C=SNR''-B, wherein R' and R'' indicate substituents and A and B indicate any group. The total number of carbon atoms in a substituent group is indicated by the “Ci-Cj” prefix where i and j are numbers from 1 to 18. For example, C1-C3 alkylsulfonyl designates methylsulfonyl through propylsulfonyl; C2 alkoxyalkyl designates CH3OCH2; C3 alkoxyalkyl designates, for example, 15 CH3CH(OCH3), CH3OCH2CH2 or CH3CH2OCH2; and C4 alkoxyalkyl designates the various isomers of an alkyl group substituted with an alkoxy group containing a total of four carbon atoms, examples including CH3CH2CH2OCH2 and CH3CH2OCH2CH2. In the above recitations, when a compound of Formula (I) is comprised of one or more heterocyclic rings, all substituents are attached to these rings through any available carbon or nitrogen by replacement of a hydrogen on said carbon or nitrogen. 20 When a compound is substituted with a substituent bearing a subscript that indicates the number of said substituents can exceed 1, said substituents (when they exceed 1) are independently selected from the group of defined substituents. Further, when the subscript m in (R)m indicates an integer ranging from for example 0 to 4, then the number of substituents may be selected from the integers between 0 and 4 inclusive. 25 When a group contains a substituent which can be hydrogen, then, when this substituent is taken as hydrogen, it is recognized that said group is being un-substituted. The term “optionally substituted" is used herein interchangeably with the phrase “substituted or unsubstituted” or with the term “(un)substituted”. Unless otherwise indicated, an optionally substituted group may have a substituent at each substitutable position of the group, and each substitution is 30 independent of the other. An optionally substituted group also may have no substituents. Therefore, the phrase “optionally substituted with one or more substituents” means that the number of substituents may vary from zero up to the number of available positions for substitution. The term (un)substituted is referred as said groups are unsubstituted or said groups are independently substituted with the substituents selected from the group consisting of halogen, cyano, C1-C6alkyl, C2- PI External C6alkenyl, C2-C6alkynyl, C1-C6haloalkyl, C3-C8cycloalkyl, C1-C6-alkoxy, -NH(alkyl), -N(alkyl)2, and -S(O)0-2C1-C6alkyl. The term “aliphatic group” used either alone or in compound words includes straight-chain or branched substituents e.g., C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6haloalkyl, C2-C6haloalkenyl, C1-C65 alkylthio, C1-C6haloalkylthio, C1-C6alkoxy or C1-C6haloalkoxy; The term “cyclic groups” used either alone or in compound words includes fully / partially saturated or unsaturated cyclic substitutions or groups e.g., cycloalkyl, phenyl, C2-C6heterocyclyl etc. The embodiments herein and the various features and advantageous details thereof are explained with 10 reference to the non-limiting embodiments in the description. Descriptions of well-known components and processing techniques are omitted so as to not unnecessarily obscure the embodiments herein. The examples used herein are intended merely to facilitate an understanding of ways in which the embodiments herein may be practiced and to further enable those of skilled in the art to practice the embodiments herein. Accordingly, the examples should not be construed as limiting the scope of the 15 embodiments herein. The description of the specific embodiments will so fully reveal the general nature of the embodiments herein that others can, by applying current knowledge, readily modify and / or adapt for various applications such specific embodiments without departing from the generic concept, and, therefore, such adaptations and modifications should and are intended to be comprehended within the meaning 20 and range of equivalents of the disclosed embodiments. It is to be understood that the phraseology or terminology employed herein is for the purpose of description and not of limitation. Therefore, while the embodiments herein have been described in terms of preferred embodiments, those skilled in the art will recognize that the embodiments herein can be practiced with modification within the spirit and scope of the embodiments as described herein. 25 Any discussion of documents, acts, materials, devices, articles and the like that has been included in this specification is solely for the purpose of providing a context for the disclosure. It is not to be taken as an admission that any or all of these matters form a part of the prior art base or were common general knowledge in the field relevant to the disclosure as it existed anywhere before the priority date of this application. 30 The numerical values mentioned in the description and the description / claims though might form a critical part of the present invention, any deviation from such numerical values shall still fall within the scope of the present invention if that deviation follows the same scientific principle as that of the present invention disclosed in the present invention. The inventive compound of the present invention may, if appropriate, be present as mixtures of different possible isomeric forms, especially of stereoisomers, 35 for example E and Z, threo and erythro, and also optical isomers, but if appropriate also of tautomers. PI External Both the E and the Z isomers, and also the threo and erythro isomers, and the optical isomers, any desired mixtures of these isomers and the possible tautomeric forms are disclosed and claimed. The term “pest” for the purpose of the present disclosure includes but is not limited to fungi, stramenopiles (oomycetes), bacteria, nematodes, mites, ticks, insects and rodents. 5 The term “plant” is understood here to mean all plants and plant populations such as desired and undesired wild plants or crop plants (including naturally occurring crop plants). Crop plants may be plants which can be obtained by conventional breeding and optimization methods or by biotechnological and genetic engineering methods or combinations of these methods, including the transgenic plants and including the plant cultivars which are protectable and non-protectable by plant 10 breeders’ rights. In the present disclosure, the term “plant” includes a living organism of the kind exemplified by trees, shrubs, herbs, grasses, ferns, and mosses, typically growing in a site, absorbing water and required substances through its roots, and synthesizing nutrients in its leaves by photosynthesis. Examples of “plant” for the purpose of the present invention include agricultural crops such as wheat, 15 rye, barley, triticale, oats or rice; beet, e.g., sugar beet or fodder beet; fruits and fruit trees such as pomes, stone fruits or soft fruits, e.g., apples, pears, plums, peaches, almonds, cherries, strawberries, raspberries, blackberries or gooseberries; leguminous plants such as lentils, peas, alfalfa or soybeans; oil plants such as rape, mustard, olives, sunflowers, coconut, cocoa beans, castor oil plants, oil palms, ground nuts or soybeans; cucurbits such as squashes, cucumber or melons; fiber plants such as cotton, 20 flax, hemp or jute; citrus fruit and citrus trees such as oranges, lemons, grapefruits or mandarins; any horticultural plants, vegetables such as spinach, lettuce, asparagus, cabbages, carrots, onions, tomatoes, potatoes, cucurbits or paprika; lauraceous plants such as avocados, cinnamon or camphor; cucurbitaceae; oleaginous plants; energy and raw material plants such as cereals, corn, soybean, other leguminous plants, rape, sugar cane or oil palm; tobacco; nuts; coffee; tea; cacao; bananas; peppers; 25 vines (table grapes and grape juice grape vines); hop; turf; sweet leaf (also called Stevia); natural rubber plants or ornamental and forestry plants such as flowers, shrubs, broad-leaved trees or evergreens, e.g., conifers; and the plant propagation material such as seeds, and the crop material of these plants. Preferably, the plants for the purpose of the present invention include but are not limited to cereals, corn, rice, soybean and other leguminous plants, fruits and fruit trees, grapes, nuts and nut trees, citrus 30 and citrus trees, any horticultural plants, cucurbitaceae, oleaginous plants, tobacco, coffee, tea, cacao, sugar beet, sugar cane, cotton, potato, tomato, onions, peppers and vegetables, ornamentals, any floricultural plants and other plants for the use of humans and animals. The term “plant parts” is understood to mean all parts and organs of plants above and below the ground. For the purpose of the present disclosure the term plant part includes but is not limited to cuttings, 35 leaves, twigs, tubers, flowers, seeds, branches, roots including taproots, lateral roots, root hairs, root PI External apex, root cap, rhizomes, slips, shoots, fruits, fruit bodies, bark, stem, buds, auxillary buds, meristems, nodes and internodes. The term “locus thereof” includes soil, surroundings of plant or plant parts and equipment or tools used before, during or after sowing / planting a plant or a plant part. 5 An application of the compounds of the present disclosure or the compound of the present disclosure in a composition optionally comprising other compatible compounds to a plant or a plant material or locus thereof includes the application by a technique known to a person skilled in the art which includes but is not limited to spraying, coating, dipping, fumigating, impregnating, injecting, and dusting. The term “applied” means adhered to a plant or plant part either physically or chemically including 10 impregnation. Accordingly, in the first aspect the present invention relates to a compound of Formula (I), Formula (I) 15 wherein, A1 represents C or N; Q is selected from 8- or 9- membered fused heterobicyclic ring system selected from Q-a to Q-t PI External wherein the expression “ “ indicates the point of attachment to a fragment and theexpression “*” indicates the point of attachment to substituted pyridine or pyrimidine ring; 5 Z is selected from a direct bond, O, N, a substituted or unsubstituted 5-6 membered heterocyclic ring or a substituted or unsubstituted 6-10 membered aryl ring; wherein said heterocyclic ring and aryl ring can be substituted by one to three substituents independently selected from halogen, cyano, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-haloalkyl, C3-C8-cycloalkyl, C1-C6-alkoxy, -NH(C1-C6alkyl), - N(C1-C6alkyl)2, or -S(O)0-2C1-C6-alkyl; 10 G represents O or S; R1and R2are independently selected from the group consisting of hydrogen, halogen, cyano, C1-C4- alkyl, and C1-C4-haloalkyl; R3is selected from the group consisting of hydrogen, halogen, cyano, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6-cycloalkyl, C1-C6-alkoxy, and C1-C6 haloalkyl; 15 R4is selected from the group consisting of C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6-alkoxy, C2-C6 haloalkenyl, C3-C8 cycloalkyl, C3-C8 cycloalkyl-C1-C6 alkyl, C2-C6-heterocyclyl, phenyl, phenoxy, phenylthio, and -NRcRd; Rcis selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, and C3-C8 cycloalkyl; 20 Rdis selected from the group consisting of hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C2-C6 haloalkenyl, C3-C8 cycloalkyl, C3-C6-cycloalkyl-C1-C4-alkyl; or Rcand Rdsubstituents together with the atom to which they are attached or together with further atoms selected from the group consisting of C, N, O, C(=O), C(=S), and S(O)0-2 may form a 25 3- to 6-membered ring, which may optionally be substituted by one or more substituents selected from the group consisting of halogen, CN, and C1-C6 alkyl; R5is selected from the group consisting of C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6-alkoxy, C3-C8 cycloalkyl, C3-C8 cycloalkyl-C1-C6 alkyl, C2-C6 alkenyl, C2-C6 haloalkenyl, phenyl, phenoxy, phenylthio, benzyl, and C2-C6 heterocyclyl; or 30 R4and R5substituents together with the atom to which they are attached or together with further atoms selected from the group consisting of C, N, O, C(=O), C(=S), and S(O)0-2 may form a 3- to PI External 6-membered ring, which may optionally be substituted by one or more substituents selected from the group consisting of halogen, CN, and C1-C6alkyl; wherein each aliphatic group of R1, R2, R4and, R5may be optionally substituted with one or more groups of Ra; and cyclic groups of R1, R2, R4, and R5may optionally be substituted with 5 one or more groups of Rb, wherein, Rais selected from the group consisting of halogen, cyano, C1-C6alkyl, C1-C6haloalkyl, C3-C8cycloalkyl, C1-C6alkoxy, C3-C8cycloalkyloxy, C1-C6alkylthio, phenyl, and C2-C6heterocyclyl; Rbis selected from the group consisting of halogen, cyano, C1-C6 alkyl, C2-C6 alkenyl, C2- 10 C6 alkynyl, C1-C6 haloalkyl, C2-C6 haloalkenyl, C3-C8 cycloalkyl, C1-C6 alkylthio, C1-C6 haloalkylthio, C1-C6 alkoxy, and C1-C6 haloalkoxy; or salts, stereo-isomers, tautomers, polymorphs, metal complexes or N-oxides thereof. The following embodiments provide definitions, including preferred definitions, for substituents with 15 reference to the compounds of Formula (I) according to the invention. For any one of these substituents, any of the definitions given below may be combined with any definition of any other substituent given below or elsewhere in this document. In one embodiment, the present invention provides compounds of Formula (I), wherein, A1 is C. In one embodiment, the present invention provides compounds of Formula (I), wherein, A1 is N. 20 In one embodiment, the present invention provides compounds of Formula (I), wherein, Z is selected from a direct bond, O, N, a substituted or unsubstituted 5-6 membered heterocyclic ring or a substituted or unsubstituted 6-10 membered aryl ring; wherein said heterocyclic ring and aryl ring can be substituted by one to three substituents independently selected from halogen, cyano, C1-C6-alkyl, C2- C6-alkenyl, C2-C6-alkynyl, C1-C6-haloalkyl, C3-C8-cycloalkyl, C1-C6-alkoxy, -NH(C1-C6 alkyl), -N(C1- 25 C6 alkyl)2, or -S(O)0-2C1-C6-alkyl. In another embodiment, the present invention provides compounds of Formula (I), wherein, Z is a direct bond. In yet another embodiment, the present invention provides compounds of Formula (I), wherein, Z is a substituted or unsubstituted 5-6 membered aromatic heterocyclic ring; preferably pyridinyl, 30 pyrimidinyl, pyrazynyl, pyrazolyl, thiazolyl or oxazolyl. wherein said heterocyclic ring can be substituted by one to three substituents independently selected from halogen, cyano, C1-C4-alkyl, C2- C4-alkenyl, C2-C4-alkynyl, C1-C4-haloalkyl, C3-C6-cycloalkyl, C1-C4-alkoxy, -NH(C1-C6alkyl), -N(C1- C6 alkyl)2, or -S(O)0-2C1-C6-alkyl. Preferably said heterocyclic ring can be substituted by one to two substituents independently selected from halogen, cyano, C1-C4-alkyl, C1-C4-haloalkyl, C3-C6- 35 cycloalkyl or C1-C6-alkoxy PI External In one embodiment, the present invention provides compounds of Formula (I), wherein, Z is a substituted or unsubstituted 6-10 membered aryl ring; wherein said aryl ring can be substituted by one to three substituents independently selected from halogen, cyano, C1-C4-alkyl, C2-C4-alkenyl, C2-C4- alkynyl, C1-C4-haloalkyl, C3-C6-cycloalkyl, C1-C4-alkoxy, -NH(C1-C6alkyl), -N(C1-C6alkyl)2, or - 5 S(O)0-2C1-C6-alkyl. Preferably said aryl ring can be substituted by one to two substituents independently selected from halogen, cyano, C1-C4-alkyl, C1-C4-haloalkyl, C3-C6-cycloalkyl or C1-C4-alkoxy. Preferably Z is phenyl or naphthalene ring; more preferably Z is phenyl. In another embodiment, the present invention provides compounds of Formula (I), wherein, Z is O. In yet another embodiment, the present invention provides compounds of Formula (I), wherein, Z is N. 10 In one embodiment the groups R1, R2, R3, R4, and R5, of the compound of Formula (I) are described as: R1and R2are independently selected from the group consisting of hydrogen, halogen, cyano, C1-C6 alkyl, C1-C6 haloalkyl; preferably hydrogen, halogen, cyano, C1-C6 alkyl, and C1-C6 haloalkyl; preferably hydrogen, halogen, cyano, C1-C3 alkyl, CHF2 and CF3; more preferably hydrogen, F, Cl, methyl, ethyl, isopropyl, CHF2, and CF3. 15 R3is selected from the group consisting of hydrogen, halogen, cyano, C1-C6 alkyl, C1-C6-alkoxy and C1-C6 haloalkyl; preferably hydrogen, halogen, cyano, C1-C3-alkyl, C1-C3-haloalkyl, and C1-C3-alkoxy; more preferably hydrogen, fluorine, chlorine, methyl, ethyl, isopropyl, methoxy, and CF3. R4is selected from the group consisting of C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6-alkoxy, C2-C6 haloalkenyl, C3-C8 cycloalkyl, phenyl, phenylthio, C3-C8 cycloalkyl-C1-C6 alkyl, 20 C2-C6 heterocyclyl and -NRcRd; preferably C1-C6 alkyl, C3-C6 cycloalkyl-C1-C6 alkyl, C2-C6 heterocyclyl, C3-C6 cycloalkyl, -NRcRd, C1-C6 haloalkyl, C1-C6-alkoxy, C2-C6 heterocyclyl, phenyl and phenylthio; more preferably C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 haloalkyl, C1-C6-alkoxy, phenyl, and phenylthio. Rcis selected from the group consisting of hydrogen, C1-C6 alkyl, C3-C8 cycloalkyl; more preferably 25 hydrogen or C1-C6 alkyl; Rdis selected from the group consisting of C1-C6 alkyl, C1-C6- C3-C8 cycloalkyl-C1-C6 alkyl, phenyl and C2-C6 heterocyclyl; preferably C1-C6 alkyl, C1-C6 haloalkyl, and C3-C8 cycloalkyl; or Rcand Rdsubstituents together with the atom to which they are attached or together with further atoms selected from the group consisting of C, N, O, C(=O), C(=S), and S(O)0-2 may form a 30 3- to 6-membered ring, which may optionally be substituted by one or more substituents selected from the group consisting of halogen, CN or C1-C6alkyl; PI External R5is selected from the group consisting of C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6haloalkyl, C1-C6-alkoxy, C3-C8cycloalkyl, C3-C8cycloalkyl-C1-C6alkyl, C2-C6alkenyl, C2-C6haloalkenyl, phenyl, phenoxy, phenylthio, benzyl, and C2-C6heterocyclyl; optionally, R4and R5substituents together with the atom to which they are attached or together with 5 further atoms selected from the group consisting of C, N, O, C(=O), C(=S), and S(O)0-2may form a 4- to 6-membered ring, which may optionally be substituted by one or more substituents selected from the group consisting of halogen, CN, and C1-C6alkyl; wherein each aliphatic group of R1, R2, R4, and R5may be optionally substituted with one or more groups of Raand cyclic groups of R1, R2, R3, R4, and R5may optionally be substituted with one or more 10 groups of Rb, Rais selected from the group consisting of halogen, cyano, C1-C6 alkyl, C1-C6 haloalkyl, C3-C8 cycloalkyl, C1-C6 alkoxy, C3-C8 cycloalkyloxy, C1-C6 alkylthio, phenyl, and C2-C6 heterocyclyl; Rbis selected from the group consisting of halogen, cyano, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 15 alkynyl, C1-C6 haloalkyl, C2-C6 haloalkenyl, C3-C8 cycloalkyl, C1-C6 alkylthio, C1-C6 haloalkylthio, C1-C6 alkoxy, and C1-C6 haloalkoxy. Further, embodiments of this disclosure described herein, can be combined in any manner, and the descriptions of variables in the embodiments pertain not only to the compounds of Formula (I) but also to the starting compounds and to intermediate compounds useful for preparing the compounds of 20 Formula (I). In this sense, embodiments that can be combined according to the present invention, are illustrated in the following: In one embodiment, the present invention provides compounds of Formula (I), wherein, Z is a direct bond, O, N, substituted or unsubstituted 5-6 membered heterocyclic ring or substituted or 25 unsubstituted 6-10 membered aryl ring; preferably Z is a direct bond, substituted or unsubstituted 5-6 membered heterocyclic ring; wherein said heterocyclic ring and aryl ring can be substituted by one to three substituents independently selected from halogen, cyano, C1-C6-alkyl, C2-C6-alkenyl, C2-C6- alkynyl, C1-C6-haloalkyl, C3-C8-cycloalkyl, C1-C6-alkoxy, -NH(C1-C6-alkyl), -N(C1-C6-alkyl)2, or - S(O)0-2C1-C6-alkyl; more preferably said heterocyclic ring and aryl ring can be substituted by one to30 two substituents independently selected from halogen, cyano, C1-C4-alkyl, C1-C4-haloalkyl, C3-C6- cycloalkyl or C1-C4-alkoxy,. R1and R2are independently selected from the group consisting of hydrogen, halogen, cyano, C1-C4- alkyl, and C1-C4-haloalkyl; PI External R3is selected from the group consisting of hydrogen, halogen, cyano, C1-C6alkyl, C1-C6haloalkyl, and C1-C6alkoxy; R4is selected from the group consisting of C1-C6alkyl, C3-C8cycloalkyl, C1-C6haloalkyl, C1-C6-alkoxy, C2-C6-heterocyclyl, phenyl, phenylthio, C3-C8cycloalkyl-C1-C6alkyl, and -NRcRd; 5 wherein, Rcis selected from the group consisting of hydrogen or C1-C6alkyl; Rdis selected from the group consisting of hydrogen or C1-C6alkyl; R5is selected from the group consisting of C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6haloalkyl, C1-C6-alkoxy, C3-C8cycloalkyl, C3-C8cycloalkyl-C1-C6alkyl, C2-C6alkenyl, C2-C6haloalkenyl, phenyl, phenoxy, phenylthio, benzyl, and C2-C6 heterocyclyl; wherein each 10 aliphatic group of R4and R5may be optionally substituted with one or more groups of Raand cyclic groups of R4and R5may optionally be substituted with one or more groups of Rb, Rais selected from the group consisting of halogen, cyano, C1-C6 alkyl, C1-C6 haloalkyl, C3-C8 cycloalkyl, C1-C6 alkoxy, C3-C8 cycloalkyloxy, C1-C6 alkylthio, phenyl, and C2- C6 heterocyclyl; 15 Rbis selected from the group consisting of halogen, cyano, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C2-C6 haloalkenyl, C3-C8 cycloalkyl, C1-C6 alkylthio, C1-C6 haloalkylthio, C1-C6 alkoxy, and C1-C6 haloalkoxy; or salts, stereo-isomers, tautomers, polymorphs, metal complexes or N-oxides thereof. In one embodiment, the present invention provides compounds of Formula (I), wherein, C2-C6 20 heterocyclyl of the R4or R5group is preferably selected from partially / fully saturated or unsaturated furyl, thienyl, pyrrolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrazolyl, oxazolyl, imidazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridinyl, pyridazinyl, pyrimidinyl or pyrazinyl. In a preferred embodiment, the present invention provides compounds of Formula (I) wherein, Q is selected from: 25 PI External wherein the expression “ “ indicates the point of attachment to a fragment and theexpression “*” indicates the point of attachment to substituted pyridine or pyrimidine ring. 5 In one preferred embodiment, the present invention provides compounds of Formula (I) wherein, R1and R2are independently selected from the group consisting of hydrogen, halogen, cyano, C1-C6 alkyl, C1-C6 haloalkyl; R3is selected from the group consisting of hydrogen, halogen, cyano, C1-C6 alkyl, C1-C6-alkoxy and 10 C1-C6 haloalkyl R4is selected from the group consisting of C1-C6 alkyl, C1-C6 haloalkyl, C1-C6-alkoxy, C3-C8 cycloalkyl, and C3-C8 cycloalkyl-C1-C6 alkyl; preferably C1-C6 alkyl, C3-C6 cycloalkyl-C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 haloalkyl, and C1-C6-alkoxy; R5is selected from the group consisting of C1-C6 alkyl, C1-C6 haloalkyl, C1-C6-alkoxy, C3-C8 cycloalkyl, 15 C3-C8 cycloalkyl-C1-C6 alkyl, C2-C6 alkenyl, C2-C6 haloalkenyl, phenyl, phenoxy, phenylthio, benzyl, and C2-C6 heterocyclyl; R4and R5substituents together with the atom to which they are attached or together with further atoms selected from the group consisting of C, N, O, C(=O), C(=S), and S(O)0-2 may form a 3- to 6-membered ring, which may optionally be substituted by one or more substituents selected from 20 the group consisting of halogen, CN, and C1-C6alkyl; Q is selected from: PI External wherein the expression “ “ indicates the point of attachment to a fragment and the5 expression “*” indicates the point of attachment to substituted pyridine or pyrimidine ring; and Z is a direct bond or a substituted or unsubstituted 5-6 membered aromatic heterocyclic ring selected from pyridinyl, pyrimidinyl, pyrazynyl, pyrazolyl, thiazolyl or oxazolyl. wherein said heterocyclic ring can be substituted by one to two substituents independently selected from halogen, cyano, C1-C4-alkyl, 10 C1-C6-haloalkyl, C3-C6-cycloalkyl or C1-C4-alkoxy. The following embodiments apply to compounds of Formula (I). These embodiments are independent and interchangeable. Any one embodiment may be combined with any other embodiment, where chemically allowed. In other words, any of the features described in the following embodiments may (where chemically allowable) be combined with the features described in one or more other 15 embodiments. In particular, where a compound is exemplified or illustrated in this specification, any two or more of the embodiments listed below, expressed at any level of generality, which encompass PI External that compound may be combined to provide a further embodiment which forms part of the present disclosure. In one embodiment, the present invention provides compounds of Formula (I), wherein the fused heterocyclic ring system Q can be selected 5 In another embodiment, the present invention provides compounds of Formula (I), wherein the fused heterocyclic ring system Q can be selected In yet another embodiment, the present invention provides compounds of Formula (I), wherein the fused heterocyclic ring system Q can be selected 10 In yet another embodiment, the present invention provides compounds of Formula (I), wherein the fused heterocyclic ring system Q can be selected In yet another embodiment, the present invention provides compounds of Formula (I), wherein the fused heterocyclic ring system Q can be selected 15 In yet another embodiment, the present invention provides compounds of Formula (I), wherein the fused heterocyclic ring system Q can be selected PI External In yet another embodiment, the present invention provides compounds of Formula (I), wherein the fused heterocyclic ring system Q can be selected In yet another embodiment, the present invention provides compounds of Formula (I), wherein the fused heterocyclic ring system Q can be selected 5 In yet another embodiment, the present invention provides compounds of Formula (I), wherein the fused heterocyclic ring system Q can be selected as .In yet another embodiment, the present invention provides compounds of Formula (I), wherein the fused heterocyclic ring system Q can be selected 10 In yet another embodiment, the present invention provides compounds of Formula (I), wherein the fused heterocyclic ring system Q can be selected as . In another embodiment, the present invention provides compounds of Formula (I), wherein the fused heterocyclic ring system Q can be selected as . 15 In another embodiment, the present invention provides compounds of Formula (I), wherein the fused heterocyclic ring system Q can be selected as . PI External In yet another embodiment, the present invention provides compounds of Formula (I), wherein the fused heterocyclic ring system Q can be selected In yet another embodiment, the present invention provides compounds of Formula (I), wherein the fused heterocyclic ring system Q can be selected 5 In yet another embodiment, the present invention provides compounds of Formula (I), wherein the fused heterocyclic ring system Q can be selected In yet another embodiment, the present invention provides compounds of Formula (I), wherein the fused heterocyclic ring system Q can be selected 10 In yet another embodiment, the present invention provides compounds of Formula (I), wherein the fused heterocyclic ring system Q can be selected In yet another embodiment, the present invention provides compounds of Formula (I), wherein the fused 15 heterocyclic ring system Q can be selected In yet another embodiment, the present invention provides compounds of Formula (I), wherein the fused heterocyclic ring system Q can be selected as . PI External In a more preferred embodiment, the present invention provides compounds of Formula (I), wherein the fused heterocyclic ring system Q can be selected In a more preferred embodiment, the present invention provides compounds of Formula (I), wherein 5 the fused heterocyclic ring system Q can be selected Wherein, the expression “ ” indicates the point of attachment to a fragment - and theexpression “*” indicates the point of attachment to substituted pyridine or a pyrimidine ring; 10 In a more preferred embodiment, the present invention provides compounds of Formula (I), wherein the fused heterocyclic ring system Q is selected from: In one embodiment, the present invention provides compounds of Formula (I), Z is a direct bond. 15 In another embodiment, the present invention provides compounds of Formula (I), Z is substituted or unsubstituted 5-6 membered heterocyclic ring; wherein said heterocyclic ring can be substituted by one to three substituents independently selected from halogen, cyano, C1-C6-alkyl, C2-C6-alkenyl, C2-C6- alkynyl, C1-C6-haloalkyl, C3-C8-cycloalkyl, C1-C6-alkoxy, -NH(C1-C6-alkyl), -N(C1-C6-alkyl)2, or - S(O)0-2C1-C6-alkyl. 20 In yet another embodiment, the present invention provides compounds of Formula (I), Z is a substituted or unsubstituted 6membered aryl ring. wherein said aryl ring can be substituted by one to three PI External substituents independently selected from halogen, cyano, C1-C6-alkyl, C2-C6-alkenyl, C2-C6- alkynyl, C1-C6-haloalkyl, C3-C8-cycloalkyl, C1-C6-alkoxy, -NH(C1-C6-alkyl), -N(C1-C6-alkyl)2, or -S(O)0-2C1- C6-alkyl. In an embodiment R1and R2are independently selected from the group consisting of hydrogen, halogen, 5 cyano, C1-C4-alkyl, C1-C4-haloalkyl; In a preferred embodiment the present invention provides compounds of Formula (I), wherein, R1and R2are independently selected from the group consisting of hydrogen, chloro, fluoro, cyano, methyl, ethyl, isopropyl, CHF2, and CF3; In an embodiment, the present invention provides compounds of Formula (I), wherein, R3is C1-C6 alkyl. 10 In another embodiment, the present invention provides compounds of Formula (I), wherein R3is C1-C6 haloalkyl. In yet another embodiment, the present invention provides compounds of Formula (I), wherein R3is halogen. In yet another embodiment, the present invention provides compounds of Formula (I), wherein R3is C1- 15 C6 alkoxy. In a preferred embodiment, the present invention provides compounds of Formula (I), wherein R3is CF3. In another preferred embodiment, the present invention provides compounds of Formula (I), wherein R3is fluoro or chloro. 20 In a preferred embodiment, the present invention provides compounds of Formula (I), wherein R3is CH3. In a preferred embodiment, the present invention provides compounds of Formula (I), wherein R4is C1- C6 alkyl. In a preferred embodiment, the present invention provides compounds of Formula (I), wherein R4is C1- 25 C6 alkyl optionally substituted with Rawherein Rais selected from F, CN, methyl, ethyl, (n, iso) propyl, methoxy, CF3, cyclopropyl, C2-C6 heterocyclyl; In a preferred embodiment, the present invention provides compounds of Formula (I), wherein R5is C1- C6 alkyl optionally substituted with Rawherein Rais selected from F, CN, methyl, ethyl, (n, iso) propyl, methoxy, CF3, cyclopropyl, phenoxy, phenylthio C2-C6 heterocyclyl; 30 In a preferred embodiment, the present invention provides compounds of Formula (I), wherein R5is C1- C6alkyl optionally substituted with Rawherein Rais selected from F, CN, methyl, ethyl, (n, iso) propyl, methoxy, CF3, cyclopropyl, phenyl, phenylthio C2-C6heterocyclyl; In a preferred embodiment the present invention provides compounds of Formula (I), wherein C3-C6 cycloalkyl is selected from cyclopropyl, cyclobutyl cyclopentyl or cyclohexyl. Preferably, cyclopropyl 35 or cyclobutyl. PI External The present invention also relates to a method for preparing compounds of Formula (I). Compounds of the present invention can exist as one or more stereoisomers. The various stereoisomers include enantiomers, diastereomers, atropisomers, and geometric isomers. One skilled in the art will appreciate that one stereoisomer may be more active and / or may exhibit more beneficial effects when 5 enriched relative to the other stereoisomer(s) or when separated from the other stereoisomer(s). Additionally, the skilled artisan knows how to separate, enrich, and / or to selectively prepare said stereoisomers. Compounds of the present invention may be present as a mixture of stereoisomers, individual stereoisomers or as an optically active form. In case the compounds of Formula (I) are appearing as the cationic part of a salt or are capable of 10 forming such a cationic part of a salt, the respective anionic part can be inorganic or organic. Alternatively, in case the compounds of Formula (I) are appearing as the anionic part of a salt or are capable of forming such an anionic part of a salt, the respective cationic part can be inorganic or organic. Examples of the inorganic anion part of the salt include but are not limited to chloride, bromide, iodide, fluoride, sulfate, phosphate, nitrate, nitrite, hydrogen carbonates, and hydrogen sulfate. Examples of the 15 organic anion part of the salt include but are not limited to formate, alkanoates, carbonates, acetates, trifluoroacetate, trichloroacetate, propionate, glycolate, thiocyanate, lactate, succinate, malate, citrates, benzoates, cinnamates, oxalates, alkyl sulfates, alkyl sulfonates, aryl sulfonates, bis-arylsulfonates, alkyl phosphonates, aryl phosphonates, aryl diphosphonates, p-toluenesulfonate, and salicylate. Examples of the inorganic cation part of the salt include but are not limited to alkali and alkaline earth 20 metals. Examples of the organic cation part of the salt include but are not limited to cations derived from pyridine, methyl amine, imidazole, benzimidazole, histidine, phosphazene, tetramethyl ammonium, tetrabutylammonium, choline, and trimethylamine. Metal ions in the metal complexes of the compounds of Formula (I) are especially the ions of the elements of the second main group, especially calcium and magnesium, of the third and fourth main 25 groups, especially aluminum, tin and lead, and also of the first to eighth transition groups, especially chromium, manganese, iron, cobalt, nickel, copper, zinc and others. Particular preference is given to the metal ions of the elements of the fourth period and the first to eighth transition groups. Here, the metals can be present in the various valances that they can assume. Another embodiment of the present invention discloses the compounds of Formula (I), salts, metal 30 complexes, stereo-isomers, diastereoisomers, enantiomers, chiral isomers, atropisomers, conformers, rotamers, tautomers, optical isomers, polymorphs, geometric isomers, or N-oxides thereof and compositions with the excipient, inert carrier or any other essential ingredients such as surfactants, additives, solid diluents, and liquid diluents. Compounds selected from Formula (I), (including all stereoisomers, N-oxides, and salts thereof), 35 typically exist in more than one form, and Formula (I) thus includes all crystalline and non-crystalline PI External forms of the compounds that Formula (I) represents. Non-crystalline forms include embodiments which are solids such as waxes and gums as well as embodiments which are liquids such as solutions and melts. Crystalline forms include embodiments which represent essentially a single crystal type and embodiments which represent a mixture of polymorphs (i.e. different crystalline types). The term 5 “polymorph” refers to a particular crystalline form of a chemical compound that can crystallize in different crystalline forms, these forms having different arrangements and / or conformations of the molecules in the crystal lattice. Although polymorphs can have the same chemical composition, they can also differ in composition due to the presence or absence of co-crystallized water or other molecules, which can be weakly or strongly bound in the lattice. Polymorphs can differ in such chemical, physical, 10 and biological properties as crystal shape, density, hardness, color, chemical stability, melting point, hygroscopicity, suspensibility, dissolution rate, and biological availability. One skilled in the art will appreciate that a polymorph of a compound represented by Formula (I) can exhibit beneficial effects (e.g., suitability for preparation of useful formulations, improved biological performance) relative to another polymorph or a mixture of polymorphs of the same compound represented by Formula (I). 15 Preparation and isolation of a particular polymorph of a compound represented by Formula (I) can be achieved by methods known to those skilled in the art including, for example, crystallization using selected solvents and temperatures. In one embodiment the present invention provides a method for the preparation of compound of formula (I) comprising the step of: 20 a. reacting a compound of formula (A-2) with a compound of Formula (D-1) in the presence of suitable reagents to obtain a compound of formula (I), according to the scheme below: ; wherein, LG represents halogen, tosylate, triflate or mesylate; A1, Q, Z, G, R3, R4and R5are same as defined in first aspect of the specification. 25 The present invention also relates to compositions for controlling or preventing insect and mite pests. The said compositions comprise a biologically effective amount of a compound of Formula (I) and at least one additional component selected from the group consisting of surfactants and auxiliaries. PI External Another embodiment of the present invention relates to compounds of Formula (I) or their N-oxides or salts into customary types of agrochemical compositions, e. g. solutions, emulsions, suspensions, dusts, powders, pastes, granules, pressings, capsules, and mixtures thereof. Examples for composition types are suspensions (e.g., SC, OD, FS), emulsifiable concentrates (e.g., EC), emulsions (e.g., EW, EO, ES, 5 ME), capsules (e.g., CS, ZC), pastes, pastilles, wettable powders or dusts (e.g., WP, SP, WS, DP, DS), pressings (e.g., BR, TB, DT), granules (e.g., WG, SG, GR, FG, GG, MG), insecticidal articles (e.g., LN), as well as gel formulations for the treatment of plant propagation materials such as seeds (e.g., GF). These and further types of compositions are defined in the "Catalogue of pesticide formulation types and international coding system", Technical Monograph No. 2, 6thEd. May 2008, CropLife 10 International. The above-mentioned compositions are prepared in a known manner such as described by Mollet and Grubemann, “Formulation Technology”, Wiley VCH, Weinheim, 2001; or Knowles, “New Developments in Crop Protection Product Formulation”, Agrow Reports DS243, T&F Informa, London, 2005. Examples for suitable auxiliaries for formulations and / or agrochemical compositions 15 according to the invention are solvents, liquid carriers, solid carriers or fillers, surfactants, dispersants, emulsifiers, wetters, adjuvants, solubilizers, penetration enhancers, protective colloids, adhesion agents, thickeners, humectants, repellents, attractants, feeding stimulants, compatibilizers, bactericides, anti- freezing agents, anti-foaming agents, colorants, tackifiers, and binders. Suitable solvents and liquid carriers in this context are for instance water and organic solvents such as 20 mineral oil fractions of medium to high boiling point, e. g. kerosene, diesel oil, oils of vegetable or animal origin; aliphatic, cyclic and aromatic hydrocarbons, e.g., toluene, paraffin, tetrahydronaphthalene, alkylated naphthalenes; alcohols, e. g. ethanol, propanol, butanol, benzyl alcohol, cyclohexanol; glycols; dimethyl sulfoxide; ketones, e. g. cyclohexanone; esters, e. g. lactates, carbonates, fatty acid esters, gamma-butyrolactone; fatty acids; phosphonates; amines; amides, e. g. N- 25 methyl pyrrolidone, fatty acid dimethyl amides; and mixtures thereof. Suitable solid carriers or fillers are for instance mineral earths, e. g. silicates, silica gels, talc, kaolins, limestone, lime, chalk, clays, dolomite, diatomaceous earth, bentonite, calcium sulphate, magnesium sulphate, magnesium oxide; polysaccharides, e. g. cellulose, starch; fertilizers, e. g. ammonium sulphate, ammonium phosphate, ammonium nitrate, ureas; products of vegetable origin, e. g. cereal meal, tree bark meal, wood meal, 30 nutshell meal, and mixtures thereof. Suitable surfactants are surface-active compounds, for instance such as anionic, cationic, nonionic and amphoteric surfactants, block polymers, polyelectrolytes, and mixtures thereof. Such surfactants can be used as emulsifier, dispersant, solubilizer, wetter, penetration enhancer, protective colloid, or adjuvant. Suitable anionic surfactants are for instance alkali, alkaline earth or ammonium salts of sulfonates, 35 sulphates, phosphates, carboxylates, and mixtures thereof. Examples of sulfonates are alkyl aryl sulfonates, diphenyl sulfonates, alpha-olefin sulfonates, lignin sulfonates, sulfonates of fatty acids and PI External oils, sulfonates of ethoxylated alkylphenols, sulfonates of alkoxylated aryl phenols, sulfonates of condensed naphthalenes, sulfonates of dodecyl-and tridecylbenzenes, sulfonates of naphthalenes and alkyl naphthalenes, sulfosuccinates or sulfosuccinamates. Examples of sulphates are sulphates of fatty acids and oils, of ethoxylated alkylphenols, of alcohols, of ethoxylated alcohols, or of fatty acid esters. 5 Examples of phosphates are phosphate esters. Examples of carboxylates are alkyl carboxylates, and carboxylated alcohol or alkylphenol ethoxylates. Suitable nonionic surfactants are for instance alkoxylates, N-substituted fatty acid amides, amine oxides, esters, sugar-based surfactants, polymeric surfactants, and mixtures thereof. Examples of alkoxylates are compounds such as alcohols, alkylphenols, amines, amides, arylphenols, fatty acids or 10 fatty acid esters which have been alkoxylated with 1 to 50 equivalents. Ethylene oxide and / or propylene oxide may be employed for the alkoxylation, preferably ethylene oxide. Examples of N-substituted fatty acid amides are fatty acid glucamides or fatty acid alkanolamides. Examples of esters are fatty acid esters, glycerol esters or monoglycerides. Examples of sugar-based surfactants are sorbitans, ethoxylated sorbitans, sucrose, and glucose esters or alkylpolyglucosides. 15 Examples of polymeric surfactants are homo- or copolymers of vinyl pyrrolidone, vinyl alcohols, or vinyl acetate. Suitable cationic surfactants are for instance quaternary surfactants, for example quaternary ammonium compounds with one or two hydrophobic groups, or salts of long-chain primary amines. Suitable amphoteric surfactants are alkylbetains and imidazolines. Suitable block polymers are for instance 20 block polymers of the A-B or A-B-A type comprising blocks of polyethylene oxide and polypropylene oxide, or of the A-B-C type comprising alkanol, polyethylene oxide and polypropylene oxide. Suitable polyelectrolytes are for instance polyacids or polybases. Examples of polyacids are alkali salts of polyacrylic acid or polyacid comb polymers. Examples of polybases are polyvinyl amines or polyethylene amines. 25 Suitable adjuvants are compounds, which have a negligible or even no pesticidal activity themselves, and which improve the biological performance of the compound of Formula (I) on the target. Suitable thickeners are for instance polysaccharides (e. g. xanthan gum, carboxymethyl cellulose), inorganic clays (organically modified or unmodified), polycarboxylates, and silicates. Suitable bactericides are for instance bronopol and isothiazolinone derivatives such as 30 alkylisothiazolinones and benzisothiazolinones. Suitable anti-freezing agents are for instance ethylene glycol, propylene glycol, urea, and glycerin. Suitable anti-foaming agents are for instance silicones, long chain alcohols, and salts of fatty acids. PI External Suitable colorants (e. g. in red, blue, or green) are for instance pigments of low water solubility and water-soluble dyes. Examples are inorganic colorants (e. g. iron oxide, titan oxide, iron hexacyanoferrate) and organic colorants (e. g. alizarin-, azo-, and phthalocyanine colorants). Suitable tackifiers or binders are for instance polyvinyl pyrrolidones, polyvinyl acetates, polyvinyl 5 alcohols, polyacrylates, biological or synthetic waxes, and cellulose ethers. Another embodiment of the present invention provides agrochemical compositions containing a compound of Formula (I), which comprise the active substance between 0.01 and 95 % by weight, preferably between 0.1 and 90 %, and more preferably between 1 and 70 %, in particular between 10 and 60 % by weight of the active substance. The active substances are employed in a purity of from 90 10 % to 100 %, preferably from 95 % to 100 % (according to NMR spectrum). Water-soluble concentrates (LS), suspoemulsions (SE), flowable concentrates (FS), powders for dry treatment (DS), water-dispersible powders for slurry treatment (WS), water-soluble powders (SS), emulsions (ES), emulsifiable concentrates (EC) and gels (GF) are usually employed for the purposes of the treatment of plant propagation materials, particularly seeds. The compositions in question give, after 15 two-to-tenfold dilution, active substance concentrations of from 0.01 to 60 % by weight, preferably from 0.1 to 40 % by weight in the ready-to-use preparations. Application can be carried out before or during sowing. Methods for applying compounds of Formula (I) and compositions thereof, respectively, on to plant propagation material, especially seeds, include dressing, coating, pelleting, dusting, soaking and in- 20 furrow application methods of the propagation material. Preferably, compounds of Formula (I) or the compositions thereof, respectively, are applied on to the plant propagation material in a way such that the germination is not induced, e. g. by seed dressing, pelleting, coating, and dusting. When employed in plant protection, the amounts of active substances applied are, depending on the kind of effect desired, ranging from 0.001 to 2 kg per ha, preferably from 0.005 to 2 kg per ha, more 25 preferably from 0.05 to 0.9 kg per ha, in particular from 0.1 to 0.75 kg per ha. For the treatment of plant propagation materials such as seeds, e. g. by dusting, coating or drenching seed, amounts of the active substance ranging from 0.1 to 1000 g, preferably from 1 to 1000 g, more preferably from 1 to 100 g and most preferably from 5 to 100 g, per 100 kilogram of plant propagation material (preferably seed) are generally required. 30 When used in the protection of materials or stored products, the amount of active substance applied depends on the kind of application area and on the desired effect. Amounts customarily applied in the protection of materials are ranging from 0.001 g to 2 kg, preferably from 0.005 g to 1 kg, of active substance per cubic meter of treated material. Various types of oils, wetters, adjuvants, fertilizer, or micronutrients, and other pesticides (e.g., 35 herbicides, insecticides, fungicides, growth regulators, safeners) may be added to the active substances or the compositions comprising them as premix or, if appropriate, not until immediately prior to use PI External (tank mix). These agents can be admixed with the compositions according to the present invention in a weight ratio of 1:100 to 100:1, preferably 1:10 to 10:1. The user can apply the compositions according to the present invention usually from a predosage device, a knapsack sprayer, a spray tank, a spray plane, or an irrigation system. Usually, the agrochemical 5 composition is made up with water, buffer, and / or further auxiliaries to the desired application concentration and the ready-to-use spray liquor or the agrochemical composition according to the present invention is obtained in this way. Usually, 20 to 2000 liters, preferably 50 to 400 liters, of the ready-to-use spray liquor are applied per hectare of agricultural useful area. According to one embodiment, individual components of the composition according to the present 10 invention such as parts of a kit or parts of a binary or ternary mixture may be mixed by the user himself in a spray tank and further auxiliaries may be used in addition, if appropriate. The compounds and compositions of the present invention are in this way agronomically useful for protecting field crops from phytophagenic invertebrate pests, and also nonagronomically for protecting other horticultural crops and plants from phytophagenic invertebrate pests. This utility includes 15 protecting crops and other plants (i.e. both agronomically and nonagronomically) that contain genetic material introduced by genetic engineering (i.e. transgenic) or modified by mutagenesis to provide advantageous traits. Compounds of the present invention are characterized by favorable metabolic and / or soil residual patterns and exhibit activity controlling a spectrum of agronomic and non-agronomic invertebrate pests. 20 Compounds of the present invention are preventively and / or curatively valuable active ingredients in the field of pest control, even at low rates of application, which can be used against pesticide resistant pests such as insects, and / or have a very favorable biocidal spectrum and are well tolerated by warm- blooded species, fish, and plants. Compounds of the present invention display activity against economically important agronomic, forest, 25 greenhouse, nursery, ornamentals, food and fiber, public and animal health, domestic and commercial structure, household and stored product pests. These include larvae of the order Lepidoptera such as armyworms, cutworms, loopers, and heliothines in the family Noctuidae (e.g., fall armyworm (Spodoptera fugiperda J. E. Smith), beet armyworm (Spodoptera exigua Hubner), black cutworm (Agrotis ipsilon Hufnagel), cabbage looper (Trichoplusia ni Hubner), tobacco budworm (Heliothis 30 virescens Fabricius)); borers, casebearers, webworms, coneworms, cabbageworms, and skeletonizers from the family Pyralidae (e.g., European corn borer (Ostrinia nubilalis Hubner), navel orangeworm (Amyelois transitella Walker), corn root webworm (Crambus caliginosellus Clemens), sod webworm (Herpetogramma licarsisalis Walker)); leafrohers, budworms, seed worms, and fruit worms in the family Tortricidae (e.g., codling moth (Cydia pomonella Linnaeus), grape berry moth (Endopiza viteana 35 Clemens), oriental fruit moth (Grapholita molesta Busck)); and many other economically important lepidoptera (e.g., diamondback moth (Plutella xylostella Linnaeus), pink bollworm (Pectinophora PI External gossypiella Saunders), gypsy moth (Lymantria dispar Linnaeus)); nymphs and adults of the order Blattodea mcluding cockroaches from the families Blattellidae and Blattidae (e.g., oriental cockroach (Blatta orientalis Linnaeus), Asian cockroach (Blatella asahinai Mizukubo), German cockroach (Blattella gemnanica Linnaeus), brownbanded cockroach (Supella longipalpa Fabricius), American 5 cockroach (Periplaneta americana Linnaeus), brown cockroach (Periplaneta brunnea Burmeister), Madeira cockroach (Leucophaea maderae Fabricius)); foliar feeding larvae and adults of the order Coleoptera including weevils from the families Anthribidae, Bruchidae, and Curculionidae (e.g., boll weevil (Anthonomus grandis Boheman), rice water weevil (Lissorhoptrus oryzophilus Kuschel), granary weevil (Sitophilus granarius Linnaeus), rice weevil (Sitophilus oryzae Linnaeus)); flea beetles, 10 cucumber beetles, rootworms, leaf beetles, potato beetles, and leafminers in the family Chrysomelidae (e.g., Colorado potato beetle (Leptinotarsa decemLineata Say), western corn rootworm (Diabrotica virgifera LeConte)); chafers and other beetles from the family Scaribaeidae (e.g., Japanese beetle (Popillia japonica Newman) and European chafer (Rhizotrogus majalis Razoumowsky)); carpet beetles from the family Dermestidae; wireworms from the family Elateridae; bark beetles from the family 15 Scolytidae and flour beetles from the family Tenebrionidae. In addition it includes: adults and larvae of the order Dermaptera including earwigs from the family Forficulidae (e.g., European earwig (Forficula auricularia Linnaeus), black earwig (Chelisoches mono Fabricius)); adults and nymphs of the orders Hemiptera and Homoptera such as plant bugs from the family Miridae, cicadas from the family Cicadidae, leafhoppers (e.g., Empoasca spp.) from the family Cicadellidae, planthoppers from the 20 families Fulgoroidae and Delphacidae, treehoppers from the family Membracidae, psyllids from the family Psyllidae, whitefiies from the family Aleyrodidae, aphids from the family Aphididae, phylloxera from the family Phylloxeridae, mealybugs from the family Pseudococcidae, scales from the families Coccidae, Diaspididae, and Margarodidae, lace bugs from the family Tingidae, stink bugs from the family Pentatomidae, cinch bugs (e.g., Blissus spp.) and other seed bugs from the family Lygaeidae, 25 spittlebugs from the family Cercopidae squash bugs from the family Coreidae, and red bugs and cotton stainers from the family Pyrrhocoridae. Also included are adults and larvae of the order Acari (mites) such as spider mites and red mites in the family Tetranychidae (e.g., European red mite (Panonychus ulmi Koch), two spotted spider mite (Tetranychus urticae Koch), McDaniel mite (Tetranychus mcdanieli McGregor)), flat mites in the family Tenuipalpidae (e.g., citrus flat mite (Brevipalpus lewisi 30 McGregor)), rust and bud mites in the family Eriophyidae and other foliar feeding mites and mites important in human and animal health, i.e. dust mites in the family Epidermoptidae, follicle mites in the family Demodicidae, grain mites in the family Glycyphagidae, ticks in the order Ixodidae (e.g., deer tick (Ixodes scapularis Say), Australian paralysis tick (Ixodes holocyclus Neumann), American dog tick (Dermacentor variabilis Say), lone star tick (Amblyomma americanum Linnaeus) and scab and itch 35 mites in the families Psoroptidae, Pyemotidae, and Sarcoptidae; adults and immatures of the order Orthoptera including grasshoppers, locusts and crickets (e.g., migratory grasshoppers (e.g., Melanoplus sanguinipes Fabricius, M. differentialis Thomas), American grasshoppers (e.g., Schistocerca PI External americana Drury), desert locust (Schistocerca gregaria Forskal), migratory locust (Locusta migratoria Linnaeus), house cricket (Acheta domesticus Linnaeus), mole crickets (Gryllotalpa spp.)); adults and immatures of the order Diptera including leafminers, midges, fruit flies (Tephritidae), fruit flies (e.g., Oscinella frit Linnaeus), soil maggots, house flies (e.g., Musca domestica Linnaeus), lesser house flies 5 (e.g., Fannia canicularis Linnaeus, F.femoralis Stein), stable flies (e.g., Stomoxys calcitrans Linnaeus), face flies, horn flies, blow flies (e.g., Chiysomya spp., Phonnia spp.), and other muscoid fly pests, horse flies (e.g., Tabanus spp.), botflies (e.g., Gastrophilus spp., Oestrus spp.), cattle grubs (e.g., Hypoderma spp.), deer flies (e.g., Chrysops spp.), keds (e.g., Melophagus ovinus Linnaeus) and other Brachycera, mosquitoes (e.g., Aedes spp., Anopheles spp., Culex spp.), black flies (e.g., Prosimulium spp., Simulium 10 spp.), biting midges, sand flies, sciarids, and other Nematocera; adults and immatures of the order Thysanoptera including onion thrips (Thrips tabaci Lindeman) and other foliar feeding thrips; insect pests of the order Hymenoptera including ants (e.g., red carpenter ant (Camponotus ferrugineus Fabricius), black carpenter ant (Camponotus pennsylvanicus De Geer), Pharaoh ant (Monomorium pharaonis Linnaeus), little fire ant (Wasmannia auropunctata Roger), fire ant (Solenopsis geminata 15 Fabricius), red imported fire ant (Solenopsis invicta Buren), Argentine ant (Iridomyrmex humilis Mayr), crazy ant (Paratrechina longicornis Latreille), pavement ant (Tetramorium caespitum Linnaeus), cornfield ant (Lasius alienus Fδrster), odorous house ant (Tapinoma sessile Say)), bees (including carpenter bees), hornets, yellow jackets and wasps; insect pests of the order Isoptera including the eastern subterranean termite (Reticulitermes flavipes Kollar), western subterranean termite 20 (Reticulitermes hesperus Banks), Formosan subterranean termite (Coptotermes formosanus Shiraki), West Indian drywood termite (Incisitermes immigrans Snyder) and other termites of economic importance; insect pests of the order Thysanura such as silverfish (Lepisma saccharina Linnaeus) and firebrat (Thermobia domestica Packard); insect pests of the order Mallophaga and including the head louse (Pediculus humanus capitis De Geer), body louse (Pediculus humanus Linnaeus), chicken body 25 louse (Menacanthus stramineus Nitszch), dog biting louse (Trichodectes cams De Geer), fluff louse (Goniocotes gallinae De Geer), sheep body louse (Bovicola ovis Schrank), short-nosed cattle louse (Haematopinus eurystemus Nitzsch), long-nosed cattle louse (Linognathus vituli Linnaeus) and other sucking and chewing parasitic lice that attack man and animals; insect pests of the order Siphonoptera including the oriental rat flea (Xenopsylla cheopis Rothschild), cat flea (Ctenocephalides felis Bouche), 30 dog flea (Ctenocephatides canis Curtis), hen flea (Ceratophyllus gallinae Schrank), sticktight flea (Echidnophaga gallinacea Westwood), human flea (Pulex irritans Linnaeus) and other fleas afflicting mammals and birds. Additional arthropod pests covered include: spiders in the order Araneae such as the brown recluse spider (Loxosceles reclusa Gertsch and Mulaik) and the black widow spider (Latrodectus mactans Fabricius), and centipedes in the order Scutigeromorpha such as the house 35 centipede (Scutigera coleoptrata Linnaeus). Activity also includes members of the Classes Nematoda, Cestoda, Trematoda, and Acanthocephala including economically important members of the orders Strongylida, Ascaridida, Oxyurida, Rhabditida, Spirurida, and Enoplida such as but not limited to PI External economically important agricultural pests (i.e. root knot nematodes in the genus Meloidogyne, lesion nematodes in the genus Pratylenchus, stubby root nematodes in the genus Trichodorus, etc.) and animal and human health pests (i.e. all economically important flukes, tapeworms, and roundworms such as Strongylus vulgaris in horses, Toxocara canis in dogs, Haemonchus contortus in sheep, Dirofllaria 5 immitis Leidy in dogs, Anoplocephala peifoliata in horses, Fasciola hepatica Linnaeus in ruminants, etc.). Compounds of the present invention show particularly activity against pests in the order Homoptera including: Acyrthisiplionpisum Harris (pea aphid), Aphis craccivora Koch (cowpea aphid), Aphis fabae Scopoli (black bean aphid), Aphis gossypii Glover (cotton aphid, melon aphid), Aphis pomi De Geer 10 (apple aphid), Aphis spiraecola Patch (spirea aphid), Aulacorthum solani Kaltenbach (foxglove aphid), Chaetosiphon fragaefolii Cockerell (strawberry aphid), Diuraphis noxia Kurdjumov / Mordvilko (Russian wheat aphid), Dysaphis plantaginea Paaserini (rosy apple aphid), Eriosoma lanigerum Hausmann (woolly apple aphid), Hyalopterus pruni Geoffroy (mealy plum aphid), Lipaphis erysimi Kaltenbach (tarnip aphid), Metopolophium dirrhodum Walker (cereal aphid), Macrosipum euphorbiae 15 Thomas (potato aphid), Myzus persicae Sulzer (peach-potato aphid, green peach aphid), Nasonovia ribisnigri Mosley (lettuce aphid), Pemphigus spp. (root aphids and gall aphids), Rhopalosiphum maidis Fitch (corn leaf aphid), Rhopalosiphum padi Linnaeus (bird cherry-oat aphid), Schizaphis graminum Rondani (greenbug), Sitobion avenae Fabricius (English grain aphid), Therioaphis maculata Buckton (spotted alfalfa aphid), Toxoptera aurantii, Boyer de Fonscolombe (black citrus aphid), and Toxoptera 20 citiicida Kirkaldy (brown citrus aphid); Adelges spp. (adelgids); Phylloxera devastatrix Pergande (pecan phylloxera); Bemisia tabaci Gennadius (tobacco whitefly, sweetpotato whitefly), Bemisia argentifolii Bellows and Perring (silverleaf whitefly), Dialeurodes citri Ashmead (citrus whitefly) and Trialeurodes vaporariorum Westwood (greenhouse whitefly); Empoasca fabae Harris, (potato leafhopper), Laodelphax striatellus Fallen (smaller brown planthopper), Macrolestes quadrilineatus 25 Forbes (aster leafhopper), Nephotettix cinticeps Uhler (green leafhopper), Nephotettix nigropictus Stal (rice leafhopper), Nilaparvata lugens Stal (brown planthopper), Peregrinus maidis Ashmead (corn planthopper), Sogatella furcifera Horvath (white-backed planthopper), Sogatodes orizicola Muir (rice delphacid), Typhlocyba pomaria McAfee white apple leafhopper, Erythroneoura spp. (grape leafhoppers); Magicidada septendecim Linnaeus (periodical cicada); Icerya purchasi Maskell (cottony 30 cushion scale), Quadraspidiotus perniciosus Comstock (San Jose scale); Planococcus citri Risso (citrus mealybug); Pseudococcus spp. (other mealybug complex); Cacopsylla pyricola Foerster (pear psylla), Trioza diospyri Ashmead (persimmon psylla). Compounds of the present invention also have commercially significant activity on members from the order of Lepidoptera (e.g., Alabama argillacea Hubner (cotton leaf worm), Archips argyrospila Walker (fruit tree leaf roller), A. rosana Linnaeus 35 (European leaf roller) and other Archips species, Chilo suppressalis Walker (rice stem borer), Cnaphalocrosis medinalis Guenee (rice leaf roller), Crambus caliginosellus Clemens (corn root PI External webworm), Crambus teterrellus Zincken (bluegrass webworm), Cydia pomonella Linnaeus (codling moth), Earias insulana Boisduval (spiny bollworm), Earias vittella Fabricius (spotted bollworm), Helicoveipa armigera Hύbner (American bollworm), Helicoverpa zea Boddie (corn earworm), Heliothis virescens Fabricius (tobacco budworm), Herpetogramma licarsisalis Walker (sod webworm), 5 Lobesia botrana Denis and Schiffeπnύller (grape berry moth), Pectinophora gossypiella Saunders (pink bollworm), Phyllocnistis citrella Stainton (citrus leafminer), Pieris brassicae Linnaeus (large white butterfly), Pieris rapae Linnaeus (small white butterfly), Plutella xylostella Linnaeus (diamondback moth), Spodoptera exigua Hubner (beet armyworm), Spodoptera litura Fabricius (tobacco cutworm, cluster caterpillar), Spodoptera frugiperda J. E. Smith (fall armyworm), Trichoplusia ni Hύbner 10 (cabbage looper) and Tula absoluta Meyrick (tomato leafminer)). The compounds also have activity on members from the order Hemiptera including: Acrostemum hilare Say (green stink bug), Anasa tristis De Geer (squash bug), Blissus leucopterus Say (chinch bug), Corythuca gossypii Fabricius (cotton lace bug), Cyrtopeltis modesta Distant (tomato bug), Dysdercus suturellus Herrich-S chaffer (cotton stainer), Euchistus servus Say (brown stink bug), Euchistus 15 variolrius Palisot deBeauvois (one-spotted stink bug), Graptόsthetus spp. (complex of seed bugs), Leptoglossus corculus Say (leaf- footed pine seed bug), Lygus lineolaris Palisot de Beauvois (tarnished plant bug), Nezara viridula Linnaeus (southern green stink bug), Oebalus pugnax Fabricius (rice stink bug), Oncopeltus fasciatus DaEas (large milkweed bug), Pseudatomoscelis seriatus Reuter (cotton fleahopper). 20 Other insect orders controlled by compounds of the present invention include: Thysanoptera (e.g., Frankliniella occidentalis Pergande (western flower thrip), Scirthothήps citri Moulton (citrus thrip), Sericothrips variabilis Beach (soybean thrip), and Thrips tabaci Lindeman (onion thrip); and the order Coleoptera (e.g., Leptinotarsa decemLineata Say (Colorado potato beetle), Epilachna varivestis Mulsant (Mexican bean beetle), and wireworms of the genera Agriotes, Athous or Limonius). 25 Particularly, the present invention provides the compounds of Formula (I) as active and useful compounds for controlling insects selected form sucking or piercing insects such as insects from the genera Hemiptera Diptera and Thysanoptera, , in particular the following species: Hemiptera, in particular aphids: Acyrthosiphon onobrychis, Adelges laricis, Aphidula nasturtii, Aphis fabae, Aphis forbesi, Aphis pomi, Aphis gossypii, Aphis grossulariae, Aphis schneideri, Aphis 30 spiraecola, Aphis sambuci, Acyrthosiphon pisum, Aulacorthum solani, Brachycaudus cardui, Brachycaudus helichrysi, Brachycaudus persicae, Brachycaudus prunicola, Brevicoryne brassicae, Capitophorus horni, Cerosipha gossypii, Chaetosiphon fragaefolii, Cryptomyzus ribis, Dreyfusia nordmannianae, Dreyfusia piceae, Dysaphis radicola, Dysaulacorthum pseudosolani, Dysaphis plantaginea, Dysaphis pyri, Empoasca fabae, Hyalopterus pruni, Hyperomyzus lactucae, Macrosiphum 35 avenae, Macrosiphum euphorbiae, Macrosiphon rosae, Megoura viciae, Melanaphis pyrarius, Metopolophium dirhodum, Myzus persicae, Myzus ascalonicus, Myzus cerasi, Myzus varians, PI External Nasonovia ribis-nigri, Nilaparvata lugens, Pemphigus bursarius, Perkinsiella saccharicida, Phorodon humuli, Psylla mali, Psylla piri, Rhopalomyzus ascalonicus, Rhopalosiphum maidis, Rhopalosiphum padi, Rhopalosiphum insertum, Sappaphis mala, Sappaphis mali, Schizaphis graminum, Schizoneura lanuginosa, Sitobion avenae, Trialeurodes vaporariorum, Toxoptera aurantii, and Viteus vitifolii; 5 Diptera: e.g., Aedes aegypti, Aedes albopictus, Aedes vexans, Anastrepha ludens, Anopheles maculipennis, Anopheles crucians, Anopheles albimanus, Anopheles gambiae, Anopheles freeborni, Anopheles leucosphyrus, Anopheles minimus, Anopheles quadrimaculatus, Calliphora vicina, Ceratitis capitata, Chrysomya bezziana, Chrysomya hominivorax, Chrysomya macellaria, Chrysops discalis, Chrysops silacea, Chrysops atlanticus, Cochliomyia hominivorax, Contarinia sorghicola Cordylobia 10 anthropophaga, Culicoides furens, Culex pipiens, Culex nigripalpus, Culex quinquefasciatus, Culex tarsalis, Culiseta inornata, Culiseta melanura, Dacus cucurbitae, Dacus oleae, Dasineura brassicae, Delia antique, Delia coarctata, Delia platura, Delia radicum, Dermatobia hominis, Fannia canicularis, Geomyza Tripunctata, Gasterophilus intestinalis, Glossina morsitans, Glossina palpalis, Glossina fuscipes, Glossina tachinoides, Haematobia irritans, Haplodiplosis equestris, Hippelates spp., 15 Hylemyia platura, Hypoderma lineata, Leptoconops torrens, Liriomyza sativae, Liriomyza trifolii, Lucilia caprina, Lucilia cuprina, Lucilia sericata, Lycoria pectoralis, Mansonia titillanus, Mayetiola destructor, Musca autumnalis, Musca domestica, Muscina stabulans, Oestrus ovis, Opomyza florum, Oscinella frit, Pegomya hysocyami, Phorbia antiqua, Phorbia brassicae, Phorbia coarctata, Phlebotomus argentipes, Psorophora columbiae, Psila rosae, Psorophora discolor, Prosimulium 20 mixtum, Rhagoletis cerasi, Rhagoletis pomonella, Sarcophaga haemorrhoidalis, Sarcophaga spp., Simulium vittatum, Stomoxys calcitrans, Tabanus bovinus, Tabanus atratus, Tabanus lineola, and Tabanus similis, Tipula oleracea, and Tipula paludosa; Thysanoptera: Frankliniella fusca, Frankliniella occidentalis, Frankliniella tritici, Scirtothrips citri, Thrips oryzae, Thrips palmi, and Thrips tabaci. 25 In a further embodiment, the compounds of Formula (I) , their N-oxides, their stereo-isomers, their tautomers, their polymorphs and their salts are also suitable for efficiently combating the following pests: Insects from the order of the lepidopterans (Lepidoptera), for example Agrotis ypsilon, Agrotis segetum, Alabama argillacea, Anticarsia gemmatalis, Argyresthia conjugella, Autographa gamma, Bupalus piniarius, Cacoecia murinana, Capua reticulana, Cheimatobia brumata, Chilo infuscatellus, 30 Choristoneura fumiferana, Choristoneura occidentalis, Cirphis unipuncta, Cydia pomonella, Dendrolimus pini, Diaphania nitidalis, Diatraea grandiosella, Earias insulana, Earias vittella, Elasmopalpus lignosellus, Eupoecilia ambiguella, Evetria bouliana, Feltia subterranea, Galleria mellonella, Grapholita funebrana, Grapholita molesta, Helicoverpa armigera, Helicoverpa virescens, Helicoverpa zea, Hellula undalis, Hibernia defoliaria, Hyphantria cunea, Hyponomeuta malinellus, 35 Keiferia lycopersicella, Lambdina fiscellaria, Laphygma exigua, Leucoptera coffeella, Leucoptera scitella, Lithocolletis blancardella, Lobesia botrana, Loxostege sticticalis, Leucinodes orbonalis, PI External Lymantria dispar, Lymantria monacha, Lyonetia clerkella, Malacosoma neustria, Mamestra brassicae, Orgyia pseudotsugata, Ostrinia nubilalis, Panolis flammea, Pectinophora gossypiella, Peridroma saucia, Phalera bucephala, Phthorimaea operculella, Phyllocnistis citrella, Pieris brassicae, Plathypena scabra, Plutella xylostella, Pseudoplusia includens, Rhyacionia frustrana, Scirpophaga 5 incertulas, Scrobipalpula absoluta, Sitotroga cerealella, Sparganothis pilleriana, Spodoptera frugiperda, Spodoptera littoralis, Spodoptera litura, Spodoptera exigua, Thaumatopoea pityocampa, Tortrix viridana, Trichoplusia ni, and Zeiraphera canadensis; and Beetles (Coleoptera), for example Agrilus sinuatus, Agriotes lineatus, Agriotes obscurus, Amphimallus solstitialis, Anisandrus dispar, Anthonomus grandis, Anthonomus pomorum, Aphthona euphoridae, 10 Athous haemorrhoidalis, Atomaria linearis, Blastophagus piniperda, Blitophaga undata, Bruchus rufimanus, Bruchus pisorum, Bruchus lentis, Byctiscus betulae, Cassida nebulosa, Cerotoma trifurcata, Cetonia aurata, Ceuthorrhynchus assimilis, Ceuthorrhynchus napi, Chaetocnema tibialis, Conoderus vespertinus, Crioceris asparagi, Ctenicera ssp., Diabrotica longicornis, Diabrotica semipunctata, Diabrotica undecimpunctata Diabrotica speciosa, Diabrotica virgifera, Epilachna varivestis, Epitrix 15 hirtipennis, Eutinobothrus brasiliensis, Hylobius abietis, Hypera brunneipennis, Hypera postica, Ips typographus, Lema bilineata, Lema melanopus, Leptinotarsa decemLineata, Limonius californicus, Lissorhoptrus oryzophilus, Melanotus communis, Meligethes aeneus, Melolontha hippocastani, Melolontha, Oulema oryzae, Otiorrhynchus sulcatus, Otiorrhynchus ovatus, Phaedon cochleariae, Phyllobius pyri, Phyllotreta chrysocephala, Phyllophaga sp., Phyllopertha horticola, Phyllotreta 20 nemorum, Phyllotreta striolata, Popillia japonica, Sitona lineatus, and Sitophilus granaria; Flies, mosquitoes (Diptera), e.g., Aedes aegypti, Aedes albopictus, Aedes vexans, Anastrepha ludens, Anopheles maculipennis, Anopheles crucians, Anopheles albimanus, Anopheles gambiae, Anopheles freeborni, Anopheles leucosphyrus, Anopheles minimus, Anopheles quadrimaculatus, Calliphora vicina, Ceratitis capitata, Chrysomya bezziana, Chrysomya hominivorax, Chrysomya macellaria, 25 Chrysops discalis, Chrysops silacea, Chrysops atlanticus, Cochliomyia hominivorax, Contarinia sorghicola Cordylobia anthropophaga, Culicoides furens, Culex pipiens, Culex nigripalpus, Culex quinquefasciatus, Culex tarsalis, Culiseta inornata, Culiseta melanura, Dacus cucurbitae, Dacus oleae, Dasineura brassicae, Delia antique, Delia coarctata, Delia platura, Delia radicum, Dermatobia hominis, Fannia canicularis, Geomyza Tripunctata, Gasterophilus intestinalis, Glossina morsitans, 30 Glossina palpalis, Glossina fuscipes, Glossina tachinoides, Haematobia irritans, Haplodiplosis equestris, Hippelates spp., Hylemyia platura, Hypoderma lineata, Leptoconops torrens, Liriomyza sativae, Liriomyza trifolii, Lucilia caprina, Lucilia cuprina, Lucilia sericata, Lycoria pectoralis, Mansonia titillanus, Mayetiola destructor, Musca autumnalis, Musca domestica, Muscina stabulans, Oestrus ovis, Opomyza florum, Oscinella frit, Pegomya hysocyami, Phorbia antiqua, Phorbia 35 brassicae, Phorbia coarctata, Phlebotomus argentipes, Psorophora columbiae, Psila rosae, Psorophora discolor, Prosimulium mixtum, Rhagoletis cerasi, Rhagoletis pomonella, Sarcophaga PI External haemorrhoidalis, Sarcophaga spp., Simulium vittatum, Stomoxys calcitrans, Tabanus bovinus, Tabanus atratus, Tabanus lineola, and Tabanus similis, Tipula oleracea, and Tipula paludosa; termites (Isoptera), e.g., Calotermes flavicollis, Leucotermes flavipes, Heterotermes aureus, Reticulitermes flavipes, Reticulitermes virginicus, Reticulitermes lucifugus, Reticulitermes santonensis, Reticulitermes 5 grassei, Termes natalensis, and Coptotermes formosanus; cockroaches (Blattaria Blattodea), e.g., Blattella germanica, Blattella asahinae, Periplaneta americana, Periplaneta japonica, Periplaneta brunnea, Periplaneta fuligginosa, Periplaneta australasiae, and Blatta orientalis; ants, bees, wasps, sawflies (Hymenoptera), e.g., Athalia rosae, Atta cephalotes, Atta capiguara, Atta cephalotes, Atta laevigata, Atta robusta, Atta sexdens, Atta texana, Crematogaster spp., Hoplocampa minuta, 10 Hoplocampa testudinea, Lasius niger, Monomorium pharaonis, Solenopsis geminata, Solenopsis invicta, Solenopsis richteri, Solenopsis xyloni, Pogonomyrmex barbatus, Pogonomyrmex californicus, Pheidole megacephala, Dasymutilla occidentalis, Bombus spp., Vespula squamosa, Paravespula vulgaris, Paravespula pennsylvanica, Paravespula germanica, Dolichovespula maculata, Vespa crabro, Polistes rubiginosa, Camponotus floridanus, and Linepithema humile; crickets, grasshoppers, 15 locusts (Orthoptera), e.g., Acheta domestica, Gryllotalpa, Locusta migratoria, Melanoplus bivittatus, Melanoplus femurrubrum, Melanoplus mexicanus, Melanoplus sanguinipes, Melanoplus spretus, Nomadacris septemfasciata, Schistocerca americana, Schistocerca gregaria, Dociostaurus maroccanus, Tachycines asynamorus, Oedaleus senegalensis, Zonocerus variegatus, Hieroglyphus daganensis, Kraussaria angulifera, Calliptamus italicus, Chortoicetes terminifera, and Locustana 20 pardalina; Araneida, e.g., Latrodectus mactans, and Loxosceles reclusa; fleas (Siphonaptera), e.g., Ctenocephalides felis, Ctenocephalides canis, Xenopsylla cheopis, Pulex irritans, Tunga penetrans, and Nosopsyllus fasciatus, silverfish, firebrat (Thysanura), e.g., Lepisma saccharina and Thermobia domestica, centipedes (Chilopoda), e.g., Scutigera oleoptrata, millipedes (Diplopoda), e.g., Narceus spp., Earwigs (Dermaptera), e.g., forficula auricularia, lice (Phthiraptera), e.g., Pediculus humanus 25 capitis, Pediculus humanus corporis, Pthirus pubis, Haematopinus eurysternus, Haematopinus suis, Linognathus vituli, Bovicola bovis, Menopon allinae, Menacanthus stramineus and Solenopotes capillatus. Collembola (springtails), e.g., Onychiurus ssp. They are also suitable for controlling Nematodes: plant parasitic nematodes such as root knot nematodes, Meloidogyne hapla, Meloidogyne incognita, Meloidogyne javanica, and other Meloidogyne 30 species; cyst-forming nematodes, Globodera rostochiensis and other Globodera species; Heterodera avenae, Heterodera glycines, Heterodera schachtii, Heterodera trifolii, and other Heterodera species; Seed gall nematodes, Anguina species; Stem and foliar nematodes, Aphelenchoides species; Sting nematodes, Belonolaimus longicaudatus, and other Belonolaimus species; Pine nematodes, Bursaphelenchus xylophilus and other Bursaphelenchus species; Ring nematodes, Criconema species, 35 Criconemella species, Criconemoides species, Mesocriconema species; Stem and bulb nematodes, Ditylenchus destructor, Ditylenchus dipsaci, and other Ditylenchus species; Awl nematodes, PI External Dolichodorus species; Spiral nematodes, Heliocotylenchus multicinctus, and other Helicotylenchus species; Sheath and sheathoid nematodes, Hemicycliophora species and Hemicriconemoides species; Hirshmanniella species; Lance nematodes, Hoploaimus species; false rootknot nematodes, Nacobbus species; Needle nematodes, Longidorus elongatus, and other Longidorus species; Lesion nematodes, 5 Pratylenchus neglectus, Pratylenchus penetrans, Pratylenchus curvitatus, Pratylenchus goodeyi, and other Pratylenchus species; Burrowing nematodes, Radopholus similis and other Radopholus species; Reniform nematodes, Rotylenchus robustus, and other Rotylenchus species; Scutellonema species; Stubby root nematodes, Trichodorus primitivus, and other Trichodorus species, Paratrichodorus species; Stunt nematodes, Tylenchorhynchus claytoni, Tylenchorhynchus dubius, and other 10 Tylenchorhynchus species; Citrus nematodes, Tylenchulus species; Dagger nematodes, Xiphinema species; and other plant parasitic nematode species. The compounds of Formula (I) and their salts are also useful for controlling arachnids (Arachnoidea) such as acarians (Acarina), e.g., of the families Argasidae, Ixodidae, and Sarcoptidae such as Amblyomma americanum, Amblyomma variegatum, Argas persicus, Boophilus annulatus, Boophilus 15 decoloratus, Boophilus microplus, Dermacentor silvarum, Hyalomma truncatum, Ixodes ricinus, Ixodes rubicundus, Ornithodorus moubata, Otobius megnini, Dermanyssus gallinae, Psoroptes ovis, Rhipicephalus appendiculatus, Rhipicephalus evertsi, Sarcoptes scabiei, and Eriophyidae spp. such as Aculus schlechtendali, Phyllocoptrata oleivora, and Eriophyes sheldoni; Tarsonemidae spp. such as Phytonemus pallidus and Polyphagotarsonemus latus; Tenuipalpidae spp. such as Brevipalpus 20 phoenicis; Tetranychidae spp. such as Tetranychus cinnabarinus, Tetranychus kanzawai, Tetranychus pacificus, Tetranychus telarius, and Tetranychus urticae, Panonychus ulmi, Panonychus citri, and oligonychus pratensis. In one preferred embodiment, the present invention of the compounds of Formula (I) are especially 25 useful for controlling for example western flower thrips (Frankliniella occidentalis), potato leafhopper (Empoasca fabae), rice brown planthopper (Nilaparvata lugens), rice green leafhopper (Nephotettix virescens), cotton / melon aphid (Aphis gossypii), green peach aphid (Myzus persicae), tobacco / sweetpotato whitefly (Bemisia tabaci), and silverleaf whitefly (Bemisia argentifolii). In one embodiment, the present invention further relates to a composition comprising a biologically 30 effective amount of the compound of Formula (I) and at least one additional biological active compatible compound selected from fungicides, insecticides, nematicides, acaricides, biopesticides, herbicides, plant growth regulators, biostimulants, antibiotics, fertilizers, and nutrients. Compounds used in the composition and in combination with the compound of Formula (I) are also termed as active compatible compounds. 35 The known and reported fungicides, insecticides, nematicides, acaricides, biopesticides, herbicides, plant growth regulators, biostimulants, antibiotics, and nutrients can be combined with at least one PI External compound of the Formula (I) of the present disclosure. For example, fungicides, insecticides, nematicides, acaricides, biopesticides, herbicides, plant growth regulators, biostimulants, antibiotics, fertilizers and nutrients disclosed and reported in WO2016156129 and or WO2017153200 can be combined with at least one compound of the Formula (I) of the present disclosure. 5 In certain instances, combinations with other invertebrate pest control compounds or agents, having a similar spectrum of control but a different mode of action, will be particularly advantageous for resistance management. Thus, compositions of the present invention can further comprise a biologically effective amount of at least one additional invertebrate pest control compound or agents having a similar spectrum of control but a different mode of action. Contacting a genetically modified plant to express 10 a plant protection compound (e.g., protein) or the locus of the plant with a biologically effective amount of a compound of the invention can also provide a broader spectrum of plant protection and be advantageous for resistance management. In one embodiment of the present invention, the biologically effective amount of the compound of Formula (I) in the compositions ranges from 0.1 to 99 % by weight with respect to the total weight of 15 the composition, preferably from 5 to 50 % by weight with respect to the total weight of the composition. The present invention furthermore relates to a method of combating insect, mite, and nematode pests, said method comprising contacting the insect, mite, and nematode pests, their habit, breeding ground, food supply, plant, seed, soil, area, material or environment in which the insect and mite pests are 20 growing or may grow, or the materials, plants, seeds, soils, surfaces or spaces to be protected from pest attack or infestation with a biologically effective amount of the compound or the composition of the present invention. Invertebrate pests are controlled and protection of agronomic, horticultural and specialty crops, animal and human health is achieved by applying one or more of the compounds of the present invention, in 25 an effective amount, to the environment of the pests including the agronomic and / or nonagronomic locus of infestation, to the area to be protected, or directly on the pests to be controlled. Thus, the present invention further comprises a method for the control of foliar- and soil-inhabiting invertebrates and protection of agronomic and / or nonagronomic crops, comprising contacting the invertebrates or their environment with a biologically effective amount of one or more of the compounds of the present 30 invention, or with a composition comprising at least one such compound or a composition comprising at least one such compound and an effective amount of at least one additional biologically active compound or agent. A preferred method of contact is by spraying. Alternatively, a granular composition comprising a compound of the present invention can be applied to the plant foliage or the soil. Compounds of the present invention are effective in delivery through plant uptake by contacting the 35 plant with at least one such compound or in a composition comprising a compound of the present invention applied as a soil drench of a liquid formulation, a granular formulation to the soil, a nursery PI External box treatment or a dip of transplants. Other methods of contact include application of a compound or a composition of the present invention by direct and residual sprays, aerial sprays, seed coats, microencapsulations, systemic uptake, baits, eartags, boluses, foggers, fumigants, aerosols, dusts, and many others. 5 Compounds of the present invention can be incorporated into baits that are consumed by the invertebrates or within devices such as traps and the like. Granules or baits comprising between 0.01-5 % active ingredient, 0.05-10 % moisture retaining agent(s) and 40-99 % vegetable flour are effective in controlling soil insects at very low application rates, particularly at doses of active ingredient that are lethal by ingestion rather than by direct contact. Compounds of the present invention can be applied in 10 their pure state, but most often the application will be of a formulation comprising one or more compounds with suitable carriers, diluents, and surfactants and possibly in combination with a food depending on the contemplated end use. A preferred method of application involves spraying of a water dispersion or refined oil solution of the compounds. Combinations with spray oils, spray oil concentrations, spreader, stickers, adjuvants, other solvents, and synergists such as piperonyl butoxide 15 often enhance compound efficacy. The rate of application required for an effective control (i.e. “biologically effective amount”) will depend on such factors as the species of invertebrate to be controlled, the pest's life cycle, life stage, its size, location, time of year, host crop, material or animal, feeding behavior, mating behavior, ambient moisture, temperature, and the like. Under normal circumstances, application rates of about 0.01 to 2 20 kg of active ingredient per hectare are sufficient to control pests in agronomic ecosystems, but as little as 0.0001 kg hectare may be sufficient or as much as 8 kg / hectare may be required. For nonagronomic applications, effective use rates will range from about 1.0 to 50 mg / square meter but as little as 0.1 mg / square meter may be sufficient or as much as 150 mg / square meter may be required. One skilled in the art can easily determine the biologically effective amount necessary for the desired level of 25 invertebrate pest control. The animal pest, i.e. the insects, arachnids and nematodes, the plant, soil or water in which the plant is growing can be contacted with compounds of Formula (I) , their N-oxides and salts or composition(s) containing them by any application method known in the art. As such, “contacting” includes both direct contact (applying the compounds / compositions directly on the animal pest or plant typically to the 30 foliage, stem or roots of the plant) and indirect contact (applying the compounds / compositions to the locus of the animal pest or plant). Compounds of the present invention or the pesticidal compositions comprising them may be used to protect growing plants and crops from an attack or infestation by animal pests, especially insects and mites by contacting the plant / crop with a pesticidally effective amount of at least one compound of the 35 present invention. The term “crop” refers both to growing and harvested crops. PI External Accordingly, the present invention relates to a method for protecting crops from an attack or infestation by insect and mite pests, which comprises contacting the crop with a biologically effective amount of the compound or the composition of the present invention, isomer, polymorph, N-oxide or salt thereof. Compounds of the present invention are employed as such or in the form of compositions by treating 5 the insects or the plants, plant propagation materials such as seeds, soil, surfaces, materials or rooms to be protected from insecticidal attack with an insecticidally effective amount of the active compounds. The application can be carried out both before and after the infection of the plants, plant propagation materials such as seeds, soil, surfaces, materials or rooms by the insects. Accordingly, the present invention also relates to a method for the protection of seeds from soil insects 10 and of the seedling’s roots and shoots from soil and foliar insects comprising contacting the seeds before sowing and / or after pre-germination with the compound or the composition of the present invention, N- oxide or salt thereof. Furthermore, the present invention relates to a method for treating or protecting animals against infestation or infection by parasites which comprises orally, topically or parenterally administering or 15 applying to the animals a biologically effective amount of compound or composition of the present invention, isomer, polymorph, N-oxide or veterinary acceptable salt thereof. For the use in treating crop plants, the rate of application (applying effective dosages) of the compound of the present invention may be in the range of 1 gai to 5000 gai per hectare in agricultural or horticultural crops, preferably from 10 g to 500 g per hectare, more preferably from 25 g to 300 g per 20 hectare. The compounds and the compositions of the present invention are particularly useful in the control of a multitude of insects on various cultivated plants such as cereals, root crops, oil crops, vegetables, spices, ornamentals, for example seed of durum and other wheat, barley, oats, rye, maize (fodder maize and sugar maize / sweet and field corn), soybeans, oil crops, crucifers, cotton, sunflowers, bananas, rice, 25 oilseed rape, turnip rape, sugar beet, fodder beet, eggplants, potatoes, grass, lawn, turf, fodder grass, tomatoes, leeks, pumpkin / squash, cabbage, iceberg lettuce, pepper, cucumbers, melons, Brassica species, melons, beans, peas, garlic, onions, carrots, tuberous plants such as potatoes, sugar cane, tobacco, grapes, petunias, geranium / pelargoniums, pansies, and impatiens. Particularly, the compound or the composition of the present invention are useful in protecting 30 agricultural crops such as cereals, corn, rice, soybean and other leguminous plants, fruits and fruit trees, grapes, nuts and nut trees, citrus and citrus trees, any horticultural plants, cucurbitaceae, oleaginous plants, tobacco, coffee, tea, cacao, sugar beet, sugar cane, cotton, potato, tomato, onions, peppers and other vegetables, and ornamentals. The present invention still further relates to processes for preparing the compound selected from 35 Formula (I). PI External Compounds of the present invention are effective through both contact (via soil, glass, wall, bed net, carpet, plant parts or animal parts), and ingestion (bait or plant part). Compounds of the present invention may also be applied against non-crop insect and mite pests such as ants, termites, wasps, flies, mosquitos, crickets, or cockroaches. For use against said non-crop pests, 5 compounds of the present invention are preferably used in a bait composition. The bait can be a liquid, a solid or a semisolid preparation (e.g., a gel). Solid baits can be formed into various shapes and forms suitable to the respective application e.g., granules, blocks, sticks, disks. Liquid baits can be filled into various devices to ensure proper application, e.g., open containers, spray devices, droplet sources, or evaporation sources. Gels can be based on aqueous or oily matrices and can 10 be formulated to particular needs in terms of stickiness, moisture retention or aging characteristics. The bait employed in the composition is a product, which is sufficiently attractive to incite insects such as ants, termites, wasps, flies, mosquitos, crickets etc. or cockroaches to eat it. The attractiveness can be manipulated by using feeding stimulants or sex pheromones. Food stimulants are chosen, for example, but not exclusively, from animal and / or plant proteins (meat-, fish or blood meal, insect parts, 15 egg yolk), from fats and oils of animal and / or plant origin, or mono-, oligo or polyorganosaccharides, especially from sucrose, lactose, fructose, dextrose, glucose, starch, pectin or even molasses or honey. Fresh or decaying parts of fruits, crops, plants, animals, insects or specific parts thereof can also serve as a feeding stimulant. Sex pheromones are known to be more insect specific. Specific pheromones are described in the literature and are known to those skilled in the art. 20 For use in bait compositions, the typical content of active ingredient is from 0.001 weight % to 15 weight %, desirably from 0.001 weight % to 5 weight % of the active compound. Formulations of compounds of the present invention as aerosols (e.g., in spray cans), oil sprays or pump sprays are highly suitable for the non-professional user for controlling pests such as flies, fleas, ticks, mosquitos or cockroaches. Aerosol recipes are preferably composed of the active compound, of solvents 25 such as lower alcohols (e.g., methanol, ethanol, propanol, butanol), of ketones (e.g., acetone, methyl ethyl ketone), paraffin hydrocarbons (e.g., kerosene) having boiling ranges of approximately 50 to 250 °C, dimethylformamide, N-methylpyrrolidone, dimethyl sulfoxide, aromatic hydrocarbons such as toluene, xylene, water, furthermore of auxiliaries such as emulsifiers like sorbitol monooleate, oleyl ethoxylate having 3-7 mol of ethylene oxide, fatty alcohol ethoxylate, perfume oils such as ethereal 30 oils, esters of medium fatty acids with lower alcohols, aromatic carbonyl compounds, if appropriate of stabilizers such as sodium benzoate, amphoteric surfactants, lower epoxides, triethyl orthoformate and, if required, propellants such as propane, butane, nitrogen, compressed air, dimethyl ether, carbon dioxide, nitrous oxide, or mixtures of these gases. The oil spray formulations differ from the aerosol recipes in that no propellants are used. For use in 35 spray compositions, the content of active ingredient ranges from 0.001 to 80 weight %, preferably from 0.01 to 50 weight % and most preferably from 0.01 to 15 weight %. PI External Compounds of the present invention and their respective compositions can also be used in mosquito and fumigating coils, smoke cartridges, vaporizer plates or long-term vaporizers and also in moth papers, moth pads or other heat-independent vaporizer systems. Methods to control infectious diseases transmitted by insects (e.g., malaria, dengue and yellow fever, 5 lymphatic filariasis, and leishmaniasis) with compounds of Formula (I) and its respective compositions also comprise treating surfaces of huts and houses, air spraying and impregnation of curtains, tents, clothing items, bed nets, tsetse-fly trap or the like. Insecticidal compositions for application to fibers, fabric, knitgoods, nonwovens, netting material or foils and tarpaulins preferably comprise a mixture including the insecticide, optionally a repellent and at least one binder. Suitable repellents for example10 are Ν,Ν-Diethyl-meta-toluamide (DEET), N,N-diethylphenylacetamide (DEPA), 1 -(3-cyclohexan-1 - yl-carbonyl)-2-methylpiperine, (2-hydroxymethylcyclohexyl) acetic acid lactone, 2-ethyl-1 ,3- hexandiol, indalone, Methylneodecanamide (MNDA), a pyrethroid not used for insect control such as {(+ / -)-3-allyl-2-methyl4-oxocyclopent-2-(+)-enyl-(+)-trans-chrysantemate (Esbiothrin), a repellent derived from or identical with plant extracts like limonene, eugenol, (+)-Eucamalol (1 ), (-)-l -epi- 15 eucamalol or crude plant extracts from plants like Eucalyptus maculata, Vitex rotundifolia, Cymbopogan martinii, Cymbopogan citratus (lemon grass), Cymopogan nartdus (citronella). Suitable binders are selected for example from polymers and copolymers of vinyl esters of aliphatic acids (such as vinyl acetate and vinyl versatate), acrylic and methacrylic esters of alcohols such as butyl acrylate, 2-ethylhexylacrylate, and methyl acrylate, mono and di-ethylenically unsaturated hydrocarbons such as 20 styrene, and aliphatic diens such as butadiene. The impregnation of curtains and bednets is done in general by dipping the textile material into emulsions or dispersions of the insecticide or spraying them onto the nets. Compounds of the present invention and their compositions can be used for protecting wooden materials such as trees, board fences, sleepers, etc. and buildings such as houses, outhouses, factories, but also 25 construction materials, furniture, leathers, fibers, vinyl articles, electric wires and cables etc. from ants and / or termites, and for controlling ants and termites from doing harm to crops or human being (e.g., when the pests invade into houses and public facilities). Compounds of the present invention are applied not only to the surrounding soil surface or into the under-floor soil in order to protect wooden materials but it can also be applied to lumbered articles such as surfaces of the under-floor concrete, alcove posts, 30 beams, plywoods, furniture, etc., wooden articles such as particle boards, half boards, etc. and vinyl articles such as coated electric wires, vinyl sheets, heat insulating material such as styrene foams, etc. Seed treatment The present invention still further relates to a seed comprising the compounds of the present invention, particularly in an amount ranging from about 0.0001 % to about 1 % by weight of the seed before 35 treatment. PI External Compounds of the present invention are particularly useful for the protection of the seed from soil pests and the resulting plant's roots and shoots against soil pests and foliar insects. The protection of the resulting plant's roots and shoots is preferred. More preferred is the protection of resulting plant's shoots from piercing and sucking insects, wherein the protection from aphids is most preferred. 5 The present invention therefore comprises a method for the protection of seeds from insects, in particular from soil insects and of the seedling’s roots and shoots from insects, in particular from soil and foliar insects, said method comprising contacting the seeds before sowing and / or after pregermination with a compound of the present invention. Particularly preferred is a method, wherein the plant's roots and shoots are protected, more preferably a method, wherein the plants shoots are 10 protected from piercing and sucking insects, most preferably a method, wherein the plants shoots are protected from aphids, whiteflies, hoppers, and jassids. The term seed embraces seeds and plant propagules of all kinds including but not limited to seed pieces, suckers, corms, bulbs, fruit, tubers, grains, cuttings, cut shoots and the like and means in a preferred embodiment true seeds. 15 The term seed treatment comprises all suitable seed treatment techniques known in the art such as seed dressing, seed coating, seed dusting, seed soaking, and seed pelleting. The present invention also comprises seeds coated with or containing the active compound. The seeds can be coated with seed coating compositions containing the compounds of the present invention. For example, seed coating compositions reported in EP3165092, EP3158864, WO2016198644, 20 WO2016039623, WO2015192923, CA2940002, US2006150489, US2004237395, WO2011028115, EP2229808, WO2007067042, EP1795071, EP1273219, WO200178507, EP1247436, NL1012918, and CA2083415. The term “coated with and / or containing” generally signifies that the active ingredient is for the most part on the surface of the propagation product at the time of application, although a greater or lesser 25 part of the ingredient may penetrate into the propagation product, depending on the method of application. When the said propagation product is (re)planted, it may absorb the active ingredient. Suitable seed is seed of cereals, root crops, oil crops, vegetables, spices, ornamentals, for example seed of durum and other wheat, barley, oats, rye, maize (fodder maize and sugar maize / sweet and field corn), soybeans, oil crops, crucifers, cotton, sunflowers, bananas, rice, oilseed rape, turnip rape, 30 sugarbeet, fodder beet, eggplants, potatoes, grass, lawn, turf, fodder grass, tomatoes, leeks, pumpkin / squash, cabbage, iceberg lettuce, pepper, cucumbers, melons, Brassica species, melons, beans, peas, garlic, onions, carrots, tuberous plants such as potatoes, sugar cane, tobacco, grapes, petunias, geranium / pelargoniums, pansies, and impatiens. PI External In addition, the compounds of the present invention may be used for treating seed from plants, which tolerate the action of herbicides or fungicides or insecticides owing to breeding, including genetic engineering methods. For example, the compound of the present invention can be employed in the treatment of seeds from 5 plants, which are resistant to herbicides from the group consisting of the sulfonylureas, imidazolinones, glufosinate-ammonium or glyphosate-isopropylammonium and analogous active substances (see for example, EP242236, EP242246) (WO92 / 00377) (EP257993, US5013659) or in transgenic crop plants, for example cotton, with the capability of producing Bacillus thuringiensis toxins (Bt toxins) which make the plants resistant to certain pests (EP142924, EP193259), 10 Furthermore, the compound of the present invention can be used for the treatment of seed from plants, which have modified characteristics in comparison with existing plants, which can be generated for example by traditional breeding methods and / or the generation of mutants, or by recombinant procedures). For example, a number of cases have been described of recombinant modifications of crop plants for the purpose of modifying the starch synthesized in the plants (e.g., WO92 / 11376, 15 WO92 / 14827, WO91 / 19806) or of transgenic crop plants having a modified fatty acid composition (WO91 / 13972). The seed treatment application of the compound of the present invention is carried out by spraying or by dusting the seeds before sowing of the plants and before emergence of the plants. Compositions which are especially useful for seed treatment are e.g.: 20 A. Soluble concentrates (SL, LS) B. Emulsions (EW, EO, ES) C. Suspensions (SC, OD, FS) D. Water-dispersible granules and water-soluble granules (WG, SG) E. Water-dispersible powders and water-soluble powders (WP, SP, WS) 25 F. Gel-Formulations (GF) G. Dustable powders (DP, DS) Conventional seed treatment formulations include for example flowable concentrates FS, solutions LS, powders for dry treatment DS, water dispersible powders for slurry treatment WS, water-soluble powders SS and emulsion ES and EC and gel formulation GF. These formulations can be applied to the 30 seed diluted or undiluted. Application to the seeds is carried out before sowing, either directly on the seeds or after having pregerminated the latter In a one embodiment a FS formulation is used for seed treatment. Typically, a FS formulation may comprise 1-800 g / l of active ingredient, 1-200 g / l surfactant, 0 to 200 g / l antifreezing agent, 0 to 400 g / l of binder, 0 to 200 g / l of a pigment and up to 1 liter of a solvent, preferably water. PI External Especially FS formulations of compounds of the present invention for seed treatment usually comprise from 0.1 to 80 % by weight (1 to 800 g / l) of the active ingredient, from 0.1 to 20 % by weight (1 to 200 g / l) of at least one surfactant, e.g., 0.05 to 5 % by weight of a wetter and from 0.5 to 15 % by weight of a dispersing agent, up to 20 % by weight, e.g., from 5 to 20 % of an anti-freeze agent, from 0 to 15 % 5 by weight, e.g., 1 to 15 % by weight of a pigment and / or a dye, from 0 to 40 % by weight, e.g., 1 to 40 % by weight of a binder (sticker / adhesion agent), optionally up to 5 % by weight, e.g., from 0.1 to 5 % by weight of a thickener, optionally from 0.1 to 2 % of an anti-foam agent, and optionally a preservative such as a biocide, antioxidant or the like, e.g., in an amount from 0.01 to 1 % by weight and a filler / vehicle up to 100 % by weight. 10 Seed treatment formulations may additionally comprise binders and optionally colorants. Binders can be added to improve the adhesion of the active materials on the seeds after treatment. Suitable binders are homoand copolymers from alkylene oxides like ethylene oxide or propylene oxide, polyvinylacetate, polyvinylalcohols, polyvinylpyrrolidones, and copolymers thereof, ethylene-vinyl acetate copolymers, acrylic homoand copolymers, polyethyleneamines, polyethyleneamides and 15 polyethylenepyrimidines, polysaccharides like celluloses, tylose and starch, polyolefin homoand copolymers like olefin / maleic anhydride copolymers, polyurethanes, polyesters, polystyrene homo and copolymers. Optionally, also colorants can be included in the formulation. Suitable colorants or dyes for seed treatment formulations are Rhodamin B, C.I. Pigment Red 112, C.I. Solvent Red 1 , pigment blue 15:4, 20 pigment blue 15:3, pigment blue 15:2, pigment blue 15:1 , pigment blue 80, pigment yellow 1 , pigment yellow 13, pigment red 112, pigment red 48:2, pigment red 48:1 , pigment red 57:1 , pigment red 53:1 , pigment orange 43, pigment orange 34, pigment orange 5, pigment green 36, pigment green 7, pigment white 6, pigment brown 25, basic violet 10, basic violet 49, acid red 51 , acid red 52, acid red 14, acid blue 9, acid yellow 23, basic red 10, basic red 108. 25 In the treatment of seed, the application rates of the compounds of the present invention are generally from 0.1 g to 10 kg per 100 kg of seed, preferably from 1 g to 5 kg per 100 kg of seed, more preferably from 1 g to 1 kg per 100 kg of seed and in particular from 1 g to 200 g per 100 kg of seed. The present invention therefore also provides seed comprising a compound of the Formula (I), or an agriculturally 30 useful salt of Formula (I), as defined herein. The amount of the compound of Formula (I) or the agriculturally useful salt thereof will in general vary from 0.1 g to 10 kg per 100 kg of seed, preferably from 1 g to 5 kg per 100 kg of seed, in particular from 1 g to 1 kg per 100 kg of seed. For specific crops such as lettuce the rate can be higher. PI External Animal health The present invention also provides an agricultural and / or veterinary composition comprising at least one compound of the present invention. The present invention still further relates to a use of the compound, N-oxide or veterinarily acceptable 5 salt thereof or the composition of the present invention, for the preparation of a medicament for treating or protecting animals against the infestation or infection by insect and mite pests or parasites. Compounds of Formula (I), their N-oxides and / or veterinarily acceptable salts thereof are also particularly suitable for being used for combating parasites in and on animals. One object of the present invention is therefore to provide new methods to control parasites in and on 10 animals. Another object of the present invention is to provide safer pesticides for animals. Another object of the present invention is to provide pesticides for animals that may be used in lower doses than existing pesticides. Another object of the present invention is to provide pesticides for animals, which provide a long-lasting control of parasites. The present invention also relates to compositions containing a parasiticidally effective amount of at 15 least one compound of Formula (I), N-oxide or veterinarily acceptable salt thereof and an acceptable carrier, for combating parasites in and on animals. The present invention also provides a method for treating, controlling, preventing and protecting animals against infestation and infection by parasites, which comprises orally, topically, or parenteral administering or applying to the animals a parasiticidally effective amount of a compound of the present 20 invention or a composition comprising it. The present invention also provides a process for the preparation of a composition for treating, controlling, preventing or protecting animals against an infestation or infection by parasites which comprises a parasiticidally effective amount of a compound of the present invention or a composition comprising it. 25 Activity of compounds against agricultural pests does not suggest their suitability for control of endo- and ectoparasites in and on animals which requires, for example, low, non-emetic dosages in the case of oral application, metabolic compatibility with the animal, low toxicity and a safe handling. Surprisingly it has now been found that compounds of the present invention are suitable for combating endo- and ectoparasites in and on animals. 30 Compounds of the present invention and compositions comprising them are preferably used for controlling and preventing infestations and infections of animals including warm-blooded animals (including humans) and fish. They are for example suitable for controlling and preventing infestations and infections in mammals such as cattle, sheep, swine, camels, deer, horses, pigs, poultry, rabbits, PI External goats, dogs and cats, water buffalo, donkeys, fallow deer and reindeer, and also in fur-bearing animals such as mink, chinchilla and raccoon, birds such as hens, geese, turkeys and ducks and fish such as fresh and salt-water fish like trout, carp, and eels. Compounds of the present invention and compositions comprising them are preferably used for 5 controlling and preventing infestations and infections in domestic animals such as dogs or cats. Infestations in warm-blooded animals and fish include, but are not limited to, lice, biting lice, ticks, nasal bots, keds, biting flies, muscoid flies, flies, myiasitic fly larvae, chiggers, gnats, mosquitoes and fleas. Compounds of the present invention and compositions comprising them are suitable for a systemic 10 and / or non-systemic control of ecto- and / or endo-parasites. They can be active against all or some stages of development. Compounds of the present invention are especially useful for combating ectoparasites. Compounds of the present invention are especially useful for combating parasites of the following orders and species, respectively: fleas (Siphonaptera), e.g., Ctenocephalides felis, Ctenocephalides 15 cams, Xenopsylla cheopis, Pulex irritans, Tunga penetrans, and Nosopsyllus fasciatus, cockroaches (Blattaria Blattodea), e.g., Blattella germanica, Blattella asahinae, Periplaneta americana, Periplaneta japonica, Periplaneta brunnea, Periplaneta fuligginosa, Periplaneta australasiae, and Blatta orientalis, flies, mosquitoes (Diptera), e.g., Aedes aegypti, Aedes albopictus, Aedes vexans, Anastrepha ludens, Anopheles maculipennis, Anopheles crucians, Anopheles albimanus, Anopheles 20 gambiae, Anopheles freeborni, Anopheles leucosphyrus, Anopheles minimus, Anopheles quadrimaculatus, Calliphora vicina, Chrysomya bezziana, Chrysomya hominivorax, Chrysomya macellaria, Chrysops discalis, Chrysops silacea, Chrysops atlanticus, Cochliomyia hominivorax, Cordylobia anthropophaga, Culicoides furens, Culex pi ens, Culex nigripalpus, Culex quinquefasciatus, Culex tarsalis, Culiseta inornata, Culiseta melanura, Dermatobia hominis, Fannia 25 canicularis, Gasterophilus intestinalis, Glossina morsitans, Glossina palpalis, Glossina fuscipes, Glossina tachinoides, Haematobia irritans, Haplodiplosis equestris, Hippelates spp., Hypoderma lineata, Leptoconops torrens, Lucilia caprina, Lucilia cuprina, Lucilia sericata, Lycoria pectoralis, Mansonia spp., Musca domestica, Muscina stabulans, Oestrus ovis, Phlebotomus argentipes, Psorophora columbiae, Psorophora discolor, Prosimulium mixtum, Sarcophaga haemorrhoidalis, 30 Sarcophaga sp., Simulium vittatum, Stomoxys calcitrans, Tabanus bovinus, Tabanus atratus, Tabanus lineola, and Tabanus similis, lice (Phthiraptera), e.g., Pediculus humanus capitis, Pediculus humanus corporis, Pthirus pubis, Haematopinus eurysternus, Haematopinus suis, Linognathus vituli, Bovicola bovis, Menopon gallinae, Menacanthus stramineus and Solenopotes capillatus. ticks and parasitic mites (Parasitiformes): ticks (Ixodida), e.g., Ixodes scapularis, Ixodes holocyclus, Ixodes pacificus, 35 Rhiphicephalus sanguineus, Dermacentor andersoni, Dermacentor variabilis, Amblyomma PI External americanum, Ambryomma maculatum, Ornithodorus hermsi, Ornithodorus turicata and parasitic mites (Mesostigmata), e.g., Ornithonyssus bacoti and Dermanyssus gallinae, Actinedida (Prostigmata) und Acaridida (Astigmata) e.g., Acarapis spp., Cheyletiella spp., Ornithocheyletia spp., Myobia spp., Psorergates spp., Demodex spp., Trombicula spp., Listrophorus spp., Acarus spp., Tyrophagus spp., 5 Caloglyphus spp., Hypodectes spp., Pterolichus spp., Psoroptes spp., Chorioptes spp., Otodectes spp., Sarcoptes spp., Notoedres spp., Knemidocoptes spp., Cytodites spp., and Laminosioptes spp, Bugs (Heteropterida): Cimex lectularius, Cimex hemipterus, Reduvius senilis, Triatoma spp., Rhodnius ssp., Panstrongylus ssp. and Arilus critatus, Anoplurida, e.g., Haematopinus spp., Linognathus spp., Pediculus spp., Phtirus spp., and Solenopotes spp, Mallophagida (suborders Arnblycerina and 10 Ischnocerina), e.g., Trimenopon spp., Menopon spp., Trinoton spp., Bovicola spp., Werneckiella spp., Lepikentron spp., Trichodectes spp., and Felicola spp. Roundworms Nematoda: Wipeworms and Trichinosis (Trichosyringida), e.g., Trichinellidae (Trichinella spp.), (Trichuridae,) Trichuris spp., Capillaria spp, Rhabditida, e.g., Rhabditis spp, Strongyloides spp., Helicephalobus spp, 15 Strongylida, e.g., Strongylus spp., Ancylostoma spp., Necator americanus, Bunostomum spp. (Hookworm), Trichostrongylus spp., Haemonchus contortus., Ostertagia spp., Cooperia spp., Nematodirus spp., Dictyocaulus spp., Cyathostoma spp., Oesophagostomum spp., Stephanurus dentatus, Ollulanus spp., Chabertia spp., Stephanurus dentatus , Syngamus trachea, Ancylostoma spp., Uncinaria spp., Globocephalus spp., Necator spp., Metastrongylus spp., Muellerius capillaris, 20 Protostrongylus spp., Angiostrongylus spp., Parelaphostrongylus spp. Aleurostrongylus abstrusus, and Dioctophyma renale, Intestinal roundworms (Ascaridida), e.g., Ascaris lumbricoides, Ascaris suum, Ascaridia galli, Parascaris equorum, Enterobius vermicularis (Threadworm), Toxocara canis, Toxascaris leonine, Skrjabinema spp., and Oxyuris equi, Camallanida, e.g., Dracunculus medinensis (guinea worm) Spirurida, e.g., Thelazia spp. Wuchereria spp., Brugia spp., Onchocerca spp., Dirofilari 25 spp. a, Dipetalonema spp., Setaria spp., Elaeophora spp., Spirocerca lupi, and Habronema spp, Thorny headed worms (Acanthocephala), e.g., Acanthocephalus spp., Macracanthorhynchus hirudinaceus and Oncicola spp, Planarians (Plathelminthes): Flukes (Trematoda), e.g., Faciola spp., Fascioloides magna, Paragonimus spp., Dicrocoelium spp., Fasciolopsis buski, Clonorchis sinensis, Schistosoma spp., Trichobilharzia spp., Alaria a lata, Paragonimus spp., and Nanocyetes spp, Cercomeromorpha, 30 in particular Cestoda (Tapeworms), e.g., Diphyllobothrium spp., Tenia spp., Echinococcus spp., Dipylidium caninum, Multiceps spp., Hymenolepis spp., Mesocestoides spp., Vampirolepis spp., Moniezia spp., Anoplocephala spp., Sirometra spp., Anoplocephala spp., and Hymenolepis spp. Compounds of Formula (I) and the compositions containing them are particularly useful for the control of pests from the orders Diptera, Siphonaptera, and Ixodida. PI External Moreover, the use of the compounds of Formula (I) and the compositions containing them for combating mosquitoes is one embodiment of the present invention. The use of the compounds of the present invention and the compositions containing them for combating flies is another embodiment of the present invention. 5 Furthermore, the use of the compounds of the present invention and the compositions containing them for combating fleas is still another embodiment of the present invention. The use of the compounds of the present invention and the compositions containing them for combating ticks is still another embodiment of the present invention. Compounds of the present invention also are especially useful for combating endoparasites 10 (roundworms nematoda, thorny headed worms and planarians). The administration can be carried out both prophylactically and therapeutically. The administration of the compounds of the present invention is carried out directly or in the form of suitable preparations, orally, topically / dermally or parenterally. For an oral administration to warm-blooded animals, the compounds of the present invention may be 15 formulated as animal feeds, animal feed premixes, animal feed concentrates, pills, solutions, pastes, suspensions, drenches, gels, tablets, boluses, and capsules. In addition, the compounds of the present invention may be administered to the animals in their drinking water. For oral administration, the dosage form chosen should provide the animal with 0.01 mg / kg to 100 mg / kg of animal body weight per day of the compound of the present invention, preferably with 0.5 mg / kg to 100 mg / kg of animal body 20 weight per day. Alternatively, the compounds of the present invention may be administered to animals parenterally, for example, by intraruminal, intramuscular, intravenous or subcutaneous injection. Compounds of the present invention may be dispersed or dissolved in a physiologically acceptable carrier for subcutaneous injection. Alternatively, the compounds of the present invention may be formulated into an implant for 25 subcutaneous administration. In addition, the compound of the present invention may be transdermally administered to animals. For parenteral administration, the dosage form chosen should provide the animal with 0.01 mg / kg to 100 mg / kg of animal body weight per day of the compound of the present invention. Compounds of the present invention may also be applied topically to the animals in the form of dips, 30 dusts, powders, collars, medallions, sprays, shampoos, spot-on and pour-on formulations and in ointments or oil-in-water or water-in-oil emulsions. For topical application, dips and sprays usually contain 0.5 ppm to 5,000 ppm and preferably 1 ppm to 3,000 ppm of the compound of the present invention. In addition, the compounds of the present invention may be formulated as ear tags for animals, particularly quadrupeds such as cattle and sheep. PI External Suitable preparations are: solutions such as oral solutions, concentrates for oral administration after dilution, solutions for use on the skin or in body cavities, pouring-on formulations, gels; emulsions and suspensions for oral or dermal administration; semi-solid preparations; formulations in which the active compound is processed in an ointment base or in an oil-in water or water-in-oil emulsion base; solid 5 preparations such as powders, premixes or concentrates, granules, pellets, tablets, boluses, capsules; aerosols and inhalants, and active compound-containing shaped articles. Compositions suitable for an injection are prepared by dissolving the active ingredient in a suitable solvent and optionally adding further ingredients such as acids, bases, buffer salts, preservatives, and solubilizers. 10 The solutions are filtered and filled sterile. Suitable solvents are physiologically tolerable solvents such as water, alkanols such as ethanol, butanol, benzyl alcohol, glycerol, propylene glycol, polyethylene glycols, N-methylpyrrolidone, 2-pyrrolidone, and mixtures thereof. The active compounds can optionally be dissolved in physiologically tolerable vegetable or synthetic 15 oils which are suitable for injection. Suitable solubilizers are the solvents which promote the dissolution of the active compound in the main solvent or prevent its precipitation. Examples are polyvinylpyrrolidone, polyvinyl alcohol, polyoxyethylated castor oil, and polyoxyethylated sorbitan ester. Suitable preservatives are benzyl alcohol, trichlorobutanol, p-hydroxybenzoic acid esters, and n- 20 butanol. Oral solutions are administered directly. Concentrates are administered orally after prior dilution to the use concentration. Oral solutions and concentrates are prepared according to the state of the art and as described above for injection solutions, sterile procedures not being necessary. Solutions for use on the skin are trickled on, spread on, rubbed in, sprinkled or sprayed on. 25 Solutions for use on the skin are prepared according to the state of the art and according to what is described above for injection solutions, sterile procedures not being necessary. Further suitable solvents are polypropylene glycol, phenyl ethanol, phenoxy ethanol, ester such as ethyl or butyl acetate, benzyl benzoate, ethers such as alkyleneglycol alkyl ether, e.g., dipropylenglycol monomethyl ether, ketones such as acetone, methylethylketone, aromatic hydrocarbons, vegetable and 30 synthetic oils, dimethylformamide, dimethylacetamide, transcutol, solketal, propylencarbonate, and mixtures thereof. PI External It may be advantageous to add thickeners during preparation. Suitable thickeners are inorganic thickeners such as bentonites, colloidal silicic acid, aluminium monostearate, organic thickeners such as cellulose derivatives, polyvinyl alcohols and their copolymers, acrylates and methacrylates. Gels are applied to or spread on the skin or introduced into body cavities. Gels are prepared by treating 5 solutions which have been prepared as described in the case of the injection solutions with sufficient thickener that a clear material having an ointment-like consistency results. The thickeners employed are the thickeners given above. Pour-on formulations are poured or sprayed onto limited areas of the skin. The active compound is penetrating the skin and acting systemically. Pour-on formulations are prepared by dissolving, 10 suspending or emulsifying the active compound in suitable skin-compatible solvents or solvent mixtures. If appropriate, other auxiliaries such as colorants, bio absorption-promoting substances, antioxidants, light stabilizers, adhesives are added. Suitable solvents are: water, alkanols, glycols, polyethylene glycols, polypropylene glycols, glycerol, aromatic alcohols such as benzyl alcohol, phenyl ethanol, phenoxyethanol, esters such as ethyl acetate, 15 butyl acetate, benzyl benzoate, ethers such as alkylene glycol alkyl ethers such as dipropylene glycol monomethyl ether, diethylene glycol mono-butyl ether, ketones such as acetone, methyl ethyl ketone, cyclic carbonates such as propylene carbonate, ethylene carbonate, aromatic and / or aliphatic hydrocarbons, vegetable or synthetic oils, DMF, dimethylacetamide, n-alkylpyrrolidones such as methylpyrrolidone, n-butylpyrrolidone or noctylpyrrolidone, N-methylpyrrolidone, 2-pyrrolidone, 2,2- 20 dimethyl-4-oxy-methylene-1 ,3-dioxolane and glycerol formal. Suitable colorants are all colorants permitted for the use on animals and which can be dissolved or suspended. Suitable absorption-promoting substances are, for example, DMSO, spreading oils such as isopropyl myristate, dipropylene glycol pelargonate, silicone oils and copolymers thereof with polyethers, fatty 25 acid esters, triglycerides, fatty alcohols. Suitable antioxidants are sulfites or metabisulfites such as potassium metabisulfite, ascorbic acid, butylhydroxytoluene, butylhydroxyanisole, tocopherol. Suitable light stabilizers are, for example, novantisolic acid. Suitable adhesives are, for example, cellulose derivatives, starch derivatives, polyacrylates, natural polymers such as alginates, gelatin. 30 Emulsions can be administered orally, dermally or as injections. Emulsions are either of the water-in- oil type or of the oil-in-water type. They are prepared by dissolving the active compound either in the hydrophobic or in the hydrophilic phase and homogenizing this with the solvent of the other phase with the aid of suitable emulsifiers PI External and, if appropriate, other auxiliaries such as colorants, absorption-promoting substances, preservatives, antioxidants, light stabilizers, viscosity-enhancing substances. Suitable hydrophobic phases (oils) are: Liquid paraffins, silicone oils, natural vegetable oils such as sesame oil, almond oil, castor oil, synthetic 5 triglycerides such as caprylic / capric biglyceride, triglyceride mixture with vegetable fatty acids of the chain length Cs-Ci2 or other specially selected natural fatty acids, partial glyceride mixtures of saturated or unsaturated fatty acids possibly also containing hydroxyl groups, monoand diglycerides of the Cs- do fatty acids, fatty acid esters such as ethyl stearate, di-n-butyryl adipate, hexyl laurate, dipropylene glycol perlargonate, esters of a branched fatty acid of medium chain length with saturated fatty alcohols 10 of chain length C16-C18, isopropyl myristate, isopropyl palmitate, caprylic / capric acid esters of saturated fatty alcohols of chain length C12-C18, isopropyl stearate, oleyl oleate, decyl oleate, ethyl oleate, ethyl lactate, waxy fatty acid esters such as synthetic duck coccygeal gland fat, dibutyl phthalate, diisopropyl adipate, and ester mixtures related to the latter, fatty alcohols such as isotridecyl alcohol, 2- octyldodecanol, cetylstearyl alcohol, oleyl alcohol, and fatty acids such as oleic acid and mixtures 15 thereof. Suitable hydrophilic phases are: water, alcohols such as propylene glycol, glycerol, sorbitol and mixtures thereof. Suitable emulsifiers are: non-ionic surfactants, e.g., polyethoxylated castor oil, polyethoxylated sorbitan monooleate, sorbitan monostearate, glycerol monostearate, polyoxyethyl stearate, alkylphenol polyglycol ether; ampholytic surfactants such as di-sodium N-lauryl-p-iminodipropionate or lecithin. 20 Suitable Anionic surfactants are sodium lauryl sulfate, fatty alcohol ether sulfates, mono / dialkyl polyglycol ether orthophosphoric acid ester monoethanolamine salt; suitable cation-active surfactants are cetyltrimethylammonium chloride. Suitable further auxiliaries are: substances which enhance the viscosity and stabilize the emulsion such as carboxymethylcellulose, methylcellulose and other cellulose and starch derivatives, polyacrylates, 25 alginates, gelatin, gum arabic, polyvinylpyrrolidone, polyvinyl alcohol, copolymers of methyl vinyl ether and maleic anhydride, polyethylene glycols, waxes, colloidal silicic acid or mixtures of the substances mentioned. Suspensions can be administered orally or topically / dermally. They are prepared by suspending the active compound in a suspending agent, if appropriate with addition of other auxiliaries such as wetting 30 agents, colorants, bioabsorption-promoting substances, preservatives, antioxidants, light stabilizers. Liquid suspending agents are all homogeneous solvents and solvent mixtures. Suitable wetting agents (dispersants) are the emulsifiers given above. Other auxiliaries which may be mentioned are those given above. PI External Semi-solid preparations can be administered orally or topically / dermally. They differ from the suspensions and emulsions described above only by their higher viscosity. For the production of solid preparations, the active compound is mixed with suitable excipients, if appropriate with the addition of auxiliaries, and brought into the desired form. 5 Suitable excipients are all physiologically tolerable solid inert substances. Those used are inorganic and organic substances. Inorganic substances are, for example, sodium chloride, carbonates such as calcium carbonate, hydrogencarbonates, aluminium oxides, titanium oxide, silicic acids, argillaceous earths, precipitated or colloidal silica, or phosphates. Organic substances are, for example, sugar, cellulose, foodstuff and feeds such as milk powder, animal meal, grain meals and shreds, starches. 10 Suitable auxiliaries are preservatives, antioxidants, and / or colorants which have been mentioned above. Other suitable auxiliaries are lubricants and glidants such as magnesium stearate, stearic acid, talc, bentonites, disintegration-promoting substances such as starch or crosslinked polyvinylpyrrolidone, binders such as starch, gelatin or linear polyvinylpyrrolidone, and dry binders such as microcrystalline cellulose. 15 In general, “parasiticidally effective amount” means the amount of active ingredient needed to achieve an observable effect on the growth, including death, retardation, prevention, removal and destruction, or otherwise diminishing the occurrence and activity of the target organisms. The parasiticidally effective amount can vary for the various compounds / compositions used in the present invention. A parasiticidally effective amount of the compositions will also vary according to the prevailing 20 conditions such as desired parasiticidal effect and duration, target species, mode of application, and the like. The compositions which can be used in the present invention generally comprise from about 0.001 to 95 % of the compound of the present invention. Generally, it is favorable to apply the compounds of the present invention in total amounts of 0.5 mg / kg to 100 mg / kg per day, preferably 1 mg / kg to 50 mg / kg per day. Ready-to-use preparations contain the 25 compounds acting against parasites, preferably ectoparasites, in concentrations of 10 ppm to 80 per cent by weight, preferably from 0.1 to 65 per cent by weight, more preferably from 1 to 50 per cent by weight, most preferably from 5 to 40 per cent by weight. Preparations are diluted before use containing the compounds acting against ectoparasites in concentrations of 0.5 to 90 per cent by weight, preferably of 1 to 50 per cent by weight. Furthermore, the preparations comprise the compounds of the present 30 invention against endoparasites in concentrations of 10 ppm to 2 per cent by weight, preferably of 0.05 to 0.9 per cent by weight, very particularly preferably of 0.005 to 0.25 per cent by weight. In a one embodiment, the compositions comprising the compounds of the present invention are applied dermally / topically. PI External In another embodiment, the topical application is conducted in the form of compound-containing shaped articles such as collars, medallions, ear tags, bands for fixing at body parts, and adhesive strips and foils. Generally, it is favorable to apply solid formulations which release compounds of the present invention 5 in total amounts of 10 mg / kg to 300 mg / kg, preferably 20 mg / kg to 200 mg / kg, most preferably 25 mg / kg to 160 mg / kg body weight of the treated animal in the course of three weeks. For the preparation of the shaped articles, thermoplastic and flexible plastics as well as elastomers and thermoplastic elastomers are used. Suitable plastics and elastomers are polyvinyl resins, polyurethane, polyacrylate, epoxy resins, cellulose, cellulose derivatives, polyamides and polyester which are 10 sufficiently compatible with the compounds of the present invention. A detailed list of plastics and elastomers as well as preparation procedures for the shaped articles is given e.g., in WO 2003 / 086075. Digital Technologies Compounds of the invention can be used in combination with models e.g., embedded in computer programs for site specific crop management, satellite farming, precision farming or precision 15 agriculture. Such models support a site-specific management of agricultural sites with data from various sources such as soils, weather, crops (e.g., type, growth stage, plant health), weeds (e.g., type, growth stage), diseases, pests, nutrients, water, moisture, biomass, satellite data, yield etc. with the purpose to optimize profitability, sustainability and protection of the environment. Particularly, such models can help to optimize agronomical decisions, control the precision of pesticide applications and record the 20 work performed. As an example, the compounds of the invention can be applied to a crop plant according to an appropriate dose regime if a model models the development of a pest and calculates that a threshold has been reached for which it is recommendable to apply the compound of the invention to the crop plant. Commercially available systems which include agronomic models are e.g., FieldScriptsTM from The 25 Climate Corporation, XarvioTM from BASF, AGLogicTM from John Deere, etc. Compounds of the invention can also be used in combination with smart spraying equipment such as e.g., spot spraying or precision spraying equipment attached to or housed within a farm vehicle such as a tractor, robot, helicopter, airplane, unmanned aerial vehicle (UAV) such as a drone, etc. Such an equipment usually includes input sensors (such as e.g., a camera) and a processing unit configured to 30 analyze the input data and provide a decision, based on the analysis of the input data, to apply the compound of the invention to the crop plants (respectively the weeds) in a specific and precise manner. The use of such smart spraying equipment usually also requires position systems (e.g., GPS receivers) to localize recorded data and to guide or to control farm vehicles; geographic information systems (GIS) to represent the information on intelligible maps, and appropriate farm vehicles to perform the required 35 farm action such as the spraying. PI External In an example, pests can be detected from imagery acquired by a camera. In an example the pests can be identified and / or classified based on that imagery. Such identification and / or classification can make use of image processing algorithms. Such image processing algorithms can utilize machine learning algorithms such as trained neutral networks, decision trees and artificial intelligence algorithms. In this 5 manner, the compounds described herein can be applied only where needed. Positive crop response: Compounds of the present invention not only control insect and mite pests effectively but also show positive crop response such as plant growth enhancement effects like enhanced root growth, enhanced tolerance to drought, high salt, high temperature, chill, frost or light radiation, improved flowering, 10 enhanced nutrient utilization (such as improved nitrogen assimilation), enhanced quality plant products, higher number of productive tillers, enhanced resistance to insect pests and the like, which results in higher yields. General synthesis scheme: The invention will now be illustrated in further details by the following examples, without imposing 15 any limitation thereto, and it is understood that a person skilled in the art can utilize these descriptions to its fullest extent. Scheme-1: In one of the preferred embodiments, the compounds of Formula (I), wherein Z is a direct bond, can be 20 prepared by cross-coupling reactions between the compounds of Formula A-1 and phosphine oxides or phosphine sulfides of Formula D-1 (G = O, S) following the procedures that are described in various literature (Scheme-1; see, for example, Org. Lett. 2012, 14, 4370–4373, Org. Lett. 2013, 15, 5362– 5365, Org. Biomol. Chem., 2012, 10, 3500-3505, J. Organomet. Chem. 2016, 820, 120-124, US0055000295 and CN116462709) and in the literature cited therein. Moreover, the compounds of 25 Formula I, wherein G = S and Z is a direct bond, can also be prepared from the phosphine oxides of Formula I, wherein G = O and Z is a direct bond, in the presence of various thionating agents, for instance, Berzelius reagent, Lawesson’s reagent, Belleau’s reagent, and Jan Bergman’s reagent, as described in various literature (Scheme-1; for examples, see WO2016000581 and Beilstein J. Org. Chem.2020, 16, 88–105) and the literature cited therein. Thionation reactions are typically carried out 30 in solvents, preferably in benzene, toluene, xylenes, THF, 1,4-dioxane, 1,2-dichloroethane, and chlorobenzene and at temperatures between 20-200 °C. Compounds of Formula D-1 can either be commercially obtained or synthesized by methods that are described in US20190270704, Org. Lett. PI External 2019, 21, 2597-2601, Org. Lett. 2017, 19(14), 3899-3902, WO2024013205, Synthesis 2020, 52, 141– 149, CN116462709 and J. Org. Chem. 1996, 61, 434−435, and in the literature that are further cited therein. The description of the common variables, as they have been defined above for the compounds of Formula (I), remains same for the compounds of Formula A-1. 5 The C-P coupling reactions are usually carried out in the presence of solvents, while the solvents that can be used for this reaction are not particularly limited as long as they do not adversely affect the reaction. For example, ethers such as 1,4-dioxane, tetrahydrofuran, and diethylene glycol dimethyl ether; aromatic hydrocarbons such as benzene, toluene, and xylenes; N-amides such as N,N- dimethylformamide, N-dimethylacetamide, and 1-methyl-2-pyrrolidone; alcohols such as methanol, 10 ethanol, propanol, butanol, 2-propanol, and 2-methyl-2-propanol; halogenated solvents such as chlorobenzene, dichloromethane, chloroform, 1,2-dichloroethane, and 1,1,2,2-tetrachloroethane; nitriles such as acetonitrile; or water or a mixture thereof may serve this purpose. The reaction is carried out in the presence of a base selected from, but not limited to, metal alkoxides such as sodium methoxide, sodium ethoxide, potassium tert-butoxide, and sodium tert-butoxide; inorganic bases such 15 as sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, cesium carbonate, sodium phosphate, tribasic potassium phosphate, potassium hydrogen phosphate, and potassium hydride; organic bases such as triethylamine, N,N-diisopropylethylamine, and pyridine. The palladium catalysts that can be used for this reaction include, but are not limited to, inorganic palladium salts such as palladium chloride, organic palladium complexes such as palladium acetate, 20 tetrakis(triphenylphosphine)palladium(0), bis (triphenylphosphine)palladium(II) chloride, 1,1'-bis (diphenylphosphino) phenylpalladium (II) chloride, 1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium, and tris(dibenzylidene acetone)dipalladium(0). Similar transformations can also be carried out using suitable nickel catalysts; Ni(COD)2, NiCl2(dppf), NiBr2, NiCl2(Ph3P)2, and NiCl2(DME) are some of the most commonly used catalysts for this 25 transformation. A person skilled in the art can further use ligands in combination with the above-mentioned catalysts for a fruitful transformation. A list of possible ligands for this transformation include, but are not limited to, pyridine, triphenylphosphine, tris(o-tolyl)phosphine, tricyclohexylphosphine, tri-tert-butyl phosphonium tetrafluoroborate, 1,2-bis(dicyclohexylphosphino)ethane, (oxydi-2,1-30 phenylene)bis[dicyclohexyl] phosphine, 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene, 2- dicyclohexylphosphino-2′-(N,N-dimethylamino)biphenyl, 2-dicyclohexylphosphino-2′,4′,6′- triisopropylbiphenyl, 2-dicyclohexylphosphino-2′,6′-dimethoxybiphenyl, 2-dicyclohexylphosphino- 2′,6′-diisopropoxybiphenyl, 2-di-tert-butylphosphino-2′,4′,6′-triisopropylbiphenyl, 2-di-tert- butylphosphino-3,4,5,6-tetramethyl-2′,4′,6′-triisopropyl-1,1′-biphenyl, (2-biphenylyl) di-tert-35 butylphosphine; 2-(di-tert-butylphosphino)biphenyl, 2-di-tert-butylphosphino-3,4,5,6-tetramethyl- 2′,4′,6′-triisopropyl-1,1′-biphenyl, 1,1′-ferrocenediyl-bis(diphenylphosphine), 2-di-tert- PI External butylphosphino-2′-methylbiphenyl, 2-methyl-2′-dicyclohexylphosphinobiphenyl, and [1,1′-biphenyl]- 3-sulfonic acid, 2′-(dicyclohexylphosphino)-2,6-dimethoxy- sodium salt. The preferred ligands include pyridine, 1,2-bis(dicyclohexylphosphino)ethane, 2-(di-tert-butylphosphino)biphenyl, 2- dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl, 2-di-tert-butylphosphino-3,4,5,6-tetramethyl- 5 2′,4′,6′-triisopropyl-1,1′-biphenyl (Oxydi-2,1-phenylene)bis[dicyclohexyl] phosphine, 1,1′- ferrocenediyl-bis(diphenylphosphine), and 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene. Furthermore, a person skilled in the art can contemplate myriads of pre-catalysts that can also utilized for such transformations. Halogens such as chloro-, bromo-, and iodo- are the most trivial leaving groups (LG) that can be used in this transformation. However, a person skilled in the art can effortlessly 10 envision that besides halogens, tosylates, mesylates, triflates, and even boronic acids / esters would also be effective in comparable manners, allowing fruitful transformations. The reactions can be performed at a temperature range of 0-200 °C, preferably at a temperature range of 50-150 °C for a duration of time between 30 minutes to 24 hours. Additionally, the reaction can also be performed with microwave- assistance, a tool which can be particularly useful for the substrates where to obtain C-P coupling 15 products can be challenging with traditional heating methods. A person skilled in the art can also envision photocatalytic as well as dual-photocatalytic transformations to obtain the compounds of Formula I. For suitable methods, see, for example, Chem. Sci., 2015, 6, 1194-1198, ACS Catal. 2016, 6(12), 8410–8414, and Chem. Eur. J.2015, 21(13), 4962- 4965, and the literature cited therein. Furthermore, the compounds of Formula I can also be obtained 20 using electrochemically-assisted synthetic methods that are depicted in the literature, for example, Org. Biomol. Chem., 2018, 16, 4495-4500, and in the literature cited therein. Scheme-2: In another preferred embodiment, compounds of Formula (I), wherein Z is (un)substituted 25 aryls / heteroaryls, can be prepared by cross-coupling reactions between the compounds of Formula A-2 and phosphine oxides or phosphine sulfides of Formula D-1 (G= O, S) following the general C-P coupling protocols (Scheme-2) that have been illustrated above in the description of scheme 1. The general C-P coupling protocols have also been described in various literature (see, for example, Org. Lett.2012, 14, 4370–4373, Org. Lett.2013, 15, 5362–5365, Org. Biomol. Chem., 2012, 10, 3500-3505, 30 Journal of Organometallic Chemistry 2016, 820, 120-124, US0055000295, and CN116462709) and in the literature cited therein. Compounds of Formula I, wherein G = S and Z is (un)substituted aryls / heteroaryls, can also be prepared from the phosphine oxides of Formula I, wherein G = O and Z PI External is (un)substituted aryl / heteroaryls, in the presence of various thionating agents, for instance, Berzelius reagent, Lawesson’s reagent, Belleau’s reagent, and Jan Bergman’s reagent, as described in various literature (Scheme-1; see, for example, WO2016000581 and Beilstein J. Org. Chem.2020, 16, 88–105) and the literature cited therein. Compounds of Formula D-1 can either be commercially obtained or 5 synthesized by methods which are described in US 20190270704, Org. Lett.2019, 21, 2597-2601, Org. Lett.2017, 19(14), 3899-3902, Synthesis 2020, 52, 141–149, CN116462709, and J. Org. Chem.1996, 61, 434−435 and in the literature further cited therein. The description of the common variables, as they have been defined above for the compounds of Formula (I), remains the same for the compounds of Formula A-2. 10 Scheme-3: According to the scheme 3, the present invention provides methods for the preparation of compounds of the Formula A-2, wherein A1 and R3are as defined above, via Csp2-Csp2cross-coupling reactions 15 between the compounds of Formula A-1 and B’ using the procedures that are described for various coupling reactions in the literature (For coupling reactions such as Suzuki, Kumada, Stille, Negishi, and Hiyama, see Tetrahedron 2002, 58(14), 2885-2890, J. Org. Chem., 2005, 70, 2832-2834, J. Org. Chem., 2008, 73, 7380-7382, Org. Lett., 2007, 9, 2239-2242, and Synthesis, 2001, 15, 2231-2233) and in the literature that are cited therein. Furthermore, the compounds of Formula A-2 can also be prepared 20 via C-N cross-coupling reactions between A-1 and B” using Ullmann, Chan-Lam or Buchwald-Hartwig conditions. For recent reviews on C-N coupling, see Chem. Rev.2016, 116, 12564−12649, Catal. Sci. Technol., 2024, 14, 2320-2351, and Org. Process Res. Dev.2022, 26, 1690−1750. The compounds of Formula B’ and B” can either be obtained commercially or synthesized by the methods that are analogous to which are described in e.g., WO2003076422, WO2019002606, J. Org. Chem. 1995, 60, 25 7508-7510, WO2009027679, J. Am. Chem. Soc. 2007, 129, 14193-14195, Eur. J. Org Chem. 2018, 2018, 120-125, Org. lett. 2018, 20, 6188-6192 and J. Org. Chem. 2004, 69, 8305-8314, and in the literature further cited therein. The description of the common variables, as they have been defined above for the compounds of Formula (I), remains the same for the compounds of Formula A-1 and A- 2. PI External The Csp2-Csp2cross-coupling reactions are usually carried out in the presence of solvents, while the solvents that can be used for this reaction are not particularly limited as long as they do not adversely affect the reaction. For example, ethers such as 1,4-dioxane, tetrahydrofuran, and diethylene glycol dimethyl ether; aromatic hydrocarbons such as benzene, toluene, and xylenes; N-amides such as N,N- 5 dimethylformamide, N-dimethylacetamide, and 1-methyl-2-pyrrolidone; alcohols such as methanol, ethanol, propanol, butanol, 2-propanol, 2-methyl-2-propanol, and 2-Methyl-2-butanol; halogenated solvents such as chlorobenzene, dichloromethane, chloroform, 1,2-dichloroethane, and 1,1,2,2- tetrachloroethane; nitriles such as acetonitrile; or water or a mixture thereof may serve this purpose. The reaction is carried out in the presence of a base selected from, but not limited to, metal alkoxides 10 such as sodium methoxide, sodium ethoxide, potassium tert-butoxide, and sodium tert-butoxide; inorganic bases such as sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, cesium carbonate, sodium phosphate, tribasic potassium phosphate, potassium hydrogen phosphate, and potassium hydride; organic bases such as triethylamine, N,N-diisopropylethylamine, and pyridine. The palladium catalysts that can be used for this reaction include, but are not limited to, 15 inorganic palladium salts such as palladium chloride, organic palladium complexes such as palladium acetate, tetrakis(triphenylphosphine)palladium(0), bis (triphenylphosphine)palladium(II) chloride, 1,1'- bis (diphenylphosphino) phenylpalladium (II) chloride, 1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium, and tris(dibenzylidene acetone)dipalladium(0). A person skilled in the art also knows that not only palladium but nickel catalysts such as nickel(II) 20 acetylacetonate, nickel(II)bis(triphenylphosphine) dichloride, bis(tricyclohexylphosphine)nickel(II) dichloride, and (PPh3)2Ni(o-tolyl)Cl would also be suitable for the above transformations. A person skilled in the art can further use ligands in combination with the above-mentioned catalysts for a fruitful transformation. A list of possible ligands for this transformation include, but are not limited to, pyridine, triphenylphosphine, tris(o-tolyl)phosphine, tricyclohexylphosphine, tri-tert-25 butylphosphonium tetrafluoroborate, 1,2-bis(dicyclohexylphosphino)ethane, (oxydi-2,1- phenylene)bis[dicyclohexyl] phosphine, 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene, 2- dicyclohexylphosphino-2′-(N,N-dimethylamino)biphenyl, 2-dicyclohexylphosphino-2′,4′,6′- triisopropylbiphenyl, 2-dicyclohexylphosphino-2′,6′-dimethoxybiphenyl, 2-dicyclohexylphosphino- 2′,6′-diisopropoxybiphenyl, 2-di-tert-butylphosphino-2′,4′,6′-triisopropylbiphenyl, 2-di-tert-30 butylphosphino-3,4,5,6-tetramethyl-2′,4′,6′-triisopropyl-1,1′-biphenyl, (2-biphenylyl) di-tert- butylphosphine; 2-(di-tert-butylphosphino)biphenyl, 2-di-tert-butylphosphino-3,4,5,6-tetramethyl- 2′,4′,6′-triisopropyl-1,1′-biphenyl, 1,1′-ferrocenediyl-bis(diphenylphosphine), 2-di-tert- butylphosphino-2′-methylbiphenyl, 2-methyl-2′-dicyclohexylphosphinobiphenyl and [1,1′-biphenyl]- 3-sulfonic acid, 2′-(dicyclohexylphosphino)-2,6-dimethoxy- sodium salt. The preferred ligands include35 pyridine, 1,2-bis(dicyclohexylphosphino)ethane, 2-(di-tert-butylphosphino)biphenyl, 2- dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl, 2-di-tert-butylphosphino-3,4,5,6-tetramethyl- PI External 2′,4′,6′-triisopropyl-1,1′-biphenyl (Oxydi-2,1-phenylene)bis[dicyclohexyl] phosphine, 1,1′- ferrocenediyl-bis(diphenylphosphine), and 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene. Furthermore, a person skilled in the art can contemplate myriads of pre-catalysts that can also utilized for such transformations. Halogens such as chloro-, bromo-, and iodo- are the most trivial leaving 5 groups (LG) that can be used in this transformation. However, a person skilled in the art can effortlessly envision that besides halogens, tosylates, mesylates, and triflates would also be effective in comparable manners, allowing fruitful transformations. The reactions can be performed at a temperature range of 0-200 °C, preferably at a temperature range of 25-150 °C for a duration of time between 30 minutes to 24 hours. Additionally, the reaction can also be performed with microwave-assistance, especially for 10 substrates where C-C coupling can be challenging with traditional heating methods. The C-N coupling reactions are usually carried out in the presence of solvents and the solvents which can be used for this reaction are not particularly limited, as long as it does not adversely affect the reaction. For example, ethers such as dioxane, tetrahydrofuran, ethylene glycol, dimethyl ether, and diethylene glycol dimethyl ether; aromatic hydrocarbons such as benzene, toluene, chlorobenzene, and15 xylenes; N-amides such as N,N-dimethylformamide, N-dimethylacetamide, and 1-methyl-2- pyrrolidone; alcohols such as methanol, ethanol, propanol, butanol, 2-propanol, and 2-methyl-2- propanol; nitriles such as acetonitrile; haloalkyls such as chloroform and dichloromethane; or water or a mixture thereof may serve this purpose. The reaction is typically carried out in the presence of a base selected from, but not limited to, metal alkoxides such as sodium methoxide, sodium ethoxide, 20 potassium tert-butoxide, and sodium tert-butoxide; inorganic bases such as sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, cesium carbonate, sodium phosphate, potassium phosphate, potassium hydrogen phosphate, and potassium hydride; organic bases such as triethylamine, N,N-diisopropylethylamine, and pyridine. The C-N coupling reactions are primarily metal catalysed and as catalysts, palladium and copper are the preferred choices. The palladium 25 catalysts that can be used in these transformations include, but are not limited to, inorganic palladium salts such as palladium chloride; organic palladium complexes such as palladium acetate; tetrakis (triphenylphosphine) palladium (0), bis (triphenylphosphine) palladium (II) chloride, 1,1'-bis (diphenylphosphino) phenylpalladium (II) chloride, and tris (dibenzylidene acetone) dipalladium (0). Similar transformations can also be carried out using suitable copper catalysts such as copper(II) acetate, 30 copper(I) oxide, and copper halides such as copper(I) chloride, copper(I) bromide, and copper(I) iodide. In addition to the metal catalysts and pre-catalysts, C-N coupling reactions may optionally take place in the presence of ligands. Examples of ligands that can be used for this reaction include, but are not limited to, tris(o-tolyl)phosphine, tricyclohexylphosphine, tri-tert-butylphosphonium tetrafluoroborate, (oxydi-2,1-phenylene)bis[dicyclohexyl] phosphine, 4,5-bis(diphenylphosphino)-9,9-35 dimethylxanthene, 2-dicyclohexylphosphino-2′-(N,N-dimethylamino)biphenyl, 2- dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl, 2-dicyclohexylphosphino-2′,6′- PI External dimethoxybiphenyl, 2-dicyclohexylphosphino-2′,6′-diisopropoxybiphenyl, 2-di-tert-butylphosphino- 2′,4′,6′-triisopropylbiphenyl, 2-di-tert-butylphosphino-3,4,5,6-tetramethyl-2′,4′,6′-triisopropyl-1,1′- biphenyl, (2-biphenylyl) di-tert-butylphosphine,; 2-(di-tert-butylphosphino)biphenyl, 2-di-tert- butylphosphino-3,4,5,6-tetramethyl-2′,4′,6′-triisopropyl-1,1′-biphenyl, 1,1′-ferrocenediyl- 5 bis(diphenylphosphine), 2-di-tert-butylphosphino-2′-methylbiphenyl, 2-methyl-2′- dicyclohexylphosphinobiphenyl, and [1,1′-biphenyl]-3-sulfonic acid, 2′-(dicyclohexylphosphino)-2,6- dimethoxy- sodium salt. The preferred ligands include 2-(di-tert-butylphosphino)biphenyl, 2-di-tert- butylphosphino-3,4,5,6-tetramethyl-2′,4′,6′-triisopropyl-1,1′-biphenyl (Oxydi-2,1- phenylene)bis[dicyclohexyl] phosphine, 1,1′-ferrocenediyl-bis(diphenylphosphine, 1,10-10 phenanthroline, 4,7-dimethoxy-1,10-phenanthroline, 8-hydroxyquinoline, ethylenediamine, 1,2- dimethylethylenediamine trans-1,2-cyclohexanediamine, trans-N,N’-dimethyl-1,2- cyclohexanediamine, 1,10-phenanthroline, N,N-dimethylglycine, L-proline, (1E,2E)-oxalaldehyde dioxime, and 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene. Halogens such as chloro-, bromo-, and iodo- are the most trivial leaving groups (LG) that can be used in this transformation. However, a 15 person skilled in the art can effortlessly envision that besides halogens, tosylates, mesylates, triflates, and even boronic acids / esters would also be effective in comparable manners, allowing fruitful transformations. The reaction can be performed at a temperature range between 0-200 °C, preferably temperatures between 50-150 °C. The duration of the reaction can be between 30 minutes to 24 hours. 20 Scheme-4: According to the scheme 4, the present invention provides alternate methods for the preparation of compounds of the Formula A-2, wherein A1 and R3are as defined above, via Csp2-Csp2cross-coupling 25 reactions between the compounds of Formula A-3 and B”, wherein LG1 is more labile under the reaction conditions than LG, following the general C-C coupling procedure which has been illustrated above in the description of scheme-3. The description of the common variables, as they have been defined above for the compounds of Formula (I), remains same for A-3. 30 Scheme-5: PI External According to the scheme 5, the present invention provides methods for the preparation of compounds of Formula A-3, wherein A1 and R3are as defined above, via various functional group transformations of the compounds of Formula A-1 that are known to a person skilled in the art. All of the above reactions 5 can be performed by analogous methods that are described in the literature, see, for example, WO2003076422, WO2019002606, J. Org. Chem.1995, 60, 7508-7510, WO2009027679, J. Am. Chem. Soc.2007, 129, 14193-14195, Eur. J. Org Chem.2018, 2018, 120-125, Org. lett.2018, 20, 6188-6192, and J. Org. Chem.2004, 69, 8305-8314 and in the literature further cited therein. 10 According to one of the preferred embodiments, the compounds of Formula A-1 is represented by the compounds of Formula A-1A and A-1B. Unless it is specified otherwise, all variables in A-1A and A- 1B carry the same meaning as they have been defined above. Scheme-6: 15 According to the scheme 6, the present invention provides a method for the preparation of compounds of the general Formula A-1A and A-1B from ketones of Formula B-1, wherein A1, A2(C, N, S) and R3are as defined above. Suitably substituted heteroaryl ketones of Formula B-1 can undergo α- halogenation reactions in the presence of halogens or halogen surrogates such as bromine, N- 20 bromosuccinimide, tetrabutylammonium bromide. To obtain heteroaryl α-haloketones of the Formula B-2, the α-halogenation reaction on B-1 is typically carried out in a solvent, preferably in ethanol or 1,4-dioxane, and at temperatures between 0-100 °C, more preferably between 10-80 °C. Heteroaryl α- haloketones B-2 can further react with appropriately substituted heteroaryl amines of the Formula C-1 or C-2, wherein A1, A2, R1and R2are as defined above and LG represents leaving groups, in the presence 25 of a suitable base such as potassium carbonate, cesium carbonate, sodium bicarbonate, triethylamine and N,N- diisopropylethylamine, in solvents such as ethanol, 1,4-dioxane, 1,2-dimethoxyethane and PI External acetonitrile, and at temperatures between 50-110 °C, to form substituted 5,6- and 5,5- fused bicyclic compounds of the general Formula A-1A and A-1B, respectively (for literature references see, for example, WO2009027733, WO2016071499, and WO2022150920). According to one of the preferred embodiments, the compounds of Formula A-1 are represented by the 5 compounds of Formula A-1C. Unless it is specified otherwise, all variables in A-1C carry the same meaning as they have been defined above. Scheme-7: According to the scheme 7, the present invention provides a method for the preparation of compounds 10 of the general Formula A-1C from heteroaryl carboxylic acids of Formula B-3, wherein A1 and R3are as defined above. Heteroaryl carboxylic acids B-3 can undergo various acid- or base- catalysed esterification reactions. B-3 esters, upon base-mediated addition-elimination reactions with appropriate nitriles, wherein R1is as defined above, can form α-cyanoketones of Formula B-4, as it is depicted in e.g., WO2021224636 and in the literature that are cited therein. Bases that can be used for this15 transformation are, for example, but not limited to, sodium hydride, potassium hydride, sodium tert- butoxide, potassium tert-butoxide, lithium bis(trimethylsilyl)amide, sodium bis(trimethylsilyl)amide, and potassium bis(trimethylsilyl)amide. Solvents that are preferred for this transformation are either etherial such as tetrahydrofuran and 1,4-dioxane, or, aromatic hydrocarbons such as toluene. A wide range of temperatures can be suitable for the syntheses of α-cyanoketones B-4 at temperatures between 20 -78 °C to 90 °C. Furthermore, in the presence of hydrazine hydrate or in hydrazine hydrate and acetic acid mixtures, α-cyanoketones can form aminopyrazoles in primary alcohols as solvents, for example, ethanol or isopropanol, at elevated temperatures preferably between 40-90 °C. Such aminopyrazoles, if heated further, preferably between 80-160 °C, with suitably substituted acrylates of Formula C-3, wherein R represents alkyls groups (methyl, ethyl etc.) and R2 is as defined above, in the presence of 25 inorganic bases such as cesium carbonate, sodium carbonate, and potassium carbonate, and in solvents, for example, N,N-dimethyl formamide, can form pyrazolo pyrimidinones of the general Formula B-5, wherein, A1, R1, R2 and R3 carry their usual meaning. Pyrazolo pyrimidinones of Formula B-5 can be transformed into A-1C upon reaction with POCl3 or POBr3, either in neat conditions or in solvents, for instance, acetonitrile, 1,2-dichloroethane, dichloromethane, 1,4-dioxane, pyridine, and toluene, at a 30 temperature range between 25-100 °C (for literature references see, for example, WO2021165834). PI External According to one of the preferred embodiments, the compounds of Formula A-1 are represented by the compounds of Formula A-1D’. Unless it is specified otherwise, all variables in A-1D’ carry the same meaning as they have been defined above. Scheme-8: 5 According to the scheme 8, the present invention provides a method for the preparation of compounds of the general Formula A-1D’ starting from heteroaryl carboxylic acids of Formula B-3, wherein A1 and R3are as defined above. Heteroaryl carboxylic acids B-3 can undergo various acid- or base- catalysed esterification reactions; B-3 esters upon addition to a mixture of strong organometallic bases 10 such as lithium bis(trimethylsilyl)amide, lithium bis(trimethylsilyl)amide, and lithium diisopropylamide, and the heteroaryls of Formula C-4 in a suitable solvent such as tetrahydrofuran, at a temperature range between -78 °C to 45 °C, can form heteroaryl alkyl ketones of Formula B-6, wherein A1, R1, R2and R3are as defined above. Ketones of Formula B-6 can further react with hydroxylamine hydrochloride, in the presence of a base preferably sodium hydroxide, in solvents such as methanol, 15 water, or a methanol-water mixture, and at temperatures between 60-100 °C to form diastereomeric mixtures of oximes B-7. Anhydrides such as trifluoromethanesulfonic anhydride and trifluoroacetic anhydride, or sulfonyl chlorides preferably methane sulfonyl chloride, can convert the oximes B-7 into more labile acetyl or tosyl or mesyl oximes in the presence of a base, preferably triethylamine, in solvents such as 1,2-dichloroethane and 1,2-dimethoxyethane, and at temperatures between -10 °C to 20 50 °C. Oximes B-7, via a catalytic, intramolecular N-N bond formation reaction, can form the advanced intermediates of the general Formula A-1D’. The catalysts that can be used for such intramolecular N- N bond formations are typically iron-based, preferably FeCl2 and FeCl3. Solvents that are suitable for this transformation are 1,2-dichloroethane and 1,2-dimethoxyethane, and the preferred temperatures are between 50-150 °C (for literature references see, for example, Bioorganic & Medicinal Chemistry 2017, 25 25, 2635-2642 and WO2003050120). According to one of the preferred embodiments, the compounds of Formula A-1 are represented by the compounds of Formula A-1E. Unless it is specified otherwise, all variables in A-1E carry the same meaning as they have been defined above. Scheme-9: PI External According to the scheme 9, the present invention provides a method for the preparation of compounds of the general Formula A-1E starting from heteroaryl carboxylic acids of Formula B-3, wherein A1 and R3are as defined above. Heteroaryl carboxylic acids B-3 (or their acid chloride intermediates) and 5 appropriately substituted aryl- and heteroaryl- amines of Formula C-5, wherein A1 and R2are defined as above and X-represents halogens, can form amides of Formula B-9 using a plethora of acid (or its activated surrogate e.g., acyl chloride)-amine coupling protocols that are reported in the literature (see for example, European Journal of Organic Chemistry 2020, 30, 4641-4651). Amides of Formula B-9 can be converted into thioamides using suitable thionating agents, for instance, Lawesson’s reagent, 10 Belleau’s reagent, and phosphorus pentasulfide, in solvents such as toluene, xylenes, chlorobenzene, N,N-dimethylformamide, dimethyl sulfoxide, diphenyl ether at temperatures between 20-200 °C. B-9 thioamides in the presence of bases such as potassium carbonate, cesium carbonate, potassium tert- butoxide, sodium hydride, trisodium phosphate 1,8-diazabicyclo[5.4.0]undec-7-ene, and pyridine (also as a solvent) can undergo in situ intramolecular cyclization to form compounds of Formula A-1E,15 wherein the variables are the same as defined above (see, for example, Chemistry Select 2017, 2, 7227- 7232 and Synlett 2007, 13, 2121-2123). Amides of the general Formula B-9 can also be converted into A-1E by combining the aforementioned thioamidation and intramolecular cyclization steps in a one-pot fashion. The same transformation of the B-9 thioamides can also be achieved in the presence of Cu- catalysts e.g., CuI, CuI2, and CuBr, and ligands, preferably 1,10-phenanthroline and (±)-1,1′- 20 binaphthyl-2,2′-diamine, in suitable solvents such as acetonitrile and N,N-dimethylformamide, and in the presence of bases such as potassium carbonate, cesium carbonate, and potassium tert-butoxide, at temperatures between 70-160 °C (see, for example, Tetrahedron Letters 2023, 116, 154319). Similarly, Pd-catalysed transformations are also reported with tris(dibenzylideneacetone)dipalladium(0) in the presence of ligands such as ditert-butyl-(2-phenylphenyl)phosphane, tri-tert-butylphosphine, and di(1- 25 adamantyl)-n-butylphosphine. Suitable bases for this transformation are cesium carbonate and potassium tert-butoxide and the reaction is carried out in solvents e.g., 1,2-dimethoxyethane, tetrahydrofuran, and 1,4-dioxane, preferably at a temperature range between 60-120 °C (for literature references see, Tetrahedron Letters 2023, 44, 6073–6077). Amides of Formula B-9a, where X=H, can PI External also be transformed into A-1E in two steps. Thioamides of B-9a can be obtained from amides B-9a using thionation protocols as it is depicted above which under oxidative conditions such as bromine, iodine, 2,3-dichloro-5,6-dicyano-1,4-benzoquinone, and potassium ferricyanide, can intramolecularly cyclize into compounds of the general Formula A-1E (for literature references see, e.g., Tetrahedron 5 2007, 63, 10276-10281, Bioorganic & Medicinal Chemistry Letters 2016, 26, 4527-4535). Alternatively, metal catalysed C-S coupling with disodium sulfide, potassium sulfide or other thiol surrogates can form thiol intermediates of B-9, which if subject to strong acids such as concentrated hydrochloric acid can intramolecularly cyclize to form compounds of Formula A-1E in one pot (for literature references see, e.g., Angewandte Chemie International Edition 2009, 48, 4222-4225, 10 WO2016087418, and WO2016087371). Scheme-10: According to the scheme 10, the present invention provides an alternate method for the preparation of compounds of the general Formula A-1E starting from heteroaryl aldehydes of Formula B-10, wherein 15 A1 and R3are as defined above. Aldehydes B-10, in the presence of aryl- or heteroaryl- aminothiols of the general Formula C-6, wherein A1 and R2are as defined above and X1is -SH can form imines which can further intramolecularly cyclize with a wide variety of oxidants such as 2,3-dichloro-5,6-dicyano- 1,4-benzoquinone, Dess-Martin periodinane, lead tetraacetate, sodium metabisulfite, iodine, t-butyl hydroperoxide, silver perchlorate, silver nitrate, manganese oxide, oxygen and oxygen in presence of a 20 lanthanide catalyst, to form A-1E in one-pot. Common organic solvents, for instance, dichloromethane, tetrahydrofuran, ethanol, and N,N-dimethyl formamide are suitable for this transformation at temperatures between 28-160 °C (for literature references see, e.g., CN113416173, CN116217513). Alternatively, A-1E can also be obtained via a three-component reaction among B-10, C-6a and elemental sulfur, wherein for C-6a, A1 and R2are as defined above and X1represents halogens. In this 25 reaction, the elemental sulfur provides a source of sulfur as well as acts as an oxidizing agent. This transformation is typically Cu-catalysed, CuCl2, CuBr, and CuI are of preferred choices, in the presence of a suitable base such as potassium carbonate, and an appropriate ligand e.g., 1,10-phenanthroline. The reaction is carried out in solvents such as dimethyl sulfoxide, N,N-dimethylformamide and water, preferably at a temperature between 80-160 °C (for references, see, Chemistry - A European Journal PI External 2012, 18, 4840-4843). A metal-free, ligand-free and base-free three component reaction has also been reported recently (see, for example, Synlett 2020, 31, 2054-2058). Scheme-11: 5 According to the scheme 11, the present invention provides an alternative method for the preparation of compounds of the general Formula A-1E, starting from heteroaryl boronic acids / esters of Formula B-11, wherein A1 and R3are as defined above. Heteroaryl boronic acids / esters B-11, in the presence of heteroaryl halides of Formula C-7, wherein A1 and R2are as defined above and X is Br or I, under appropriate Pd-catalysed conditions such as tetrakis(triphenylphosphine)palladium,10 dichlorobis(triphenylphosphine)palladium and dichloro[1,1′- bis(diphenylphosphino)ferrocene]palladium(II), in the presence of bases e.g., potassium carbonate and sodium carbonate and in appropriate solvents for instance, dimethylformamide, tetrahydrofuran, water, 1,4-dioxane or in their binary mixture can undergo Suzuki or Suzuki-Miyaura type Csp2-Csp2bond formation reactions at temperatures between 70 °C-140 °C, to afford compounds of the general Formula 15 A-1E as it is depicted in the literature WO2007086800 and WO2019234243 and in the literature that are cited therein. Scheme-12: PI External According to the scheme 12, the present invention provides an alternative method for the preparation of compounds of the general Formula C-7 starting from (hetero)aryl amines of Formula C-9, wherein A1and R2are as defined above and X-represents halogens. In reactions with potassium thiocyanate, C- 9 (hetero)aryl amines can be transformed into bicyclic heteroaryl amines of the general Formula 5 C- 8, in the presence of acids such as hydrochloric acids, acetic acids, at temperatures between 20- 120 °C, in a suitable solvent or in a mixture of solvents and optionally in the presence of an oxidant such as bromine. Appropriate solvents for this transformation can be water, ethanol, and 1,4-dioxane. For the literature references for Path-A see e.g., Tetrahedron Letters 2013, 54, 830-833, Journal of Medicinal Chemistry 2019, 62, 10362-10375, and Bioorganic & Medicinal Chemistry Letters 2019, 29, 126639. 10 Bicyclic heteroaryl amines C-8 can further be converted into corresponding halo-analogues of Formula C-7 in a Sandmeyer type transformation which is typically carried out in the presence of nitrites such as tert-butyl nitrite, isoamyl nitrite and isopentyl nitrite. The reaction can optionally be Cu-catalysed, for instance, cupric bromide in combination with an appropriate halogen source such as tetrabutylammonium bromide and N-bromosuccinimide, or halogenated Cu-salts e.g., cupric bromide 15 can be used stoichiometrically to serve a dual purpose (catalyst as well as a halogen source) for this transformation. Acids such as p-toluenesulfonic acid can optionally be used in this transformation. Sandmeyer type transformations are preferably carried out in solvents such as acetonitrile, 1,2- dichloroethane, N,N-dimethylformamide, tetrahydrofuran and water or in their binary mixtures and at temperatures preferably between 0-70 °C. For literature references see, Journal of the American 20 Chemical Society 2020, 142, 14080-14089, Bioorganic & Medicinal Chemistry 2017, 25, 3406-3430, and Chemistry - A European Journal 2016, 22, 9330-9337. Alternatively, bicyclic heteroaryl amines C- 8 can be obtained in three steps starting from C-9 (hetero)aryl amines. Compounds of Formula C-9 can react with benzoyl isothiocyanate B-12 in a variety of solvents such as acetone, dichloromethane, tetrahydrofuran, acetonitrile and ethyl acetate, preferably at temperatures between 20-100 °C to form 25 compounds of the general Formula C-10 (see, for example, Journal of Medicinal Chemistry 2015, 58, 9722-9730 and Journal of Medicinal Chemistry 2017, 60, 1400-1416). Compounds C-10 can further be transformed into benzamide substituted bicyclic heteroaryls of Formula C-11 via a copper mediated (catalytic) e.g., cuprous iodide and copper sulfate, intramolecular cyclization. This transformation is usually performed in the presence of ligands such as N-(4,5-dihydro-2-oxazolyl)benzamide, bases for 30 instance, cesium carbonate and potassium carbonate, and solvents in particular dimethyl sulfoxide at temperatures between 60 °C-100 °C (see, for example, Tetrahedron Letters 2008, 49, 467-470 and Tetrahedron 2019, 75, 3865-3874). Benzamide substituted bicyclic heteroaryls of Formula C-11 can be hydrolyzed to bicyclic heteroaryl amines of Formula C-8 either in the presence of various acids e.g., sulfuric acid, or bases for instance sodium hydroxide, in solvents such as methanol, water, or in their 35 binary mixture, at a wide temperature range between 20-140 °C as described in the literature, for example, WO2009074812. PI External According to one of the preferred embodiments, the compounds of Formula A-1 are represented by the compounds of Formula A-1F. Unless it is specified otherwise, all variables in A-1F carry the same meaning as they have been defined above. 5 Scheme-13: According to the scheme 13, the present invention provides a method for the preparation of compounds of general Formula A-1 from substituted benzaldehydes of Formula B-13, wherein A1, R1, and R2are as defined above. LG and LG1represent leaving groups, preferably halogen substituents. Suitably 10 substituted benzaldehydes of the Formula B-13 can undergo nucleophilic substitution reactions in presence of nucleophilic organic or inorganic azides, either at room temperature (25 °C) or at an elevated temperature to obtain aryl-azides of the general Formula B-13. The aryl-azides having general Formula B-13 can be further reacted with heteroaryl amines of Formula C-12, wherein A1and R3are as defined above, to form imine intermediates which undergo in situ cyclization at an elevated temperature 15 to afford the desired bicyclic products of the Formula A-1F (see, for example, WO2016144351). However, depending on the substrate nature, such elevated temperature in situ cyclization method may pose additional challenges. To circumvent this, a lower-temperature Cu / ligand mediated method can be implemented to cyclize B-15, as described in the literature Chem. Commun., 2011, 47, 10133-10135 and in the literature cited therein (Step-3). 20 Scheme-14: PI External Alternatively, the compounds of Formula A-1F can be prepared as described in the scheme 14. Substituted benzaldehydes of the Formula B-13, wherein A1, R1and R2are as defined above, while LG and LG1represent a leaving group, preferably halogen substituents, are reacted with heteroaryl amines of the Formula C-12, wherein A1and R3are as defined above, either at room temperature (25 °C) or at 5 an elevated temperature to form imines of the general Formula B-15a. The imine of Formula B-15a, in the presence of a nucleophilic organic or inorganic azide, either at room temperature (25 °C) or at an elevated temperature, can first undergo an intermolecular substitution reaction followed by a consequent in situ intramolecular cyclization reaction to afford the bicyclic products of the Formula A- 1F (see, for example, WO2016144351). 10 Scheme-15: Alternatively, the compounds of Formula A-1F can be prepared as described in the scheme 15. Suitably substituted 2-nitrobenzaldehydes of Formula B-13a, wherein A1, R1and R2are as defined above, can be reacted with heterocyclic amines of Formula C-12, wherein A1 and R3are defined as above, to form 15 imines B-15b. Consequently, a reductive cyclization in the second reaction step, in presence of a suitable phosphorus (III) reagent, for example triethyl phosphite, at an elevated temperature, can afford bicyclic compounds of the Formula A-1F (see, for example, US2019029788). Several alternative reductive cyclization methods are available and can be implemented as depicted in the Org. Lett.2014, 16, 3114-3117 and in the literature cited therein. 20 Scheme-16:

[0002] PI External According to the scheme 16, the present invention provides a method for selective C-H functionalization at R1of the central pyrazole ring of general Formula A-1F, wherein the same R1represents hydrogen and all the other variables carry their usual meaning. In presence of N- chlorosuccinimide (NCS), A-1F can selectively undergo R1chlorination at the central pyrazole ring to 5 form compounds of the general Formula A-1F, wherein the pyrazole-R1represents Cl. Moreover, the same R1hydrogen of A-1F can also be alkylated in two successive steps. First, a similar R1iodination in presence of N-iodosuccinimide, followed by a metal catalysed Suzuki coupling reaction in presence of various alkyl boronic acids, represented by the general Formula R1B(OH)2, to form compounds of general Formula A-1F, wherein the pyrazole-R1represents different alkyl groups (for a comprehensive 10 review on C-H functionalization at the Indazole R1, see: Org. Biomol. Chem., 2022, 20, 7746). CHEMISTRY EXAMPLES: The following examples set forth the manner and process of making compounds of the present invention without being a limitation thereof and include the best mode contemplated by the inventors for carrying out the invention. 15 Experimental Procedure: Scheme A: Synthesis of intermediate (A) Step 1: Synthesis of 2-bromo-1-(pyridin-3-yl)ethan-1-one hydrobromide To a stirred solution of 1-(pyridin-3-yl)ethan-1-one (6 g, 49.5 mmol) in hydrobromic acid (33 % in 20 glacial acetic acid, 18 mL, 99 mmol), bromine (2.75 mL, 53.5 mmol) was added dropwise while maintaining the reaction temperature below 20 °C. The reaction mixture was warmed to room temperature (25 °C) and further stirred for 1.5 h at the same temperature. After completion of the reaction, the reaction mixture was filtered, the solid obtained was washed with dichloromethane (100 mL) and ethyl acetate (100 mL) and dried under reduced pressure to obtain 2-bromo-1-(pyridin-3- 25 yl)ethan-1-one hydrobromide (13.5 g, 48.1 mmol, 97 % yield) as an off-white solid. 1H-NMR (400 MHz, DMSO-d6) δ 9.32 (d, J = 1.5 Hz, 1H), 9.00-8.95 (m, 1H), 8.69 (dt, J = 8.1, 1.8 Hz, 1H), 7.92 (dd, J = 8.1, 5.4 Hz, 1H), 5.06 (s, 2H). ESI MS (m / z): 199.80 [M+1]. Step 2: Synthesis of 6-chloro-2-(pyridin-3-yl)imidazo[1,2-b]pyridazine PI External To a stirred solution of 2-bromo-1-(pyridin-3-yl)ethan-1-one hydrobromide (9 g, 32.0 mmol) in ethanol (200 mL), 6-chloropyridazin-3-amine (4.15 g, 32.0 mmol) and K2CO3(8.85 g, 64.1 mmol) were added and the resulting mixture was stirred at 75 °C for 5 h. After completion of the reaction, ethanol was evaporated under reduced pressure to obtain a residue which was re-dissolved in water (80 mL) and 5 extracted with 10 % methanol in dichloromethane solution. The combined organic solvent was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain a crude product, which was purified by CombiFlash® chromatography using 5 % methanol in dichloromethane as eluent to obtain the desired 6-chloro-2-(pyridin-3-yl)imidazo[1,2-b]pyridazine (A) (3 g, 13.01 mmol, 40.6 % yield) as an off-white solid. 10 Scheme-B: Synthesis of intermediate (B) Step 1: Synthesis of 3-(pyridin-3-yl)-1H-pyrazol-5-amine To a stirred solution of 3-oxo-3-(pyridin-3-yl)propane nitrile (5 g, 34.2 mmol) in ethanol (50 mL), hydrazine hydrate (5.03 mL, 103 mmol) was added, and the resulting reaction mixture was stirred in a 15 sealed tube at 80 °C for 16 h. After completion of the reaction, the solvent was evaporated and the obtained crude was purified by CombiFlash® chromatography (6-8 % MeOH in CH2Cl2 as eluents), 3- (pyridin-3-yl)-1H-pyrazol-5-amine was obtained as an off-white solid (4.1 g, 34.2 mmol, 74.8 % yield). 1H-NMR (400 MHz, DMSO-d6) δ 8.87 (q, J = 1.0 Hz, 1H), 8.44 (dd, J = 4.8, 1.6 Hz, 1H), 8.01-7.98 (m, 1H), 7.37 (dd, J = 7.8, 4.9 Hz, 1H), 5.78 (brs, 1H), 4.97 (brs, 2H). ESI MS (m / z): 161.05 [M+1]. 20 Step 2: Synthesis of 2-(pyridin-3-yl)pyrazolo[1,5-a]pyrimidin-5-ol To a stirred solution of 3-(pyridin-3-yl)-1H-pyrazol-5-amine (4.5 g, 28.1 mmol) in DMF (45 mL), Cs2CO3 (27.5 g, 84 mmol) and ethyl (E)-3-ethoxyacrylate (6.08 g, 42.1 mmol) were added and the resulting reaction mixture was stirred at 100 °C for 16 h. After completion of the reaction, the reaction mixture was poured into ice water and neutralized with 10 % HCl (pH ~ 7). The obtained product was 25 filtered and dried under reduced pressure to obtain 2-(pyridin-3-yl)pyrazolo[1,5-a]pyrimidin-5-ol as a yellow solid (3.5 g, 28.1 mmol, 58.7 % yield). 1H-NMR (400 MHz, DMSO-d6) δ 12.27 (s, 1H), 9.09 (s, 1H), 8.58 (d, J = 3.7 Hz, 1H), 8.54-8.49 (m, 1H), 8.24 (dt, J = 7.9, 2.0 Hz, 1H), 7.47 (dd, J = 7.8, 4.7 Hz, 1H), 6.41 (s, 1H), 5.99 (d, J = 7.9 Hz, 1H). ESI MS (m / z): 212.95 [M+1]. PI External Step 3: Synthesis of 5-chloro-2-(pyridin-3-yl)pyrazolo[1,5-a]pyrimidine A mixture of 2-(pyridin-3-yl)pyrazolo[1,5-a]pyrimidin-5-ol (3.5 g, 16.49 mmol) and phosphoryl trichloride (23.13 mL, 247 mmol) was stirred at 100 °C for 3 h in a sealed tube. After completion of the reaction, POCl3was evaporated under reduced pressure and the crude mixture was basified with 10 M 5 NaOH. The product obtained was filtered and dried under reduced pressure to obtain 5-chloro-2- (pyridin-3-yl)pyrazolo[1,5-a]pyrimidine (B) (3.6 g, 16.49 mmol, 95 % yield). 1H-NMR (400 MHz, DMSO-d6) δ 9.22 (dd, J = 7.2, 0.8 Hz, 2H), 8.63 (dd, J = 4.6, 1.5 Hz, 1H), 8.38 (dt, J = 8.0, 2.0 Hz, 1H), 7.54 (ddd, J = 7.9, 4.9, 0.9 Hz, 1H), 7.37 (d, J = 0.6 Hz, 1H), 7.17 (d, J = 7.0 Hz, 1H). ESI MS (m / z): 230.90 [M+1]. 10 Scheme C: Synthesis of intermediate (C) Step 1: Synthesis of N-(2,6-dichloropyridin-3-yl)-5-fluoronicotinamide To a stirred solution of 5-fluoronicotinic acid (10 g, 70.9 mmol) in N,N-dimethylformamide (100 mL), HATU (32.3 g, 85 mmol) and DIPEA (22.28 ml, 128 mmol) were added at 0 °C. The reaction mixture 15 was stirred at 40 °C for 1.5 h, then 2,6-dichloropyridin-3-amine (13.86 g, 85 mmol) was added. The resulting mixture was stirred at 25 °C for 16 h. After completion of the reaction, the reaction mixture was poured into ice water. The solid obtained was filtered and dried under reduced pressure to obtain N-(2,6-dichloropyridin-3-yl)-5-fluoronicotinamide as a pale-yellow solid (13 g, 45.4 mmol, 64.1 % yield). 201H-NMR (400 MHz, DMSO-d6) δ 10.65 (brs, 2H), 9.01 (t, J = 1.6 Hz, 2H), 8.84 (d, J = 2.7 Hz, 2H), 8.21 (ddd, J = 9.4, 2.8, 1.8 Hz, 2H), 8.18-8.13 (m, 2H), 7.67 (t, J = 4.2 Hz, 2H). ESI MS (m / z): 283.90 [M-1]. Step 2: Synthesis of 5-chloro-2-(5-fluoropyridin-3-yl)thiazolo[5,4-b]pyridine To a suspension of N-(2,6-dichloropyridin-3-yl)-5-fluoronicotinamide (13 g, 45.4 mmol) in pyridine 25 (120 mL), phosphorus pentasulfide (16.16 g, 36.4 mmol) was added and the resulting mixture was stirred at 110 °C for 20 h. After completion of the reaction, the solvent was removed under reduced pressure. The residue was suspended in ice water (100 mL) followed by the addition of saturated NaHCO3 (250 mL) and saturated NH4Cl (100 mL). The obtained solid was filtered and dried under PI External reduced pressure to isolate 5-chloro-2-(5-fluoropyridin-3-yl)thiazolo[5,4-b]pyridine as a brown solid (C) (10 g, 37.6 mmol, 83 % yield). 1H-NMR (400 MHz, DMSO-d6) δ 9.17 (t, J = 1.5 Hz, 1H), 8.83 (d, J = 2.8 Hz, 1H), 8.57 (d, J = 8.6 Hz, 1H), 8.42 (dq, J = 9.5, 1.5 Hz, 1H), 7.75 (t, J = 4.3 Hz, 1H). ESI MS (m / z): 265.85 [M+1]. 5 Scheme D’: Synthesis of intermediate (D’) Step 1: Synthesis of 2-(4-chloropyridin-2-yl)-1-(pyridin-3-yl)ethan-1-one Under N2 atmosphere, to a stirred solution of 4-chloro-2-methylpyridine (7 g, 54.9 mmol) and ethyl nicotinate (9.12 g, 60.4 mmol) in THF (120 mL), LiHMDS (65.8 mL, 65.8 mmol) was added dropwise 10 at 0 °C. The resulting reaction mixture was stirred at 25 °C for 16 h. After completion of the reaction, water (150 mL) was added to the reaction mixture and extracted with ethyl acetate (3 × 100 mL). The combined organic layers were dried over anhydrous Na2SO4, concentrated under reduced pressure and evaporated to get a crude product which was purified by CombiFlash® chromatography (10-15 % ethyl acetate in Hexane) to obtain 2-(4-chloropyridin-2-yl)-1-(pyridin-3-yl)ethan-1-one (7.8 g, 33.5 mmol, 15 61.1 % yield) as a yellow solid. 1H-NMR (400 MHz, Chloroform-d) Enol tautomer δ 15.12 (s, 1H), 9.05 (q, J = 1.1 Hz, 1H), 8.62 (dd, J = 4.9, 1.7 Hz, 1H), 8.24 (d, J = 5.6 Hz, 1H), 8.12 (ddd, J = 7.9, 2.3, 1.7 Hz, 1H), 7.37 (ddd, J = 8.0, 4.8, 0.8 Hz, 1H), 7.13 (d, J = 1.7 Hz, 1H), 7.05 (dd, J = 5.6, 2.0 Hz, 1H), 6.05 (s, 1H). Keto tautomer δ 9.27 (q, J = 1.0 Hz, 0.3H), 8.79 (dd, J = 4.6, 1.7 Hz, 0.3H), 8.45 (d, J = 5.4 Hz, 0.3H), 8.34-8.31 (m, 20 0.3H), 7.43 (ddd, J = 8.0, 4.8, 0.8 Hz, 0.3H), 7.22 (dd, J = 5.4, 2.0 Hz, 0.3H), 4.48 (s, 0.6H). Keto / Enol ≈ 1:3. ESI MS (m / z): 233.05 [M+1]. Step 2: Synthesis of 2-(4-chloropyridin-2-yl)-1-(pyridin-3-yl)ethan-1-one oxime To a stirred solution of 2-(4-chloropyridin-2-yl)-1-(pyridin-3-yl)ethan-1-one (7.8 g, 33.5 mmol) in MeOH (80 mL), hydroxylamine hydrochloride (11.65 g, 168 mmol) and 10 % aqueous NaOH (67.0 25 mL, 168 mmol) were added and the resulting mixture was stirred at 70 °C for 5 h. After completion of the reaction, water (200 mL) was added to the reaction mixture and extracted with ethyl acetate (3 × 150 mL). The combined organic layers were further washed with water (100 mL) and brine (100 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain 2-(4- PI External chloropyridin-2-yl)-1-(pyridin-3-yl)ethan-1-one oxime (7.0 g, 28.3 mmol, 84 % yield) as a pale-yellow solid. 1H-NMR (400 MHz, Chloroform-d) δ 9.15 (d, J = 1.8 Hz, 1H), 8.56 (dd, J = 5.0, 1.4 Hz, 1H), 8.40 (d, J = 5.5 Hz, 1H), 8.21 (d, J = 8.3 Hz, 1H), 7.39 (dd, J = 7.3, 5.5 Hz, 2H), 7.16 (dd, J = 5.3, 2.0 Hz, 1H), 5 4.38 (s, 2H). ESI MS (m / z): 248.05 [M+1]. Step 3: Synthesis of 5-chloro-2-(pyridin-3-yl)pyrazolo[1,5-a]pyridine To a stirred solution of 2-(4-chloropyridin-2-yl)-1-(pyridin-3-yl)ethan-1-one oxime (5.0 g, 20.19 mmol) in 1,2-dichloroethane (50 mL), methanesulfonyl chloride (1.730 mL, 22.21 mmol) was added at 0 °C and the reaction mixture was stirred for 15 min at 0 °C. After that, triethylamine (5.63 mL, 40.4 mmol) 10 was added into the mixture at 0 °C and the resulting mixture was warmed to 25 °C. After stirring for 1 h, an additional amount of triethylamine (1.407 mL, 10.09 mmol) was added and stirred further for 1 h. The reaction mixture was then filtered and washed with 1,2-dichloroethane (20 mL). Iron(III) chloride (0.327 g, 2.019 mmol) was added to the filtrate and stirred at 100 °C for 2 h, after which the reaction mixture was concentrated under reduced pressure. The crude material was purified by CombiFlash®15 chromatography on silica gel (eluent: 0-5 % MeOH in CH2Cl2) to obtain the desired product 5-chloro- 2-(pyridin-3-yl)pyrazolo[1,5-a]pyridine (D’) (3.8 g, 16.55 mmol, 82 % yield) as a pale-yellow solid. 1H-NMR (400 MHz, Chloroform-d) δ 9.17 (q, J = 1.0 Hz, 1H), 8.63 (dd, J = 4.9, 1.5 Hz, 1H), 8.40-8.38 (m, 1H), 8.31 (dt, J = 7.9, 2.0 Hz, 1H), 7.55 (q, J = 0.9 Hz, 1H), 7.45 (ddd, J = 7.9, 4.9, 0.6 Hz, 1H), 6.81 (d, J = 0.9 Hz, 1H), 6.77 (dd, J = 7.3, 2.1 Hz, 1H). ESI MS (m / z): 229.95 [M+1]. 20 Scheme E: Synthesis of intermediate (E) Step 1: Synthesis of 2-azido-5-bromobenzaldehyde 25 To a stirred solution of 5-bromo-2-fluorobenzaldehyde (25 g, 123 mmol) in N,N-dimethylformamide (175 ml), was added sodium azide (10.01 g, 154 mmol) and the resulting reaction mixture was stirred at 60 °C for 5 h. After completion of the reaction, the reaction mixture was diluted with water (500 mL) and the aqueous layer was extracted with ethyl acetate (2 × 250 mL). The combined organic layers were separated and washed with water (2 × 250 mL) and a brine solution (300 mL). The organic layer was30 dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain 2- azido-5-bromobenzaldehyde (25 g, 110.603 mmol, 90 % yield). 1H-NMR (400 MHz, DMSO-d6) δ 10.13 (s, 1H), 7.88 (dd, J = 8.6, 2.4 Hz, 1H), 7.83 (d, J = 2.2 Hz, 1H), 7.47 (d, J = 9.0 Hz, 1H). PI External Step 2: Synthesis of 5-bromo-2-(pyridin-3-yl)-2H-indazole To a stirred solution of 2-azido-5-bromobenzaldehyde (31 g, 137 mmol) in 1,4-dioxane (200 mL), pyridin-3-amine (14.20 g, 151 mmol) was added and the resulting reaction mixture was stirred at 120 5 °C for 24 h. After completion of the reaction, the reaction mixture was concentrated under reduced pressure and water was added to obtain a crude solid which was filtered off, collected and further purified by methyl tertiary butyl ether (200 mL) trituration to obtain the desired 5-bromo-2-(pyridin-3- yl)-2H-indazole (E) (31 g, 113.089 mmol, 82 % yield). 1H-NMR (400 MHz, DMSO-d6) δ 9.31 (d, J = 2.4 Hz, 1H), 9.18 (d, J = 0.6 Hz, 1H), 8.66 (dd, J = 4.7, 10 1.4 Hz, 1H), 8.47 (dq, J = 8.3, 1.4 Hz, 1H), 8.05 (d, J = 1.2 Hz, 1H), 7.73 (t, J = 9.5 Hz, 1H), 7.65-7.62 (m, 1H), 7.41 (dd, J = 9.2, 1.8 Hz, 1H). ESI MS (m / z): 275.90 [M+1]. Scheme F: Synthesis of intermediate (F) Under N2 atmosphere, to a stirred solution of 5-bromo-2-(pyridin-3-yl)-2H-indazole (2 g, 7.30 mmol), 15 (6-chloropyridin-3-yl)boronic acid (1.378 g, 8.76 mmol) in 1,4-dioxane (50 mL) and water (2 mL), were added dichloro[1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloromethane adduct (0.596 g, 0.730 mmol) and cesium carbonate (2.377 g, 7.30 mmol) and the resulting reaction mixture was stirred at 96 °C for 16 h. After completion of the reaction, 10 % methanol in dichloromethane (50 mL) was added and the reaction mixture was filtered through a celite bed using a sintered funnel. The 20 filtrate was dried over anhydrous sodium sulfate and concentrated to obtain a residue. The crude product was purified using an automated flash column chromatography (eluent: ethyl acetate / hexane) to obtain 5-(6-chloropyridin-3-yl)-2-(pyridin-3-yl)-2H-indazole (1.47 g, 4.79 mmol, 66 % yield). 1H-NMR (400 MHz, DMSO-d6) δ 9.38-9.36 (m, 1H), 9.31 (dd, J = 4.9, 0.9 Hz, 1H), 8.81 (dd, J = 2.8, 0.6 Hz, 1H), 8.67-8.66 (m, 1H), 8.55-8.51 (m, 1H), 8.25-8.21 (m, 1H), 8.19-8.17 (m, 1H), 7.90-7.86 25 (m, 1H), 7.74-7.70 (m, 1H), 7.68-7.64 (m, 1H), 7.61 (dd, J = 8.3, 0.6 Hz, 1H). ESI MS (m / z): 306.95 [M+1]. Scheme G: Synthesis of intermediate (G) PI External Step 1: Synthesis of 2-(pyridin-3-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-indazole To a stirred solution of 5-bromo-2-(pyridin-3-yl)-2H-indazole (E) (2 g, 7.30 mmol) and B2Pin2(2.409 g, 9.48 mmol) in 1,4-dioxane (50 mL), potassium acetate (2.148 g, 21.89 mmol) was added at 25 °C 5 under nitrogen atmosphere. The solution was further degassed for 10 minutes with nitrogen. After that, 1,1'-bis(diphenylphosphino)ferrocenedichloropalladium(II) (0.267 g, 0.365 mmol) was added and the reaction mixture was stirred at 96 °C for 16 h. After completion of the reaction, 10 % methanol in dichloromethane (50 mL) was added into the reaction mixture and it was filtered through a sintered funnel (equipped with a celite bed). The filtrate was dried over anhydrous sodium sulfate and 10 concentrated under reduced pressure to obtain a residue. The crude residue was purified by an automated flash column chromatography (eluent: hexane / ethyl acetate) to obtain 2-(pyridin-3-yl)-5- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-indazole (2 g, 6.23 mmol, 85 % yield). 1H-NMR (400 MHz, Chloroform-d) δ 9.25 (s, 1H), 8.68 (s, 1H), 8.50 (s, 1H), 8.42 (d, J = 7.6 Hz, 1H), 8.29 (s, 1H), 7.75-7.68 (m, 2H), 7.60-7.52 (m, 1H), 1.38 (d, J = 3.4 Hz, 12H). ESI MS (m / z): 321.75 15 [M+1]. Step 2: Synthesis of 5-(2-chloropyrimidin-5-yl)-2-(pyridin-3-yl)-2H-indazole Under N2 atmosphere, to a stirred solution of 2-(pyridin-3-yl)-5-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)-2H-indazole (2 g, 6.23 mmol), 5-bromo-2-chloropyrimidine (1.204 g, 6.23 mmol) in 1,4-dioxane (45 mL) and water (5 mL), 1,1'-bis(diphenylphosphino)ferrocenedichloropalladium(II) 20 (0.456 g, 0.623 mmol) and cesium carbonate (2.029 g, 6.23 mmol) were added and the resulting reaction mixture was stirred at 96 °C for 16 h. After completion of the reaction, 10 % methanol in dichloromethane (50 mL) was added into the reaction mixture and it was filtered through a sintered funnel (equipped with a celite bed). The filtrate was dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain a residue. The crude residue was purified by an25 automated flash column chromatography (eluent: hexane / ethyl acetate) to obtain 5-(2-chloropyrimidin- 5-yl)-2-(pyridin-3-yl)-2H-indazole (G) (580 mg, 1.885 mmol, 30.3 % yield). 1H-NMR (400 MHz, DMSO-d6) δ 9.38 (d, J = 2.4 Hz, 1H), 9.36 (d, J = 1.0 Hz, 1H), 9.20 (s, 2H), 8.67 (dd, J = 4.6, 1.5 Hz, 1H), 8.54 (dq, J = 8.3, 1.4 Hz, 1H), 8.29 (d, J = 1.7 Hz, 1H), 7.91 (d, J = 9.0 Hz, 1H), 7.79 (dd, J = 9.0, 1.7 Hz, 1H), 7.66 (dd, J = 8.1, 4.4 Hz, 1H). ESI MS (m / z): 308.05 [M+1]. PI External Scheme H: Synthesis of phosphine oxide (H) Step 1: Synthesis of ethyl ethylphosphinate 5 Under N2 atmosphere, to a stirred solution of triethyl phosphite (2.064 mL, 12.04 mmol) in tetrahydrofuran (20 mL), ethylmagnesium bromide (12.04 mL, 12.04 mmol) was added dropwise at 25 °C. The resulting reaction mixture was stirred at 55 °C for 3 h. After that, the reaction mixture was cooled to 25 °C and 6 N HCl was added into it to make the solution acidic (pH~2). It was further 10 evaporated under reduced pressure and the obtained residue was re-dissolved in CH2Cl2 and filtered. The filtrate was evaporated under reduced pressure to obtain (ethyl ethylphosphinate (1.4 g, 11.47 mmol, 95 % yield) as a colorless liquid which was used directly to the next step. 1H-NMR (400 MHz, CHLOROFORM-D) δ 7.17 (d, J = 540.2 Hz, 1H), 4.25-4.07 (m, 2H), 1.93-1.82 (m, 2H), 1.42-1.30 (m, 3H), 1.26-1.10 (m, 3H). 15 Step 2: Synthesis of ethyl(isopropyl)phosphine oxide Under N2atmosphere, to a stirred solution of ethyl ethylphosphinate (1.0 g, 8.19 mmol) in tetrahydrofuran (20 mL), isopropyl magnesium bromide (32.8 mL, 16.38 mmol) was added dropwise at 0 °C. The reaction mixture was stirred at 25 °C for 16 h. Afterwards, the reaction mixture was cooled 20 to 0 °C and a solution of potassium carbonate (2.83 g, 20.47 mmol) in 10 mL water was added to form a precipitate. The precipitate was filtered, and the filtrate was evaporated under reduced pressure to obtain ethyl(isopropyl)phosphine oxide (H) (500.0 mg, 8.19 mmol, 51 % yield) as a yellow liquid which was used directly into the next step. 1H-NMR (400 MHz, CHLOROFORM-D) δ 7.11-5.98 (m, 1H), 2.04-1.90 (m, 1H), 1.88-1.63 (m, 2H), 25 1.38-1.01 (m, 9H) Example 1: Synthesis of dimethyl(2-(pyridin-3-yl)-2H-indazol-5-yl)phosphine oxide (Compound Number 2) 30 PI External To a stirred solution of 5-bromo-2-(pyridin-3-yl)-2H-indazole (600 mg, 2.189 mmol) (E) in 1,4-dioxane (12 mL), triethylamine (0.915 mL, 6.57 mmol) and dimethylphosphine oxide (222 mg, 2.85 mmol) were added and the solution was degassed with N2for 5 min. After that, xantphos (253 mg, 0.438 mmol), dichloro[1,1'-bis(diphenylphosphino)ferrocene]palladium(II) (179 mg, 0.219 mmol) were 5 added and the reaction mixture was stirred at 96 °C for 16 h. After completion of the reaction, the solvent was removed under reduced pressure to obtain a crude residue which was further purified by reverse phase prep-HPLC (solvent system: 10 mM ammonium acetate aqueous buffer and acetonitrile) to afford dimethyl(2-(pyridin-3-yl)-2H-indazol-5-yl)phosphine oxide (Compound Number 2) (252 mg, 0.929 mmol, 42.4 % yield) as an off-white solid. 10 Note: Similar transformations have also been achieved using Pd2(dba)3 or Pd(OAc)2 as catalysts and Cs2CO3 as a base. Example 2: Synthesis of dipropyl(5-(2-(pyridin-3-yl)-2H-indazol-5-yl)pyridin-2-yl)phosphine oxide (Compound Number 91) 15 To a stirred solution of 5-(6-chloropyridin-3-yl)-2-(pyridin-3-yl)-2H-indazole (F) (300 mg, 0.978 mmol), triethylamine (0.409 mL, 2.93 mmol) and dipropylphosphine oxide (171 mg, 1.271 mmol) in 1,4-dioxane (10 mL) was degassed with N2for 5 min. Xantphos (113 mg, 0.196 mmol), dichloro[1,1'- bis(diphenylphosphino)ferrocene]palladium(II) dichloromethane adduct (80 mg, 0.098 mmol) were 20 added further and the reaction mixture was stirred at 140 °C for 3 h in microwave. After completion of the reaction, 10 % methanol in dichloromethane (50 mL) was added to the reaction mixture and filtered through a celite bed. The filtrate was dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain a residue. This crude product was purified by an automated flash column chromatography followed by a preparative HPLC to obtain dipropyl(5-(2-(pyridin-3-yl)-2H-indazol-5- 25 yl)pyridin-2-yl)phosphine oxide (Compound Number 91) (173 mg, 0.428 mmol, 43.7 % yield). Note: For similar transformations, Pd2(dba)3 and Cs2CO3 have also been used instead of Pd(dppf)Cl2 (or its dichloromethane adduct) and Et3N, respectively. Example 3: Synthesis of diethyl (2-(pyridin-3-yl)-2H-indazol-5-yl)phosphonate (Compound 30 Number 102) PI External To a stirred solution of 5-bromo-2-(pyridin-3-yl)-2H-indazole (4.0 g, 14.59 mmol), diethyl phosphonate (2.418 g, 17.51 mmol) in 1,4-dioxane, cesium carbonate (4.75 g, 14.59 mmol) was added, degassed with N2for 5 mins and then Pd2(dba)3(1.336 g, 1.459 mmol), Xantphos (1.689 g, 2.92 mmol) were added. The resulting reaction mixture was stirred at 96 °C for 16 h. After completion of the reaction, 5 10 % methanol in dichloromethane (100 mL) was added and the reaction mixture was filtered through a celite bed. The filtrate was dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain a residue. The crude product was purified by an automated flash column chromatography (eluent: methanol / dichloromethane) to obtain diethyl (2-(pyridin-3-yl)-2H-indazol-5- yl)phosphonate (Compound Number 102) (4.0 g, 12.07 mmol, 83 % yield). 10 Example 4: Synthesis of S,S-di-p-tolyl (2-(pyridin-3-yl)-2H-indazol-5-yl)phosphonodithioate (Compound Number 123) 15 Step-1: Synthesis of (2-(pyridin-3-yl)-2H-indazol-5-yl)phosphonic acid Diethyl (2-(pyridin-3-yl)-2H-indazol-5-yl)phosphonate (Compound Number 102) (4.0 g, 12.07 mmol) was added portion wise to a concentrated hydrochloric acid (33.3 mL, 1087 mmol) solution and the resulting reaction mixture was stirred at 100 °C for 36 h. After completion of the reaction, the solution was cooled to 0 °C at which a precipitate was formed which was filtered and the filter cake was further 20 rinsed with water to obatin (2-(pyridin-3-yl)-2H-indazol-5-yl)phosphonic acid (2.7 g, 9.81 mmol, 81 % yield). 1H-NMR (400 MHz, DMSO-d6) δ 9.36 (s, 1H), 9.34 (d, J = 2.7 Hz, 1H), 8.68 (dd, J = 4.8, 1.3 Hz, 1H), 8.51 (dq, J = 8.4, 1.3 Hz, 1H), 8.18 (d, J = 15.2 Hz, 1H), 7.79 (dd, J = 8.8, 2.4 Hz, 1H), 7.67 (dd, J = 8.3, 4.6 Hz, 1H), 7.56-7.51 (m, 1H).31P-NMR (162 MHz, DMSO-d6) δ 13.4. ESI MS (m / z): 275.65 25 [M+1]. Step-2: Synthesis of S,S-di-p-tolyl (2-(pyridin-3-yl)-2H-indazol-5-yl)phosphonodithioate To a suspension of (2-(pyridin-3-yl)-2H-indazol-5-yl)phosphonic acid (1.8 g, 6.54 mmol) in dichloromethane: acetonitrile (1:1; 30 mL), DMF (0.076 mL, 0.981 mmol) and oxalyl chloride (0.859 mL, 9.81 mmol) were added at 0 °C. After refluxing for 30 min at 80 °C, the reaction mixture 30 was concentrated under reduced pressure. The obtained yellow solid was re-dissolved in dichloromethane (30.0 mL). To this solution, triethylamine (2.279 mL, 16.35 mmol) and 4- PI External methylbenzenethiol (1.219 g, 9.81 mmol) were added at 0 °C. After stirring for 30 minutes at 25 °C, water (20 mL), was added and dichloromethane was evaporated under reduced pressure. Methanol (50 mL) was added to this crude mixture to form a precipitate which was collected by filtration to obtain S,S-di-p-tolyl (2-(pyridin-3-yl)-2H-indazol-5-yl)phosphonodithioate (Compound Number 123) (1.97 g, 5 4.05 mmol, 62 % yield) was obtained as a yellow solid. Example 5: Synthesis of S-(p-tolyl) ethyl(2-(pyridin-3-yl)-2H-indazol-5-yl)phosphinothioate (Compound Number 138) Under N2atmosphere, to a stirred solution of S,S-di-p-tolyl (2-(pyridin-3-yl)-2H-indazol-5- 10 yl)phosphonodithioate (Compound Number 123) (1.5 g, 3.08 mmol) in THF (20 mL), ethylmagnesium bromide solution (4.10 mL, 12.31 mmol) was added dropwise at -78 °C and the mixture was stirred at the same temperature for 1 h. After completion of the reaction, the reaction mixture was quenched by aqueous NH4Cl solution (100 mL) and extracted with ethyl acetate (3 × 75 mL). The combined organic layers were evaporated and the obtained crude material was purified by flash column15 chromatography. The desired product S-(p-tolyl) ethyl(2-(pyridin-3-yl)-2H-indazol-5- yl)phosphinothioate (Compound Number 138) (0.9 g, 2.287 mmol, 74.4 % yield) was obtained as an off-white solid. Example 6: Synthesis of ethyl(methyl)(2-(pyridin-3-yl)-2H-indazol-5-yl)phosphine oxide 20 (Compound Number 154) Under N2 atmosphere, to a solution of S-(p-tolyl) ethyl(2-(pyridin-3-yl)-2H-indazol-5- yl)phosphinothioate 138 (250 mg, 0.635 mmol) in THF (10 mL), methylmagnesium chloride (1.271 mL, 1.271 mmol) was added dropwise at 0 °C and the mixture was stirred at 25 °C for 4 h. After 25 completion of the reaction, the reaction mixture was quenched with water (50 mL) and extracted with ethyl acetate (3 × 50 mL). The organic layers were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained crude residue was purified by column chromatography (5-7 % MeOH in dichloromethane). The desired product ethyl(methyl)(2-(pyridin-3- yl)-2H-indazol-5-yl)phosphine oxide (Compound Number 154) was isolated as an off-white solid (120 30 mg, 0.421 mmol, 66.2 % yield). PI External Example 7: Synthesis of dimethyl(2-(pyridin-3-yl)-2H-indazol-5-yl) phosphine sulfide (Compound Number 288) 5 To a solution of dimethyl(2-(pyridin-3-yl)-2H-indazol-5-yl)phosphine oxide 2 (300 mg, 1.106 mmol) in 1,4-dioxane (10 mL), Lawesson's reagent (671 mg, 1.659 mmol) was added and the reaction mixture was stirred at 95 °C for 16 h. After completion of the reaction, the solvent was removed under reduced pressure to obtain a crude residue which was further purified by reverse phase prep-HPLC to obtain dimethyl(2-(pyridin-3-yl)-2H-indazol-5-yl)phosphine sulfide (Compound Number 288) (150 mg, 0.522 10 mmol, 47.2 % yield) as an off-white solid. Table 1: Representative compounds of the present disclosure were prepared according to the suitable starting material and method as described above. Comp. no. Structure Analytical Data 1H-NMR (400 MHz, DMSO-d6) δ 9.40 (t, J = 2.8 Hz, 2H), 8.67 (dd, J = 4.6, 1.2 Hz, 1H), 8.56 (dq, J = 8.4, 1.3 Hz, 1H), 7.96-7.93 (m, 1H), 1 7.66 (dd, J = 8.4, 4.8 Hz, 1H), 7.59 (dd, J = 13.7, 6.1 Hz, 1H), 7.48- 7.44 (m, 1H), 1.81 (d, J = 13.4 Hz, 6H); ESI MS (m / z): 271.9 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.37 (d, J = 0.6 Hz, 1H), 9.35 (d, J = 2.1 Hz, 1H), 8.67 (dd, J = 4.7, 1.4 Hz, 1H), 8.50 (dq, J = 8.4, 1.3 Hz, 2 1H), 8.27 (dt, J = 13.3, 1.1 Hz, 1H), 7.86-7.83 (m, 1H), 7.67-7.60 (m, 2H), 1.70 (s, 3H), 1.67 (s, 3H); ESI MS (m / z): 271.9 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.44 (d, J = 1.0 Hz, 1H), 9.31 (t, J = 1.3 Hz, 1H), 8.70 (d, J = 2.2 Hz, 1H), 8.60 (dt, J = 10.0, 2.3 Hz, 1H), 3 7.93 (dt, J = 8.8, 1.0 Hz, 1H), 7.60 (qd, J = 6.8, 0.9 Hz, 1H), 7.49-7.45 (m, 1H), 1.81 (d, J = 13.2 Hz, 6H); ESI MS (m / z): 289.9 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.41 (d, J = 0.7 Hz, 1H), 9.27 (q, J = 0.9 Hz, 1H), 8.71-8.70 (m, 1H), 8.53 (dt, J = 9.9, 2.4 Hz, 1H), 8.27 4 (dt, J = 13.4, 1.2 Hz, 1H), 7.85-7.82 (m, 1H), 7.64 (td, J = 9.1, 1.3 Hz, 1H), 1.71-1.63 (m, 6H); ESI MS (m / z): 289.9 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.56 (s, 2H), 9.43 (d, J = 0.7 Hz, 1H), 9.29 (s, 1H), 8.29 (dt, J = 13.4, 1.1 Hz, 1H), 7.86 (dt, J = 9.0, 0.9 5 Hz, 1H), 7.65 (td, J = 9.1, 1.3 Hz, 1H), 1.69 (d, J = 13.4 Hz, 6H); ESI MS (m / z): 272.5 [M+1]. PI External 1H-NMR (400 MHz, DMSO-d6) δ 9.36-9.33 (m, 2H), 8.68 (dd, J = 4.6, 1.5 Hz, 1H), 8.50 (dq, J = 8.3, 1.4 Hz, 1H), 8.26 (d, J = 12.5 Hz, 1H), 6 7.84 (dt, J = 8.9, 0.9 Hz, 1H), 7.68-7.64 (m, 1H), 7.55 (td, J = 8.6, 1.1 Hz, 1H), 2.06-1.86 (m, 4H), 0.94 (dt, J = 16.5, 7.7 Hz, 6H); ESI MS (m / z): 299.95 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.55 (s, 2H), 9.42 (d, J = 0.5 Hz, 1H), 9.28 (s, 1H), 8.27 (d, J = 12.2 Hz, 1H), 7.86-7.84 (m, 1H), 7.60- 7 7.55 (m, 1H), 2.04-1.88 (m, 4H), 0.94 (dt, J = 16.6, 7.7 Hz, 6H); ESI MS (m / z): 300.95 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.40 (s, 1H), 9.27 (s, 1H), 8.72 (d, J = 2.4 Hz, 1H), 8.53 (dt, J = 9.9, 2.3 Hz, 1H), 8.27-8.20 (m, 1H), 7.85- 8 7.82 (m, 1H), 7.59-7.54 (m, 1H), 2.06-1.83 (m, 4H), 1.04-0.87 (m, 6H); ESI MS (m / z): 317.55 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.38 (d, J = 1.0 Hz, 2H), 8.67 (dd, J = 4.8, 1.3 Hz, 1H), 8.55 (dq, J = 8.3, 1.4 Hz, 1H), 7.94 (dt, J = 8.6, 1.0 9 Hz, 1H), 7.65 (ddd, J = 8.3, 4.6, 0.7 Hz, 1H), 7.59 (ddd, J = 12.7, 6.7, 0.9 Hz, 1H), 7.50-7.45 (m, 1H), 2.19-2.00 (m, 4H), 0.95 (dt, J = 16.9, 7.7 Hz, 6H); ESI MS (m / z): 299.55 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.59 (s, 2H), 9.46 (s, 1H), 9.27 (s, 1H), 7.95 (d, J = 8.6 Hz, 1H), 7.60 (q, J = 6.2 Hz, 1H), 7.51-7.47 (m, 10 1H), 2.20-2.00 (m, 4H), 0.95 (dt, J = 16.8, 7.6 Hz, 6H); ESI MS (m / z): 301.05 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.42 (s, 1H), 9.31 (s, 1H), 8.70 (d, J = 2.4 Hz, 1H), 8.60 (dt, J = 10.0, 2.3 Hz, 1H), 7.93 (d, J = 8.8 Hz, 1H), 11 7.60 (q, J = 6.2 Hz, 1H), 7.51-7.46 (m, 1H), 2.20-2.00 (m, 4H), 0.95 (dt, J = 16.9, 7.7 Hz, 6H); ESI MS (m / z): 318 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.31 (d, J = 0.7 Hz, 1H), 9.19 (d, J = 2.4 Hz, 1H), 8.38 (dd, J = 8.6, 2.7 Hz, 1H), 8.28-8.24 (m, 1H), 7.83 12 (dt, J = 8.8, 1.0 Hz, 1H), 7.62 (td, J = 9.1, 1.3 Hz, 1H), 7.50 (d, J = 8.3 Hz, 1H), 2.56 (s, 3H), 1.68 (d, J = 13.2 Hz, 6H); ESI MS (m / z): 285.95 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.30 (d, J = 1.0 Hz, 1H), 9.18 (d, J = 2.7 Hz, 1H), 8.37 (dd, J = 8.3, 2.7 Hz, 1H), 8.26-8.22 (m, 1H), 7.83 13 (dt, J = 8.8, 1.0 Hz, 1H), 7.56-7.49 (m, 2H), 2.56 (s, 3H), 2.05-1.85 (m, 4H), 0.94 (dt, J = 16.5, 7.6 Hz, 6H); ESI MS (m / z): 314.1 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.34 (d, J = 0.7 Hz, 1H), 9.14 (d, J = 2.4 Hz, 1H), 8.52 (d, J = 1.0 Hz, 1H), 8.37-8.36 (m, 1H), 8.27 (dt, J 14 = 13.3, 1.1 Hz, 1H), 7.83 (dt, J = 8.8, 1.0 Hz, 1H), 7.62 (td, J = 9.1, 1.3 Hz, 1H), 2.44 (d, J = 0.5 Hz, 3H), 1.68 (d, J = 13.2 Hz, 6H); ESI MS (m / z): 285.95 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.33 (s, 1H), 9.13 (d, J = 2.4 Hz, 1H), 8.52 (s, 1H), 8.35 (s, 1H), 8.25 (d, J = 12.2 Hz, 1H), 7.83 (d, J = 15 8.8 Hz, 1H), 7.57-7.52 (m, 1H), 2.44 (s, 3H), 2.06-1.86 (m, 4H), 0.94 (dt, J = 16.5, 7.6 Hz, 6H); ESI MS (m / z): 313.05 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 8.93 (s, 1H), 8.65 (dd, J = 4.8, 1.3 16 Hz, 1H), 8.28 (d, J = 12.5 Hz, 1H), 7.99 (dd, J = 8.1, 1.2 Hz, 1H), 7.82 PI External (d, J = 8.8 Hz, 1H), 7.57-7.48 (m, 2H), 2.43 (s, 3H), 2.06-1.86 (m, 4H), 0.99-0.91 (m, 6H); ESI MS (m / z): 314 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 8.93 (d, J = 0.7 Hz, 1H), 8.66 (dd, J = 4.8, 1.6 Hz, 1H), 8.30 (dt, J = 13.4, 1.1 Hz, 1H), 7.98 (dd, J = 8.1, 17 1.5 Hz, 1H), 7.83 (dt, J = 8.8, 1.0 Hz, 1H), 7.63 (td, J = 9.2, 1.4 Hz, 1H), 7.51-7.48 (m, 1H), 2.41 (s, 3H), 1.66 (dd, J = 22.1, 13.3 Hz, 6H); ESI MS (m / z): 285.9 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.67 (d, J = 2.2 Hz, 1H), 9.54 (s, 1H), 9.08 (s, 1H), 8.91 (s, 1H), 8.29 (d, J = 13.4 Hz, 1H), 7.86 (d, J = 18 9.0 Hz, 1H), 7.66 (td, J = 9.0, 1.2 Hz, 1H), 1.69 (d, J = 13.4 Hz, 6H); ESI MS (m / z): 339.8 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.40 (d, J = 0.7 Hz, 1H), 9.26 (s, 1H), 8.72 (d, J = 2.2 Hz, 1H), 8.53 (dt, J = 9.9, 2.3 Hz, 1H), 8.24 (d, J 19 = 11.5 Hz, 1H), 7.83 (dt, J = 8.9, 0.9 Hz, 1H), 7.55-7.51 (m, 1H), 2.46- 2.36 (m, 2H), 1.08 (dd, J = 15.5, 7.2 Hz, 6H), 0.93 (dd, J = 15.6, 7.1 Hz, 6H); ESI MS (m / z): 346.05 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.59 (s, 2H), 9.49 (s, 1H), 9.33 (s, 20 1H), 9.02 (q, J = 2.1 Hz, 1H), 8.77 (dd, J = 12.6, 2.1 Hz, 1H), 1.78 (d, J = 13.4 Hz, 6H); ESI MS (m / z): 274 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.43 (s, 1H), 9.37 (d, J = 2.4 Hz, 1H), 9.00 (q, J = 2.1 Hz, 1H), 8.75-8.71 (m, 2H), 8.55 (dq, J = 8.4, 1.3 21 Hz, 1H), 7.71-7.67 (m, 1H), 1.77 (d, J = 13.4 Hz, 6H); ESI MS (m / z): 272.9 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.47 (s, 1H), 9.31 (s, 1H), 9.02 (q, J 22 = 2.1 Hz, 1H), 8.74 (dd, J = 12.1, 2.3 Hz, 2H), 8.60 (dt, J = 9.9, 2.3 Hz, 1H), 1.77 (d, J = 13.4 Hz, 6H); ESI MS (m / z): 290.85 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.00 (d, J = 2.1 Hz, 1H), 8.81 (dd, J = 4.9, 1.5 Hz, 1H), 8.27 (dq, J = 8.1, 1.4 Hz, 1H), 8.18-8.14 (m, 1H), 23 7.86 (dq, J = 8.9, 0.9 Hz, 1H), 7.74-7.69 (m, 2H), 1.71 (d, J = 13.1 Hz, 6H); ESI MS (m / z): 306 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.35-9.33 (m, 2H), 8.68 (dd, J = 4.8, 1.3 Hz, 1H), 8.49 (dq, J = 8.3, 1.4 Hz, 1H), 8.24 (d, J = 11.5 Hz, 1H), 24 7.83 (d, J = 8.8 Hz, 1H), 7.67 (dd, J = 8.3, 4.6 Hz, 1H), 7.54-7.49 (m, 1H), 2.40 (dt, J = 22.7, 7.1 Hz, 2H), 1.08 (q, J = 7.3 Hz, 6H), 0.94 (dd, J = 15.6, 7.3 Hz, 6H); ESI MS (m / z): 328 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.43 (s, 1H), 9.35 (s, 2H), 8.18 (dt, 25 J = 13.1, 1.1 Hz, 1H), 7.88 (dq, J = 9.0, 0.9 Hz, 1H), 7.74 (td, J = 9.0, 1.4 Hz, 1H), 1.73 (s, 3H), 1.69 (s, 3H); ESI MS (m / z): 306.9 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 8.94 (s, 1H), 8.89 (d, J = 2.4 Hz, 1H), 8.39 (dt, J = 9.1, 2.3 Hz, 1H), 8.17 (dd, J = 13.1, 1.1 Hz, 1H), 7.86 26 (dq, J = 9.0, 0.9 Hz, 1H), 7.73 (td, J = 9.0, 1.5 Hz, 1H), 1.71 (d, J = 13.4 Hz, 6H); ESI MS (m / z): 323.8 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.55 (s, 1H), 9.31 (s, 1H), 8.75 (d, J = 2.4 Hz, 1H), 8.61 (dt, J = 9.9, 2.3 Hz, 1H), 7.63 (dd, J = 7.3, 1.5 Hz, 27 1H), 7.56 (dd, J = 13.0, 7.3 Hz, 1H), 1.82 (d, J = 13.4 Hz, 6H); ESI MS (m / z): 323.95 [M+1]. PI External 1H-NMR (400 MHz, DMSO-d6) δ 9.48 (s, 1H), 9.28 (s, 1H), 8.74 (d, J = 2.4 Hz, 1H), 8.59 (dt, J = 9.8, 2.3 Hz, 1H), 7.64 (dd, J = 7.3, 1.2 Hz, 28 1H), 7.52 (dd, J = 11.0, 7.3 Hz, 1H), 2.59-2.52 (m, 2H), 1.16 (dd, J = 15.0, 7.0 Hz, 6H), 0.90 (dd, J = 16.0, 7.2 Hz, 6H); ESI MS (m / z): 380.25 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.72 (d, J = 0.7 Hz, 1H), 9.38 (d, J = 2.2 Hz, 1H), 8.72 (dd, J = 4.6, 1.5 Hz, 1H), 8.54 (dq, J = 8.4, 1.3 Hz, 29 1H), 8.40 (ddd, J = 8.9, 3.0, 0.9 Hz, 1H), 7.89 (dd, J = 9.0, 3.7 Hz, 1H), 7.69 (ddd, J = 8.4, 4.8, 0.7 Hz, 1H), 1.76 (s, 3H), 1.73 (s, 3H); ESI MS (m / z): 272.85 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.77 (d, J = 0.7 Hz, 1H), 9.59 (s, 2H), 9.32 (d, J = 7.6 Hz, 1H), 8.42 (ddd, J = 8.8, 2.9, 1.0 Hz, 1H), 7.91 30 (dd, J = 8.9, 3.5 Hz, 1H), 1.76 (s, 3H), 1.73 (s, 3H); ESI MS (m / z): 273.85 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.44 (s, 1H), 9.35 (d, J = 2.4 Hz, 1H), 8.71 (dd, J = 4.8, 1.3 Hz, 1H), 8.53 (dq, J = 8.3, 1.4 Hz, 1H), 7.69- 31 7.66 (m, 1H), 7.62 (dd, J = 7.3, 1.2 Hz, 1H), 7.51 (dd, J = 11.0, 7.3 Hz, 1H), 2.60-2.52 (m, 2H), 1.16 (dd, J = 14.9, 6.8 Hz, 6H), 0.91 (dd, J = 16.0, 7.2 Hz, 6H); ESI MS (m / z): 361.9 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.49 (s, 1H), 9.46 (s, 1H), 9.37 (d, J = 2.4 Hz, 1H), 8.74 (dd, J = 4.6, 1.2 Hz, 1H), 8.55 (dq, J = 8.3, 1.4 Hz, 32 1H), 8.33 (dd, J = 7.3, 1.5 Hz, 1H), 7.70 (dd, J = 8.2, 4.5 Hz, 1H), 1.67 (d, J = 13.4 Hz, 6H); ESI MS (m / z): 271.05 [M-1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.59 (s, 2H), 9.55 (d, J = 1.0 Hz, 33 1H), 9.49 (t, J = 0.7 Hz, 1H), 9.35 (s, 1H), 8.36 (dd, J = 7.3, 1.5 Hz, 1H), 1.70 (s, 3H), 1.66 (s, 3H); ESI MS (m / z): 272.05 [M-1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.53 (d, J = 0.7 Hz, 1H), 9.47 (t, J = 0.7 Hz, 1H), 9.31 (s, 1H), 8.79 (d, J = 2.2 Hz, 1H), 8.61 (dt, J = 9.8, 34 2.4 Hz, 1H), 8.34 (dd, J = 7.3, 1.5 Hz, 1H), 1.69 (s, 3H), 1.66 (s, 3H); ESI MS (m / z): 288.95 [M-1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.52 (d, J = 4.3 Hz, 1H), 9.35 (d, J = 2.4 Hz, 1H), 8.74-8.69 (m, 2H), 8.52 (dq, J = 8.3, 1.3 Hz, 1H), 8.37 35 (d, J = 3.1 Hz, 1H), 7.70 (dd, J = 8.4, 4.7 Hz, 1H), 1.79 (d, J = 13.4 Hz, 6H); ESI MS (m / z): 340 [M+1]. 1H-NMR (400 MHz, CHLOROFORM-D) δ 9.40 (s, 1H), 9.11 (d, J = 2.0 Hz, 1H), 8.77 (s, 1H), 8.64 (d, J = 2.4 Hz, 1H), 8.52 (dd, J = 6.6, 36 1.5 Hz, 1H), 8.20 (dt, J = 8.8, 2.3 Hz, 1H), 2.62-2.53 (m, 2H), 1.27 (dd, J = 15.3, 7.2 Hz, 6H), 1.11 (dd, J = 15.8, 7.2 Hz, 6H); ESI MS (m / z): 347.25 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.58 (s, 2H), 9.52 (s, 1H), 9.48 (s, 1H), 9.35 (s, 1H), 8.34 (dd, J = 6.6, 1.4 Hz, 1H), 2.46-2.39 (m, 2H), 37 1.12 (q, J = 7.2 Hz, 6H), 0.96 (dd, J = 15.4, 7.2 Hz, 6H); ESI MS (m / z): 330.1 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.45 (t, J = 1.4 Hz, 2H), 9.35 (d, J = 38 2.4 Hz, 1H), 8.74 (dd, J = 4.6, 1.5 Hz, 1H), 8.53 (dq, J = 8.4, 1.3 Hz, 1H), 8.31 (dd, J = 6.7, 1.5 Hz, 1H), 7.72-7.69 (m, 1H), 2.46-2.38 (m, PI External 2H), 1.11 (q, J = 7.3 Hz, 6H), 0.96 (dd, J = 15.3, 7.0 Hz, 6H); ESI MS (m / z): 329.05 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.52 (s, 1H), 9.46 (s, 1H), 9.29 (s, 1H), 8.79 (d, J = 2.4 Hz, 1H), 8.62-8.59 (m, 1H), 8.33 (dd, J = 7.0, 1.1 39 Hz, 1H), 2.03-1.90 (m, 4H), 1.04-0.90 (m, 6H); ESI MS (m / z): 319.3 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.48-9.46 (m, 2H), 9.36 (d, J = 2.4 Hz, 1H), 8.74 (dd, J = 4.6, 1.2 Hz, 1H), 8.54 (dq, J = 8.4, 1.3 Hz, 1H), 40 8.33 (dd, J = 6.8, 1.5 Hz, 1H), 7.72-7.69 (m, 1H), 2.03-1.92 (m, 4H), 0.94 (dt, J = 16.6, 7.7 Hz, 6H); ESI MS (m / z): 301.15 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.58 (s, 2H), 9.54 (s, 1H), 9.48 (s, 41 1H), 9.35 (s, 1H), 8.35 (dd, J = 6.8, 1.5 Hz, 1H), 2.02-1.93 (m, 4H), 0.94 (dt, J = 16.7, 7.7 Hz, 6H); ESI MS (m / z): 302 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.77 (s, 1H), 9.58 (s, 2H), 9.33 (s, 42 1H), 8.42 (dd, J = 8.9, 2.1 Hz, 1H), 7.89 (dd, J = 8.9, 3.3 Hz, 1H), 2.09- 1.99 (m, 4H), 1.03-0.94 (m, 6H); ESI MS (m / z): 302.05 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.80 (d, J = 0.7 Hz, 1H), 9.58 (s, 2H), 9.33 (s, 1H), 8.41 (ddd, J = 8.9, 2.5, 0.9 Hz, 1H), 7.86 (dd, J = 43 9.0, 3.2 Hz, 1H), 2.47-2.42 (m, 2H), 1.13 (q, J = 7.4 Hz, 6H), 0.98 (dd, J = 15.6, 7.1 Hz, 6H); ESI MS (m / z): 329.95 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.75 (d, J = 0.7 Hz, 1H), 9.30 (s, 1H), 8.77 (d, J = 2.2 Hz, 1H), 8.56 (dt, J = 9.8, 2.3 Hz, 1H), 8.40 (ddd, 44 J = 8.9, 2.7, 0.9 Hz, 1H), 7.88 (dd, J = 8.9, 3.3 Hz, 1H), 2.07-1.98 (m, 4H), 0.99 (dt, J = 16.8, 7.6 Hz, 6H); ESI MS (m / z): 319 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.78 (d, J = 0.7 Hz, 1H), 9.30 (s, 1H), 8.77 (d, J = 2.4 Hz, 1H), 8.56 (dt, J = 9.9, 2.4 Hz, 1H), 8.39 (ddd, 45 J = 9.0, 2.5, 0.9 Hz, 1H), 7.85 (dd, J = 9.0, 3.2 Hz, 1H), 2.45 (q, J = 3.4 Hz, 2H), 1.13 (q, J = 7.4 Hz, 6H), 1.03-0.95 (m, 6H); ESI MS (m / z): 347.05 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.72 (s, 1H), 9.38 (s, 1H), 8.72 (s, 46 1H), 8.53 (s, 1H), 8.39 (s, 1H), 7.87 (s, 1H), 7.69 (s, 1H), 2.02 (q, J = 7.2 Hz, 4H), 0.98 (t, J = 7.3 Hz, 6H); ESI MS (m / z): 300.95 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.75 (s, 1H), 9.38 (d, J = 2.4 Hz, 1H), 8.72 (dd, J = 4.6, 1.2 Hz, 1H), 8.54 (dq, J = 8.3, 1.4 Hz, 1H), 8.39 47 (dd, J = 8.8, 1.7 Hz, 1H), 7.84 (dd, J = 9.0, 3.2 Hz, 1H), 7.69 (dd, J = 8.1, 4.9 Hz, 1H), 2.47-2.42 (m, 2H), 1.13 (q, J = 7.4 Hz, 6H), 0.98 (dd, J = 15.4, 7.1 Hz, 6H); ESI MS (m / z): 329.1 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.79 (d, J = 0.5 Hz, 1H), 9.36 (d, J = 2.4 Hz, 1H), 8.71 (dd, J = 4.8, 1.3 Hz, 1H), 8.53 (dq, J = 8.4, 1.3 Hz, 1H), 8.45 (ddd, J = 8.9, 3.2, 0.9 Hz, 1H), 7.98 (dd, J = 8.8, 3.9 Hz, 1H), 48 7.79 (ddd, J = 11.7, 8.2, 1.3 Hz, 4H), 7.68 (dd, J = 8.2, 4.5 Hz, 1H), 7.63-7.59 (m, 2H), 7.56-7.52 (m, 4H); ESI MS (m / z): 396.95 [M+1]. PI External 1H-NMR (400 MHz, DMSO-d6) δ 9.75 (d, J = 0.5 Hz, 1H), 9.31 (s, 1H), 8.77 (d, J = 2.7 Hz, 1H), 8.58 (dt, J = 9.8, 2.3 Hz, 1H), 8.41 (ddd, 49 J = 9.0, 3.0, 0.9 Hz, 1H), 7.90 (dd, J = 8.8, 3.7 Hz, 1H), 1.74 (d, J = 13.7 Hz, 6H); ESI MS (m / z): 290.95 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.37 (d, J = 0.7 Hz, 1H), 9.30 (d, J = 2.4 Hz, 1H), 8.68 (dd, J = 4.6, 1.5 Hz, 1H), 8.47 (dq, J = 8.4, 1.3 Hz, 50 1H), 8.10-8.06 (m, 1H), 7.87 (dt, J = 9.0, 1.0 Hz, 1H), 7.71-7.61 (m, 7H), 7.58-7.54 (m, 4H), 7.45 (td, J = 9.2, 1.3 Hz, 1H); ESI MS (m / z): 395.95 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.42 (s, 1H), 9.23 (s, 1H), 8.72 (d, J = 2.4 Hz, 1H), 8.50 (dt, J = 9.9, 2.3 Hz, 1H), 8.09 (d, J = 13.9 Hz, 1H), 51 7.86 (d, J = 8.8 Hz, 1H), 7.69-7.54 (m, 10H), 7.48-7.43 (m, 1H) ESI MS (m / z): 414 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.52 (s, 2H), 9.43 (s, 1H), 9.29 (s, 1H), 8.11 (d, J = 13.8 Hz, 1H), 7.89 (dt, J = 8.9, 0.9 Hz, 1H), 7.69-7.62 52 (m, 6H), 7.58-7.54 (m, 4H), 7.47 (td, J = 9.3, 1.1 Hz, 1H); ESI MS (m / z): 396.95 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.82 (d, J = 0.7 Hz, 1H), 9.29 (s, 1H), 8.76 (d, J = 2.4 Hz, 1H), 8.55 (dt, J = 9.8, 2.3 Hz, 1H), 8.45 (ddd, 53 J = 8.9, 3.2, 0.9 Hz, 1H), 7.99 (dd, J = 8.9, 3.8 Hz, 1H), 7.81-7.76 (m, 4H), 7.64-7.52 (m, 6H); ESI MS (m / z): 415 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.84 (s, 1H), 9.57 (s, 2H), 9.33 (s, 54 1H), 8.47 (dd, J = 9.0, 2.4 Hz, 1H), 8.00 (dd, J = 9.0, 3.9 Hz, 1H), 7.81- 7.76 (m, 4H), 7.64-7.52 (m, 6H); ESI MS (m / z): 398 [M+1]. 1H-NMR (400 MHz, CHLOROFORM-D) δ 9.23 (d, J = 2.2 Hz, 1H), 8.78 (d, J = 4.9 Hz, 1H), 8.70 (dd, J = 4.8, 1.3 Hz, 1H), 8.58 (d, J = 1.0 Hz, 1H), 8.45 (dd, J = 6.1, 1.2 Hz, 1H), 8.33 (dq, J = 8.3, 1.3 Hz, 1H), 55 8.14 (d, J = 0.7 Hz, 1H), 7.91 (d, J = 9.0 Hz, 1H), 7.71-7.68 (m, 2H), 7.53 (q, J = 4.2 Hz, 1H), 1.87 (s, 3H), 1.83 (s, 3H); ESI MS (m / z): 348.9 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.47-9.46 (m, 2H), 9.35 (d, J = 2.2 Hz, 1H), 8.74 (dd, J = 4.6, 1.5 Hz, 1H), 8.53 (dq, J = 8.3, 1.4 Hz, 1H), 56 8.37 (dd, J = 7.0, 1.3 Hz, 1H), 7.71 (ddd, J = 8.4, 4.8, 0.6 Hz, 1H), 1.98-1.89 (m, 4H), 1.87-1.74 (m, 2H), 1.01-0.96 (m, 6H), 0.77-0.73 (m, 6H); ESI MS (m / z): 357.15 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.73 (d, J = 1.0 Hz, 1H), 9.38 (d, J = 2.4 Hz, 1H), 8.72 (dd, J = 4.8, 1.3 Hz, 1H), 8.54 (dq, J = 8.4, 1.3 Hz, 1H), 8.41 (ddd, J = 8.9, 2.7, 0.9 Hz, 1H), 7.93 (dd, J = 8.9, 3.3 Hz, 1H), 57 7.69 (ddd, J = 8.3, 4.6, 0.7 Hz, 1H), 2.02-1.95 (m, 4H), 1.92-1.82 (m, 2H), 0.97 (d, J = 6.6 Hz, 6H), 0.74 (d, J = 6.4 Hz, 6H); ESI MS (m / z): 357.1 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.36 (d, J = 0.6 Hz, 1H), 9.32 (d, J = 2.1 Hz, 1H), 8.68 (dd, J = 4.7, 1.4 Hz, 1H), 8.48 (dq, J = 8.3, 1.4 Hz, 58 1H), 8.34-8.30 (m, 1H), 7.84-7.78 (m, 3H), 7.66 (ddd, J = 8.3, 4.8, 0.7 Hz, 1H), 7.61-7.49 (m, 4H), 2.42 (dtd, J = 18.8, 7.6, 1.9 Hz, 2H), 1.03 (dt, J = 17.3, 7.6 Hz, 3H); ESI MS (m / z): 348.15 [M+1]. PI External 1H-NMR (400 MHz, DMSO-d6) δ 9.80 (d, J = 0.6 Hz, 1H), 9.30 (t, J = 1.1 Hz, 1H), 8.77 (d, J = 2.1 Hz, 1H), 8.56 (dt, J = 9.8, 2.3 Hz, 1H), 59 8.38 (ddd, J = 9.0, 2.9, 0.9 Hz, 1H), 7.87-7.80 (m, 3H), 7.59-7.49 (m, 3H), 2.59-2.50 (m, 1H), 2.46-2.33 (m, 1H), 1.05 (dt, J = 17.6, 7.6 Hz, 3H); ESI MS (m / z): 367.05 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.51 (s, 2H), 9.40 (d, J = 0.9 Hz, 1H), 9.26 (s, 1H), 8.34-8.30 (m, 1H), 7.83-7.75 (m, 3H), 7.58 (td, J = 60 9.0, 1.3 Hz, 1H), 7.55-7.46 (m, 3H), 2.43-2.35 (m, 2H), 1.00 (dt, J = 17.4, 7.6 Hz, 3H); ESI MS (m / z): 348.95 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.77 (d, J = 0.7 Hz, 1H), 9.37 (d, J = 2.7 Hz, 1H), 8.72 (dd, J = 4.6, 1.5 Hz, 1H), 8.54 (dq, J = 8.5, 1.4 Hz, 1H), 8.38 (ddd, J = 8.8, 3.0, 1.0 Hz, 1H), 7.86-7.80 (m, 3H), 7.69 (ddd, 61 J = 8.4, 4.7, 0.7 Hz, 1H), 7.58-7.49 (m, 3H), 2.57-2.50 (m, 1H), 2.46- 2.35 (m, 1H), 1.05 (dt, J = 17.7, 7.6 Hz, 3H); ESI MS (m / z): 349 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.37 (d, J = 2.4 Hz, 1H), 9.34 (d, J = 0.6 Hz, 1H), 8.83 (d, J = 5.2 Hz, 1H), 8.68 (dd, J = 4.7, 1.4 Hz, 1H), 8.53 (dq, J = 8.3, 1.4 Hz, 1H), 8.35 (s, 1H), 8.24 (dd, J = 5.7, 1.4 Hz, 62 1H), 7.96-7.90 (m, 2H), 7.81 (dd, J = 9.2, 1.8 Hz, 1H), 7.67 (dd, J = 8.4, 4.7 Hz, 1H), 2.07-1.96 (m, 4H), 0.99 (dt, J = 16.7, 7.7 Hz, 6H); ESI MS (m / z): 377 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.36 (d, J = 2.4 Hz, 1H), 9.29 (s, 1H), 8.66 (dd, J = 4.8, 1.3 Hz, 1H), 8.52 (dq, J = 8.3, 1.3 Hz, 1H), 8.17 (s, 1H), 8.13 (d, J = 5.4 Hz, 1H), 7.83 (d, J = 9.0 Hz, 1H), 7.71 (dd, J 63 = 9.3, 1.7 Hz, 1H), 7.65 (dd, J = 8.2, 4.5 Hz, 1H), 7.18 (dd, J = 5.4, 1.7 Hz, 1H), 7.02 (d, J = 1.0 Hz, 1H), 3.66 (t, J = 7.6 Hz, 2H), 3.47-3.40 (m, 2H), 1.98-1.92 (m, 4H), 1.61 (dd, J = 11.1, 5.3 Hz, 2H); ESI MS (m / z): 349.95 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.27 (q, J = 0.9 Hz, 1H), 9.13 (d, J = 0.6 Hz, 1H), 8.58 (dd, J = 4.7, 1.7 Hz, 1H), 8.41 (dt, J = 8.0, 2.0 Hz, 64 1H), 8.35-8.32 (m, 1H), 7.66 (dd, J = 9.3, 4.1 Hz, 1H), 7.51 (ddd, J = 7.9, 4.7, 0.8 Hz, 1H), 1.84 (s, 3H), 1.80 (s, 3H); ESI MS (m / z): 273.05 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.32 (ddd, J = 7.0, 2.6, 0.9 Hz, 1H), 9.26 (q, J = 1.0 Hz, 1H), 8.64 (dd, J = 4.6, 1.7 Hz, 1H), 8.41 (dt, J = 65 8.1, 2.0 Hz, 1H), 7.57-7.54 (m, 2H), 7.43 (dd, J = 7.1, 2.9 Hz, 1H), 2.47-2.42 (m, 2H), 1.15 (dd, J = 15.4, 7.1 Hz, 6H), 1.01 (dd, J = 15.9, 7.1 Hz, 6H); ESI MS (m / z): 329.05 [M+1]. 1H-NMR (400 MHz, MeOD) δ 9.50 (s, 1H), 9.23 (q, J = 3.4 Hz, 1H), 9.14 (d, J = 8.1 Hz, 1H), 8.85 (d, J = 4.4 Hz, 1H), 8.13-8.10 (m, 1H), 66 7.62 (q, J = 3.5 Hz, 1H), 7.54 (s, 1H), 1.93 (d, J = 3.2 Hz, 3H), 1.90 (s, 3H); ESI MS (m / z): 273 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.34-9.32 (m, 1H), 9.26 (d, J = 1.5 Hz, 1H), 8.65 (dd, J = 4.6, 1.7 Hz, 1H), 8.41 (dt, J = 8.0, 2.0 Hz, 1H), 67 7.55 (dd, J = 6.8, 5.9 Hz, 2H), 7.47 (q, J = 3.4 Hz, 1H), 2.09-2.00 (m, 4H), 1.02 (dt, J = 17.1, 7.6 Hz, 6H); ESI MS (m / z): 300.95 [M+1]. PI External 1H-NMR (400 MHz, DMSO-d6) δ 9.36 (d, J = 2.4 Hz, 1H), 9.35 (d, J = 0.7 Hz, 1H), 8.67 (dd, J = 4.8, 1.3 Hz, 1H), 8.59 (s, 1H), 8.52 (dq, J 68 = 8.3, 1.4 Hz, 1H), 8.22-8.18 (m, 2H), 8.06 (td, J = 7.8, 3.7 Hz, 1H), 7.90-7.86 (m, 2H), 7.66 (dd, J = 8.2, 4.8 Hz, 1H), 1.77 (s, 3H), 1.73 (s, 3H); ESI MS (m / z): 349.05 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.37 (d, J = 2.2 Hz, 1H), 9.33 (d, J = 1.0 Hz, 1H), 9.19 (d, J = 1.7 Hz, 1H), 8.67 (dd, J = 4.6, 1.5 Hz, 1H), 8.53 (dq, J = 8.4, 1.3 Hz, 1H), 8.35 (td, J = 5.2, 2.7 Hz, 1H), 8.27 (s, 69 1H), 7.99 (q, J = 4.2 Hz, 1H), 7.90 (d, J = 9.0 Hz, 1H), 7.80 (dd, J = 9.3, 1.7 Hz, 1H), 7.68-7.64 (m, 1H), 2.44 (qd, J = 7.2, 3.1 Hz, 2H), 1.22-1.10 (m, 6H), 0.98 (dd, J = 15.6, 7.1 Hz, 6H); ESI MS (m / z): 405.3 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.37 (d, J = 2.7 Hz, 1H), 9.34 (s, 1H), 9.17 (d, J = 2.2 Hz, 1H), 8.67 (dd, J = 4.6, 1.2 Hz, 1H), 8.55-8.52 (m, 1H), 8.33 (td, J = 5.3, 2.8 Hz, 1H), 8.24 (s, 1H), 8.03 (dd, J = 7.8, 70 5.4 Hz, 1H), 7.90 (d, J = 9.0 Hz, 1H), 7.78 (dd, J = 9.0, 1.7 Hz, 1H), 7.66 (dd, J = 8.2, 4.8 Hz, 1H), 1.72 (s, 3H), 1.68 (s, 3H); ESI MS (m / z): 349 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.37 (d, J = 2.4 Hz, 1H), 9.34 (s, 1H), 9.18 (d, J = 2.0 Hz, 1H), 8.67 (d, J = 4.9 Hz, 1H), 8.53 (d, J = 9.5 Hz, 1H), 8.36-8.33 (m, 1H), 8.26 (s, 1H), 8.03-8.00 (m, 1H), 7.90 (d, J 71 = 9.3 Hz, 1H), 7.79 (dd, J = 9.0, 1.7 Hz, 1H), 7.66 (dd, J = 8.2, 4.8 Hz, 1H), 2.04-1.94 (m, 4H), 1.02-0.94 (m, 6H); ESI MS (m / z): 377.05 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.37 (d, J = 2.4 Hz, 1H), 9.34 (s, 1H), 9.18 (d, J = 2.0 Hz, 1H), 8.67 (d, J = 4.9 Hz, 1H), 8.53 (d, J = 9.5 Hz, 1H), 8.36-8.33 (m, 1H), 8.26 (s, 1H), 8.03-8.00 (m, 1H), 7.90 (d, J 72 = 9.3 Hz, 1H), 7.79 (dd, J = 9.0, 1.7 Hz, 1H), 7.66 (dd, J = 8.2, 4.8 Hz, 1H), 2.04-1.94 (m, 4H), 1.02-0.94 (m, 6H); ESI MS (m / z): 366.9 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.22 (d, J = 1.5 Hz, 1H), 8.86 (d, J = 2.7 Hz, 1H), 8.68 (dd, J = 8.3, 2.9 Hz, 1H), 8.50-8.46 (m, 1H), 8.17 73 (dd, J = 8.3, 4.9 Hz, 1H), 1.78 (s, 3H), 1.74 (s, 3H); ESI MS (m / z): 307.9 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.22 (d, J = 1.5 Hz, 1H), 8.86 (d, J = 2.7 Hz, 1H), 8.68 (dd, J = 8.3, 2.9 Hz, 1H), 8.50-8.46 (m, 1H), 8.17 74 (dd, J = 8.3, 4.9 Hz, 1H), 1.78 (s, 3H), 1.74 (s, 3H); ESI MS (m / z): 290.9 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.33 (q, J = 1.0 Hz, 1H), 8.82 (dd, J = 4.7, 1.7 Hz, 1H), 8.65 (dd, J = 8.6, 2.8 Hz, 1H), 8.52 (ddd, J = 8.0, 75 2.4, 1.6 Hz, 1H), 8.15 (dd, J = 8.3, 4.9 Hz, 1H), 7.67 (ddd, J = 8.0, 4.8, 0.8 Hz, 1H), 1.77 (s, 3H), 1.74 (s, 3H); ESI MS (m / z): 289.9 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.39 (s, 1H), 9.30 (s, 1H), 8.83 (d, J 76 = 5.1 Hz, 1H), 8.72 (d, J = 2.4 Hz, 1H), 8.57 (dt, J = 10.0, 2.3 Hz, 1H), 8.36 (s, 1H), 8.24 (d, J = 4.2 Hz, 1H), 7.96 (dd, J = 5.1, 2.0 Hz, 1H), PI External 7.91 (d, J = 9.0 Hz, 1H), 7.83 (dd, J = 9.0, 1.7 Hz, 1H), 2.05-1.96 (m, 4H), 0.99 (dt, J = 16.8, 7.7 Hz, 6H); ESI MS (m / z): 395.1 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.21 (d, J = 1.7 Hz, 1H), 8.86 (d, J = 2.7 Hz, 1H), 8.67 (dd, J = 8.2, 2.3 Hz, 1H), 8.46 (dq, J = 9.3, 1.5 Hz, 77 1H), 8.12 (q, J = 4.2 Hz, 1H), 2.52 (d, J = 3.4 Hz, 1H), 2.45 (d, J = 7.3 Hz, 1H), 1.12 (dd, J = 15.2, 7.1 Hz, 6H), 0.97 (dd, J = 15.6, 7.1 Hz, 6H); ESI MS (m / z): 364.1 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.31 (d, J = 1.7 Hz, 1H), 8.82 (dd, J = 4.8, 1.6 Hz, 1H), 8.65 (dd, J = 8.3, 2.2 Hz, 1H), 8.51 (dt, J = 8.2, 2.0 Hz, 1H), 8.11 (q, J = 4.2 Hz, 1H), 7.67 (ddd, J = 8.1, 4.9, 0.7 Hz, 1H), 78 2.52 (d, J = 5.6 Hz, 1H), 2.45 (d, J = 7.1 Hz, 1H), 1.12 (dd, J = 15.2, 7.1 Hz, 6H), 0.97 (dd, J = 15.8, 7.2 Hz, 6H); ESI MS (m / z): 345.95 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.58 (s, 2H), 9.41 (s, 1H), 9.29 (s, 1H), 8.83 (d, J = 5.4 Hz, 1H), 8.39 (s, 1H), 8.26 (d, J = 4.4 Hz, 1H), 79 7.97-7.92 (m, 2H), 7.86-7.83 (m, 1H), 1.72 (d, J = 13.7 Hz, 6H); ESI MS (m / z): 349.95 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.58 (d, J = 1.0 Hz, 1H), 9.35 (d, J = 2.2 Hz, 1H), 8.69 (dd, J = 4.6, 1.5 Hz, 1H), 8.57 (d, J = 9.0 Hz, 1H), 80 8.55-8.51 (m, 2H), 8.38 (dd, J = 9.3, 1.0 Hz, 1H), 8.16 (td, J = 7.8, 3.6 Hz, 1H), 8.04-8.01 (m, 1H), 7.68 (dd, J = 8.6, 5.1 Hz, 1H), 1.79 (d, J = 13.4 Hz, 6H); ESI MS (m / z): 350.1 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.58 (d, J = 1.0 Hz, 1H), 9.35 (d, J = 2.2 Hz, 1H), 8.69 (dd, J = 4.6, 1.5 Hz, 1H), 8.57 (d, J = 9.0 Hz, 1H), 81 8.55-8.51 (m, 2H), 8.38 (dd, J = 9.3, 1.0 Hz, 1H), 8.16 (td, J = 7.8, 3.6 Hz, 1H), 8.04-8.01 (m, 1H), 7.68 (dd, J = 8.6, 5.1 Hz, 1H), 1.79 (d, J = 13.4 Hz, 6H); ESI MS (m / z): 405.25 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.21 (t, J = 1.5 Hz, 1H), 8.86 (d, J = 2.7 Hz, 1H), 8.68 (dd, J = 8.3, 2.4 Hz, 1H), 8.47 (ddd, J = 9.4, 2.8, 1.8 82 Hz, 1H), 8.15 (q, J = 4.2 Hz, 1H), 2.10-2.00 (m, 4H), 1.00 (t, J = 7.7 Hz, 3H), 0.95 (t, J = 7.7 Hz, 3H); ESI MS (m / z): 336 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.58 (s, 2H), 9.41 (d, J = 0.7 Hz, 1H), 9.29 (s, 1H), 8.84 (d, J = 5.1 Hz, 1H), 8.39 (s, 1H), 8.24 (d, J = 83 5.6 Hz, 1H), 7.97-7.92 (m, 2H), 7.84 (dd, J = 9.0, 1.7 Hz, 1H), 2.05- 1.96 (m, 4H), 1.01 (t, J = 7.7 Hz, 3H), 0.96 (t, J = 7.7 Hz, 3H); ESI MS (m / z): 378.05 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.58 (s, 2H), 9.41 (d, J = 1.0 Hz, 1H), 9.28 (s, 1H), 8.62 (s, 1H), 8.25-8.21 (m, 2H), 8.07 (td, J = 7.8, 3.7 84 Hz, 1H), 7.90-7.88 (m, 2H), 1.77 (s, 3H), 1.73 (s, 3H); ESI MS (m / z): 350.05 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.58 (s, 2H), 9.42 (d, J = 0.9 Hz, 1H), 9.28 (s, 1H), 8.60 (d, J = 1.5 Hz, 1H), 8.25-8.22 (m, 1H), 8.20 85 (dd, J = 9.3, 1.7 Hz, 1H), 8.07 (td, J = 7.8, 3.4 Hz, 1H), 7.90-7.86 (m, 2H), 2.10-2.01 (m, 4H), 1.03 (t, J = 7.6 Hz, 3H), 0.99 (t, J = 7.8 Hz, 3H); ESI MS (m / z): 378.15 [M+1]. PI External 1H-NMR (400 MHz, DMSO-D6) δ 9.32 (q, J = 1.0 Hz, 1H), 8.82 (dd, J = 4.7, 1.7 Hz, 1H), 8.65 (dd, J = 8.3, 2.4 Hz, 1H), 8.52 (ddd, J = 7.9, 86 2.3, 1.7 Hz, 1H), 8.13 (q, J = 4.3 Hz, 1H), 7.67 (ddd, J = 8.1, 4.7, 0.8 Hz, 1H), 2.09-1.99 (m, 4H), 1.00 (t, J = 7.6 Hz, 3H), 0.95 (t, J = 7.6 Hz, 3H); ESI MS (m / z): 318 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.39 (dd, J = 7.3, 0.7 Hz, 1H), 9.27 (q, J = 1.0 Hz, 1H), 8.97 (dd, J = 5.1, 0.7 Hz, 1H), 8.72 (dd, J = 6.0, 1.1 Hz, 1H), 8.65 (dd, J = 4.6, 1.7 Hz, 1H), 8.42 (dt, J = 8.1, 2.0 Hz, 87 1H), 8.32 (td, J = 3.5, 1.7 Hz, 1H), 7.89 (d, J = 7.6 Hz, 1H), 7.58-7.54 (m, 2H), 1.74 (s, 3H), 1.71 (s, 3H); ESI MS (m / z): 350.15 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.51 (s, 2H), 9.42 (s, 1H), 8.70 (dd, 88 J = 8.3, 2.4 Hz, 1H), 8.16 (dd, J = 8.3, 4.6 Hz, 1H), 2.10-2.00 (m, 4H), 0.97 (dt, J = 17.0, 7.6 Hz, 6H); ESI MS (m / z): 318.85 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.51 (s, 2H), 9.42 (s, 1H), 8.70 (dd, J = 8.3, 2.2 Hz, 1H), 8.13 (q, J = 4.2 Hz, 1H), 2.52 (s, 1H), 2.46 (d, J = 89 7.3 Hz, 1H), 1.12 (dd, J = 15.2, 7.1 Hz, 7H), 0.97 (dd, J = 15.6, 7.1 Hz, 6H); ESI MS (m / z): 346.85 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.37-9.35 (m, 2H), 8.67 (dd, J = 4.8, 1.3 Hz, 1H), 8.58 (s, 1H), 8.52 (dq, J = 8.4, 1.3 Hz, 1H), 8.21 (d, J = 8.1 Hz, 1H), 8.17 (dd, J = 9.2, 1.6 Hz, 1H), 8.06 (td, J = 7.8, 3.4 Hz, 90 1H), 7.87 (t, J = 4.6 Hz, 2H), 7.66 (dd, J = 8.1, 4.9 Hz, 1H), 2.09-2.01 (m, 4H), 1.01 (dt, J = 16.7, 7.7 Hz, 6H); ESI MS (m / z): 376.95 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.37 (d, J = 2.4 Hz, 1H), 9.33 (s, 1H), 9.18 (d, J = 2.0 Hz, 1H), 8.67 (dd, J = 4.8, 1.3 Hz, 1H), 8.53 (dq, J = 8.4, 1.3 Hz, 1H), 8.34 (td, J = 5.3, 2.8 Hz, 1H), 8.25 (s, 1H), 8.01 91 (dd, J = 7.7, 5.0 Hz, 1H), 7.90 (d, J = 9.0 Hz, 1H), 7.79 (dd, J = 9.0, 1.7 Hz, 1H), 7.66 (dd, J = 8.7, 5.0 Hz, 1H), 2.01-1.94 (m, 4H), 1.55- 1.49 (m, 2H), 1.37-1.29 (m, 2H), 0.91 (t, J = 7.3 Hz, 6H); ESI MS (m / z): 404.95 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.55 (s, 2H), 9.41 (s, 1H), 9.29 (s, 1H), 8.28 (d, J = 12.5 Hz, 1H), 7.85 (d, J = 8.8 Hz, 1H), 7.59 (t, J = 8.7 92 Hz, 1H), 2.00-1.89 (m, 4H), 1.52-1.46 (m, 2H), 1.35-1.22 (m, 2H), 0.90 (t, J = 7.3 Hz, 6H); ESI MS (m / z): 329.15 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.35-9.33 (m, 2H), 8.68 (d, J = 4.6 Hz, 1H), 8.50 (d, J = 8.6 Hz, 1H), 8.25 (d, J = 12.5 Hz, 1H), 7.83 (d, J 93 = 8.6 Hz, 1H), 7.67 (dd, J = 8.4, 5.0 Hz, 1H), 7.56 (t, J = 8.2 Hz, 1H), 1.99-1.90 (m, 4H), 1.49 (d, J = 7.1 Hz, 2H), 1.31 (s, 2H), 0.90 (t, J = 7.3 Hz, 6H); ESI MS (m / z): 328.15 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.75 (s, 1H), 9.30 (s, 1H), 8.77 (d, J = 2.4 Hz, 1H), 8.56 (dt, J = 9.8, 2.3 Hz, 1H), 8.40 (dd, J = 8.8, 2.0 Hz, 94 1H), 7.88 (dd, J = 8.9, 3.3 Hz, 1H), 2.05-1.98 (m, 4H), 1.58-1.50 (m, 2H), 1.39-1.31 (m, 2H), 0.90 (t, J = 7.3 Hz, 6H); ESI MS (m / z): 347 [M+1]. PI External 1H-NMR (400 MHz, DMSO-d6) δ 9.34-9.30 (m, 2H), 8.70 (d, J = 3.7 Hz, 1H), 8.53 (d, J = 8.1 Hz, 1H), 7.66 (dd, J = 7.9, 5.0 Hz, 1H), 7.59 95 (s, 1H), 7.49 (q, J = 3.4 Hz, 1H), 2.10-1.97 (m, 4H), 1.62-1.50 (m, 2H), 1.47-1.33 (m, 2H), 0.92 (t, J = 7.3 Hz, 6H); ESI MS (m / z): 329.1 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.72 (d, J = 0.9 Hz, 1H), 9.38 (d, J = 2.4 Hz, 1H), 8.72 (dd, J = 4.7, 1.4 Hz, 1H), 8.54 (dq, J = 8.3, 1.4 Hz, 1H), 8.40 (dq, J = 8.9, 1.2 Hz, 1H), 7.87 (dd, J = 8.9, 3.4 Hz, 1H), 7.70 96 (ddd, J = 8.4, 4.7, 0.6 Hz, 1H), 2.07-1.96 (m, 4H), 1.60-1.48 (m, 2H), 1.41-1.29 (m, 2H), 0.90 (dd, J = 7.6, 7.0 Hz, 6H); ESI MS (m / z): 328.95 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.35 (td, J = 3.5, 2.4 Hz, 1H), 9.17 (t, J = 1.6 Hz, 1H), 8.67 (d, J = 2.7 Hz, 1H), 8.35-8.31 (m, 1H), 7.62 97 (d, J = 0.7 Hz, 1H), 7.53 (q, J = 3.5 Hz, 1H), 1.77 (d, J = 13.9 Hz, 6H); ESI MS (m / z): 290.9 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.34 (dq, J = 7.0, 1.2 Hz, 1H), 9.16 (d, J = 1.5 Hz, 1H), 8.67 (d, J = 2.8 Hz, 1H), 8.32 (dq, J = 9.8, 1.5 Hz, 98 1H), 7.62 (d, J = 0.6 Hz, 1H), 7.49 (q, J = 3.4 Hz, 1H), 2.10-2.00 (m, 4H), 1.02 (dt, J = 17.1, 7.6 Hz, 6H); ESI MS (m / z): 318.9 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.34-9.32 (m, 1H), 9.16 (t, J = 1.6 Hz, 1H), 8.67 (d, J = 2.7 Hz, 1H), 8.32 (dq, J = 9.8, 1.5 Hz, 1H), 7.62 99 (d, J = 0.7 Hz, 1H), 7.50 (dd, J = 7.0, 3.1 Hz, 1H), 2.10-1.97 (m, 4H), 1.60-1.51 (m, 2H), 1.45-1.33 (m, 2H), 0.92 (dd, J = 7.6, 7.1 Hz, 6H); ESI MS (m / z): 346.95 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.33-9.31 (m, 1H), 9.16 (t, J = 1.6 Hz, 1H), 8.67 (d, J = 2.7 Hz, 1H), 8.34-8.30 (m, 1H), 7.63 (d, J = 0.7 100 Hz, 1H), 7.46 (dd, J = 7.1, 2.9 Hz, 1H), 2.46-2.43 (m, 2H), 1.15 (dd, J = 15.3, 7.2 Hz, 6H), 1.01 (dd, J = 15.9, 7.1 Hz, 6H); ESI MS (m / z): 346.9 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.39 (s, 1H), 9.26 (s, 1H), 8.72 (d, J = 2.4 Hz, 1H), 8.55-8.51 (m, 1H), 8.25 (d, J = 12.7 Hz, 1H), 7.85-7.82 101 (m, 1H), 7.60-7.55 (m, 1H), 2.00-1.90 (m, 4H), 1.48 (s, 2H), 1.29 (d, J = 20.8 Hz, 2H), 0.90 (t, J = 7.3 Hz, 6H); ESI MS (m / z): 346.05 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.40 (d, J = 0.7 Hz, 1H), 9.33 (d, J = 2.2 Hz, 1H), 8.69 (dd, J = 4.6, 1.2 Hz, 1H), 8.50 (dq, J = 8.4, 1.3 Hz, 102 1H), 8.31 (dt, J = 15.5, 1.1 Hz, 1H), 7.88-7.85 (m, 1H), 7.67 (ddd, J = 8.4, 4.8, 0.7 Hz, 1H), 7.53-7.48 (m, 1H), 4.08-3.96 (m, 4H), 1.24 (t, J = 7.1 Hz, 6H); ESI MS (m / z): 331.95 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.76 (s, 1H), 9.33 (s, 1H), 8.93 (d, J = 5.1 Hz, 1H), 8.77 (d, J = 2.4 Hz, 1H), 8.72 (d, J = 5.9 Hz, 1H), 8.58 103 (dt, J = 9.9, 2.4 Hz, 1H), 8.45 (d, J = 10.0 Hz, 1H), 8.29-8.28 (m, 1H), 8.20 (d, J = 9.3 Hz, 1H), 1.74 (s, 3H), 1.70 (s, 3H); ESI MS (m / z): 368 [M+1]. PI External 1H-NMR (400 MHz, DMSO-d6) δ 9.70 (s, 1H), 9.33 (s, 1H), 8.75 (d, J = 2.2 Hz, 1H), 8.60-8.55 (m, 3H), 8.40 (d, J = 8.3 Hz, 1H), 8.16 (td, J 104 = 7.8, 3.5 Hz, 1H), 8.05-8.02 (m, 1H), 1.80 (s, 3H), 1.76 (s, 3H) ESI MS (m / z): 367.9 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.42 (d, J = 0.9 Hz, 1H), 9.40 (s, 2H), 9.32 (s, 1H), 8.72 (d, J = 2.4 Hz, 1H), 8.58 (dt, J = 10.0, 2.3 Hz, 105 1H), 8.36 (t, J = 1.2 Hz, 1H), 7.94 (d, J = 9.2 Hz, 1H), 7.86 (dd, J = 9.2, 1.8 Hz, 1H), 1.81 (d, J = 13.8 Hz, 6H); ESI MS (m / z): 368.05 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.37 (d, J = 2.4 Hz, 1H), 9.32 (d, J = 0.7 Hz, 1H), 8.94 (s, 1H), 8.67 (dd, J = 4.8, 1.3 Hz, 1H), 8.53 (dq, J = 8.3, 1.4 Hz, 1H), 8.22 (s, 1H), 8.09 (dd, J = 3.4, 2.2 Hz, 1H), 7.89 (d, 106 J = 9.0 Hz, 1H), 7.77 (dd, J = 9.3, 1.7 Hz, 1H), 7.66 (dd, J = 8.7, 5.0 Hz, 1H), 2.74 (s, 3H), 1.74 (d, J = 13.2 Hz, 6H); ESI MS (m / z): 363.3 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.37 (d, J = 2.2 Hz, 1H), 9.33 (d, J = 0.7 Hz, 1H), 8.68 (dd, J = 4.8, 1.3 Hz, 1H), 8.53 (dq, J = 8.3, 1.4 Hz, 1H), 8.31 (t, J = 0.7 Hz, 1H), 8.06 (dd, J = 6.2, 1.6 Hz, 1H), 7.90 (d, J 107 = 9.0 Hz, 1H), 7.82-7.78 (m, 2H), 7.67 (ddd, J = 8.3, 4.6, 0.7 Hz, 1H), 2.62 (s, 3H), 1.69 (d, J = 13.4 Hz, 6H); ESI MS (m / z): 362.95 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.38 (s, 1H), 9.36 (s, 2H), 9.28 (s, 1H), 8.68 (d, J = 2.8 Hz, 1H), 8.54 (dt, J = 10.0, 2.3 Hz, 1H), 8.34 (s, 108 1H), 7.89 (d, J = 9.2 Hz, 1H), 7.83 (dd, J = 9.2, 1.5 Hz, 1H), 2.13-1.94 (m, 4H), 1.10-1.00 (m, 6H); ESI MS (m / z): 396.2 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.36 (d, J = 2.7 Hz, 1H), 9.29 (d, J = 0.7 Hz, 1H), 8.68-8.64 (m, 2H), 8.52 (dq, J = 8.3, 1.4 Hz, 1H), 7.92 109 (d, J = 5.9 Hz, 1H), 7.86-7.84 (m, 2H), 7.68-7.64 (m, 1H), 7.41 (dd, J = 9.3, 1.5 Hz, 1H), 2.39 (s, 3H), 1.69 (d, J = 13.4 Hz, 6H); ESI MS (m / z): 363 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.39 (s, 2H), 9.38-9.38 (m, 2H), 8.68 (dd, J = 4.6, 1.5 Hz, 1H), 8.54 (dq, J = 8.3, 1.4 Hz, 1H), 8.35 (d, J = 110 1.5 Hz, 1H), 7.94 (d, J = 9.0 Hz, 1H), 7.84 (dd, J = 9.0, 1.7 Hz, 1H), 7.69-7.65 (m, 1H), 1.81 (d, J = 13.7 Hz, 6H); ESI MS (m / z): 350.05 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.40-9.38 (m, 4H), 8.68 (dd, J = 4.6, 1.5 Hz, 1H), 8.54 (dq, J = 8.3, 1.4 Hz, 1H), 8.36 (t, J = 1.2 Hz, 1H), 111 7.93 (d, J = 9.0 Hz, 1H), 7.85 (dd, J = 9.0, 1.7 Hz, 1H), 7.68-7.65 (m, 1H), 2.15-2.03 (m, 4H), 1.08 (dt, J = 17.0, 7.7 Hz, 6H); ESI MS (m / z): 378.1 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.36 (d, J = 2.1 Hz, 1H), 9.28 (d, J = 0.9 Hz, 1H), 8.67 (dd, J = 4.7, 1.4 Hz, 1H), 8.52 (dq, J = 8.4, 1.3 Hz, 112 1H), 7.87-7.83 (m, 4H), 7.66 (ddd, J = 8.3, 4.8, 0.7 Hz, 1H), 7.43 (dd, J = 8.9, 1.5 Hz, 1H), 2.54 (s, 3H), 2.03-1.93 (m, 4H), 1.00 (dt, J = 16.5, 7.6 Hz, 6H); ESI MS (m / z): 390.95 [M+1]. PI External 1H-NMR (400 MHz, DMSO-d6) δ 9.36 (d, J = 2.2 Hz, 1H), 9.28 (d, J = 1.0 Hz, 1H), 8.67 (dd, J = 4.6, 1.5 Hz, 1H), 8.53 (dq, J = 8.5, 1.3 Hz, 113 1H), 7.87-7.83 (m, 4H), 7.69-7.65 (m, 1H), 7.42 (dd, J = 9.3, 1.5 Hz, 1H), 2.54 (s, 3H), 1.69 (d, J = 13.4 Hz, 6H); ESI MS (m / z): 363.2 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.38 (d, J = 2.4 Hz, 1H), 9.33 (d, J = 0.7 Hz, 1H), 9.15 (t, J = 2.1 Hz, 1H), 8.90 (dd, J = 5.9, 1.7 Hz, 1H), 8.68 (dd, J = 4.8, 1.3 Hz, 1H), 8.55 (dq, J = 8.4, 1.3 Hz, 1H), 8.48 (dt, 114 J = 11.7, 2.1 Hz, 1H), 8.25 (s, 1H), 7.91 (d, J = 9.3 Hz, 1H), 7.80 (dd, J = 9.0, 1.7 Hz, 1H), 7.69-7.66 (m, 1H), 1.80 (d, J = 13.7 Hz, 6H); ESI MS (m / z): 349.14 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.37 (d, J = 2.2 Hz, 1H), 9.31 (d, J = 0.7 Hz, 1H), 9.15 (t, J = 2.1 Hz, 1H), 8.84 (dd, J = 5.1, 1.7 Hz, 1H), 8.67 (dd, J = 4.8, 1.3 Hz, 1H), 8.53 (dq, J = 8.3, 1.4 Hz, 1H), 8.40 (dt, 115 J = 10.6, 2.1 Hz, 1H), 8.23 (s, 1H), 7.90 (d, J = 9.0 Hz, 1H), 7.78 (dd, J = 9.0, 1.7 Hz, 1H), 7.67 (dd, J = 8.3, 5.4 Hz, 1H), 2.14-2.00 (m, 4H), 0.99 (dt, J = 17.0, 7.6 Hz, 6H); ESI MS (m / z): 377.25 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.23-9.36 (1H), 8.73-8.82 (1H), 116 8.59-8.70 (1H), 8.44-8.54 (1H), 8.17-8.28 (1H), 7.85-8.01 (1H), 7.53- 7.71 (1H), 1.62-1.81 (6H); ESI MS (m / z): 289.05 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.30 (dd, J = 2.4, 0.7 Hz, 1H), 8.78 (dd, J = 4.8, 1.6 Hz, 1H), 8.60 (dd, J = 10.9, 0.9 Hz, 1H), 8.49 (ddd, J 117 = 8.0, 2.4, 1.7 Hz, 1H), 8.23 (dd, J = 8.4, 1.6 Hz, 1H), 7.89-7.85 (m, 1H), 7.64 (ddd, J = 8.0, 4.8, 0.9 Hz, 1H), 2.06-1.94 (m, 4H), 0.95 (dt, J = 16.9, 7.6 Hz, 6H); ESI MS (m / z): 316.95 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.37 (d, J = 2.4 Hz, 1H), 9.32 (d, J = 1.0 Hz, 1H), 8.96 (d, J = 2.0 Hz, 1H), 8.67 (dd, J = 4.8, 1.3 Hz, 1H), 8.53 (dq, J = 8.3, 1.4 Hz, 1H), 8.24 (s, 1H), 8.08 (s, 1H), 7.88 (d, J = 118 9.0 Hz, 1H), 7.79 (dd, J = 9.2, 1.6 Hz, 1H), 7.66 (dd, J = 8.3, 4.9 Hz, 1H), 2.74 (s, 3H), 2.12-2.03 (m, 2H), 2.02-1.92 (m, 2H), 1.03 (t, J = 7.7 Hz, 3H), 0.99 (t, J = 7.7 Hz, 3H); ESI MS (m / z): 391.05 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.37-9.35 (m, 2H), 8.99 (dt, J = 5.3, 1.2 Hz, 1H), 8.67 (dd, J = 4.7, 1.4 Hz, 1H), 8.62 (s, 1H), 8.52 (dq, J = 119 8.4, 1.3 Hz, 1H), 8.25-8.17 (m, 3H), 7.86 (d, J = 9.2 Hz, 1H), 7.68-7.65 (m, 1H), 1.75 (d, J = 13.3 Hz, 6H); ESI MS (m / z): 348.95 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.37 (d, J = 0.7 Hz, 1H), 9.31 (s, 1H), 8.94 (s, 1H), 8.71 (d, J = 2.2 Hz, 1H), 8.56 (dt, J = 10.0, 2.3 Hz, 120 1H), 8.24 (s, 1H), 8.10 (d, J = 4.9 Hz, 1H), 7.89 (d, J = 9.0 Hz, 1H), 7.79 (dd, J = 9.3, 1.7 Hz, 1H), 2.74 (s, 3H), 1.74 (d, J = 13.4 Hz, 6H); ESI MS (m / z): 381.2 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.33 (s, 1H), 9.29 (s, 1H), 8.71 (d, J = 2.4 Hz, 1H), 8.55 (dd, J = 9.8, 2.2 Hz, 1H), 7.87-7.83 (m, 4H), 7.44 121 (dd, J = 8.8, 1.7 Hz, 1H), 2.54 (s, 3H), 1.69 (d, J = 13.4 Hz, 6H) ESI MS (m / z): 380.95 [M+1]. PI External 1H-NMR (400 MHz, DMSO-d6) δ 9.34 (d, J = 1.0 Hz, 1H), 9.30 (s, 1H), 8.71 (d, J = 2.9 Hz, 1H), 8.65 (s, 1H), 8.55 (dt, J = 9.9, 2.3 Hz, 122 1H), 7.91-7.88 (m, 2H), 7.84 (d, J = 9.0 Hz, 1H), 7.44 (dd, J = 8.9, 1.6 Hz, 1H), 2.40 (s, 3H), 2.00-1.95 (m, 4H), 1.01 (t, J = 7.7 Hz, 3H), 0.97 (t, J = 7.7 Hz, 3H); ESI MS (m / z): 409.25 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.36 (d, J = 1.0 Hz, 1H), 9.31 (d, J = 2.2 Hz, 1H), 8.69 (dd, J = 4.6, 1.5 Hz, 1H), 8.48 (dq, J = 8.3, 1.4 Hz, 123 1H), 8.21 (d, J = 16.1 Hz, 1H), 7.88 (dd, J = 9.0, 3.4 Hz, 1H), 7.67 (q, J = 4.4 Hz, 1H), 7.62-7.57 (m, 1H), 7.30 (dd, J = 8.1, 1.7 Hz, 4H), 7.15 (d, J = 8.1 Hz, 4H), 2.25 (s, 6H); ESI MS (m / z): 488.05 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.34 (d, J = 0.9 Hz, 1H), 9.29 (s, 1H), 8.71 (d, J = 2.4 Hz, 1H), 8.64 (s, 1H), 8.55 (dt, J = 10.0, 2.3 Hz, 124 1H), 7.92 (d, J = 5.5 Hz, 1H), 7.87-7.84 (m, 2H), 7.42 (dd, J = 8.9, 1.5 Hz, 1H), 2.39 (s, 3H), 1.69 (d, J = 13.4 Hz, 6H); ESI MS (m / z): 381.1 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.33 (d, J = 0.9 Hz, 1H), 9.29 (s, 1H), 8.70 (d, J = 2.4 Hz, 1H), 8.55 (dt, J = 10.0, 2.4 Hz, 1H), 7.88-7.82 125 (m, 4H), 7.45 (dd, J = 9.0, 1.7 Hz, 1H), 2.54 (s, 3H), 2.03-1.93 (m, 4H), 1.02 (t, J = 7.8 Hz, 3H), 0.97 (d, J = 7.6 Hz, 3H); ESI MS (m / z): 409.35 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.49 (s, 2H), 9.38 (s, 1H), 8.69 (dd, 126 J = 11.9, 0.9 Hz, 1H), 8.26 (dd, J = 8.3, 1.5 Hz, 1H), 7.98-7.93 (m, 1H), 1.74 (d, J = 13.4 Hz, 6H); ESI MS (m / z): 290.05 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.19 (t, J = 1.5 Hz, 1H), 8.82 (d, J = 2.7 Hz, 1H), 8.67 (dd, J = 11.7, 1.0 Hz, 1H), 8.44 (ddd, J = 9.4, 2.7, 1.8 127 Hz, 1H), 8.24 (dd, J = 8.4, 1.6 Hz, 1H), 7.97-7.92 (m, 1H), 1.73 (d, J = 13.4 Hz, 6H); ESI MS (m / z): 307.5 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.40 (d, J = 1.0 Hz, 1H), 9.30 (s, 1H), 8.93 (dd, J = 4.8, 1.6 Hz, 1H), 8.71 (d, J = 2.2 Hz, 1H), 8.64 (s, 128 1H), 8.56 (dt, J = 9.9, 2.3 Hz, 1H), 8.24-8.15 (m, 3H), 7.86 (d, J = 9.3 Hz, 1H), 2.10-1.94 (m, 4H), 0.98 (dt, J = 17.0, 7.7 Hz, 6H); ESI MS (m / z): 395 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.48 (s, 2H), 9.38 (s, 1H), 8.65 (dd, 129 J = 11.0, 0.7 Hz, 1H), 8.28-8.25 (m, 1H), 7.92-7.87 (m, 1H), 2.09-1.92 (m, 4H), 0.95 (dt, J = 16.8, 7.7 Hz, 6H); ESI MS (m / z): 317.95 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.44 (s, 2H), 9.38 (dd, J = 7.1, 2.4 130 Hz, 1H), 9.27 (s, 1H), 7.65 (s, 1H), 7.54 (q, J = 3.5 Hz, 1H), 1.77 (d, J = 13.7 Hz, 6H); ESI MS (m / z): 273.9 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.44 (s, 2H), 9.37 (ddd, J = 7.0, 2.9, 0.9 Hz, 1H), 9.27 (s, 1H), 7.64 (d, J = 1.0 Hz, 1H), 7.51 (dd, J = 7.0, 131 3.1 Hz, 1H), 2.10-2.01 (m, 4H), 1.04 (t, J = 7.7 Hz, 3H), 0.99 (t, J = 7.7 Hz, 3H); ESI MS (m / z): 301.95 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.57 (s, 2H), 9.36 (d, J = 0.7 Hz, 1H), 9.28 (s, 1H), 8.65 (s, 1H), 7.93 (d, J = 5.6 Hz, 1H), 7.89 (s, 1H), 132 7.87 (d, J = 9.0 Hz, 1H), 7.44 (dd, J = 8.9, 1.6 Hz, 1H), 2.39 (s, 3H), 1.69 (d, J = 13.7 Hz, 6H); ESI MS (m / z): 363.8 [M+1]. PI External 1H-NMR (400 MHz, DMSO-d6) δ 9.18 (t, J = 1.5 Hz, 1H), 8.82 (d, J = 2.7 Hz, 1H), 8.63 (dd, J = 10.8, 0.7 Hz, 1H), 8.43 (ddd, J = 9.4, 2.8, 1.8 133 Hz, 1H), 8.24 (dd, J = 8.3, 1.5 Hz, 1H), 7.91-7.86 (m, 1H), 2.08-1.92 (m, 4H), 0.97 (t, J = 7.7 Hz, 3H), 0.93 (t, J = 7.7 Hz, 3H); ESI MS (m / z): 334.9 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.57 (s, 2H), 9.36 (d, J = 1.0 Hz, 1H), 9.28 (s, 1H), 8.65 (s, 1H), 7.91-7.90 (m, 2H), 7.86 (d, J = 9.0 Hz, 134 1H), 7.45 (dd, J = 9.0, 1.5 Hz, 1H), 2.40 (s, 3H), 2.00-1.93 (m, 4H), 1.01 (t, J = 7.7 Hz, 3H), 0.97 (t, J = 7.7 Hz, 3H); ESI MS (m / z): 391.85 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.58 (s, 2H), 9.38 (d, J = 0.7 Hz, 1H), 9.28 (s, 1H), 8.97 (d, J = 2.2 Hz, 1H), 8.28 (s, 1H), 8.09 (d, J = 135 2.2 Hz, 1H), 7.90 (d, J = 9.0 Hz, 1H), 7.82 (dd, J = 9.3, 1.7 Hz, 1H), 2.74 (s, 3H), 2.12-2.03 (m, 2H), 2.01-1.92 (m, 2H), 1.03 (t, J = 7.7 Hz, 3H), 0.99 (t, J = 7.7 Hz, 3H); ESI MS (m / z): 392.15 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.58 (s, 2H), 9.39 (s, 1H), 9.28 (s, 1H), 8.95 (s, 1H), 8.26 (s, 1H), 8.10 (d, J = 4.6 Hz, 1H), 7.91 (d, J = 136 9.0 Hz, 1H), 7.80 (dd, J = 9.3, 1.7 Hz, 1H), 2.74 (s, 3H), 1.74 (d, J = 13.2 Hz, 6H); ESI MS (m / z): 363.85 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.59 (d, J = 3.7 Hz, 2H), 9.38 (d, J = 0.7 Hz, 1H), 9.28 (s, 1H), 9.15 (t, J = 2.1 Hz, 1H), 8.90 (dd, J = 5.7, 137 1.8 Hz, 1H), 8.45 (dt, J = 11.7, 2.1 Hz, 1H), 8.27 (s, 1H), 7.92 (d, J = 9.0 Hz, 1H), 7.82 (dd, J = 9.0, 1.7 Hz, 1H), 1.80 (dd, J = 13.6, 5.0 Hz, 6H); ESI MS (m / z): 349.9 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.36 (d, J = 0.7 Hz, 1H), 9.32 (d, J = 2.2 Hz, 1H), 8.69 (dd, J = 4.8, 1.3 Hz, 1H), 8.49 (dq, J = 8.4, 1.3 Hz, 1H), 8.22 (d, J = 13.9 Hz, 1H), 7.86 (dd, J = 9.0, 2.7 Hz, 1H), 7.68- 138 7.65 (m, 1H), 7.62-7.57 (m, 1H), 7.28-7.26 (m, 2H), 7.10 (d, J = 7.8 Hz, 2H), 2.32-2.26 (m, 2H), 2.22 (S, 3H), 1.04 (dt, J = 20.1, 7.6 Hz, 3H); ESI MS (m / z): 393.95 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.59 (s, 2H), 9.38 (d, J = 0.9 Hz, 1H), 9.28 (s, 1H), 9.16 (t, J = 2.1 Hz, 1H), 8.84 (dd, J = 5.0, 1.7 Hz, 139 1H), 8.40 (dt, J = 10.6, 2.1 Hz, 1H), 8.27 (s, 1H), 7.92 (d, J = 9.2 Hz, 1H), 7.81 (dd, J = 9.0, 1.7 Hz, 1H), 2.14-2.00 (m, 4H), 0.99 (dt, J = 17.1, 7.6 Hz, 6H); ESI MS (m / z): 378.1 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.58 (s, 2H), 9.35 (d, J = 1.0 Hz, 1H), 9.28 (s, 1H), 8.65 (s, 1H), 7.90 (d, J = 5.4 Hz, 2H), 7.86 (d, J = 140 8.8 Hz, 1H), 7.45 (dd, J = 8.9, 1.6 Hz, 1H), 2.40 (s, 3H), 1.99-1.93 (m, 4H), 1.58-1.50 (m, 2H), 1.38-1.30 (m, 2H), 0.92 (t, J = 7.3 Hz, 6H); ESI MS (m / z): 420.05 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.39-9.37 (m, 4H), 8.68 (dd, J = 4.6, 1.5 Hz, 1H), 8.54 (dq, J = 8.3, 1.4 Hz, 1H), 8.36 (t, J = 1.2 Hz, 1H), 141 7.93 (d, J = 9.0 Hz, 1H), 7.85 (dd, J = 9.0, 1.7 Hz, 1H), 7.68-7.65 (m, 1H), 2.16-1.98 (m, 4H), 1.59-1.47 (m, 4H), 0.97 (dd, J = 7.7, 7.0 Hz, 6H); ESI MS (m / z): 406.1 [M+1]. PI External 1H-NMR (400 MHz, DMSO-d6) δ 9.37 (d, J = 2.8 Hz, 1H), 9.34 (s, 1H), 8.82 (d, J = 4.9 Hz, 1H), 8.68 (dd, J = 4.7, 1.4 Hz, 1H), 8.54-8.51 (m, 1H), 8.34 (s, 1H), 8.23 (d, J = 4.3 Hz, 1H), 7.94-7.90 (m, 2H), 7.80 142 (dd, J = 9.0, 1.7 Hz, 1H), 7.67 (dd, J = 8.3, 4.9 Hz, 1H), 2.02-1.95 (m, 4H), 1.58-1.50 (m, 2H), 1.40-1.30 (m, 2H), 0.91 (t, J = 7.3 Hz, 6H); ESI MS (m / z): 405.1 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.55 (s, 2H), 9.46 (d, J = 1.0 Hz, 1H), 9.30 (s, 1H), 8.33 (dd, J = 15.6, 1.2 Hz, 1H), 7.89 (dd, J = 9.0, 2.9 143 Hz, 1H), 7.55-7.50 (m, 1H), 4.09-3.98 (m, 4H), 1.24 (t, J = 7.1 Hz, 6H); ESI MS (m / z): 332.95 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.45 (d, J = 1.0 Hz, 1H), 9.27 (d, J = 1.2 Hz, 1H), 8.73 (d, J = 2.2 Hz, 1H), 8.54 (dt, J = 9.9, 2.3 Hz, 1H), 144 8.31 (dt, J = 15.6, 1.1 Hz, 1H), 7.88-7.85 (m, 1H), 7.54-7.49 (m, 1H), 4.09-3.98 (m, 4H), 1.24 (t, J = 7.0 Hz, 6H); ESI MS (m / z): 349.85 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.79 (d, J = 0.5 Hz, 1H), 9.39 (d, J = 2.4 Hz, 1H), 8.73 (dd, J = 4.8, 1.3 Hz, 1H), 8.56 (dq, J = 8.3, 1.4 Hz, 145 1H), 8.39 (qd, J = 4.6, 1.0 Hz, 1H), 7.76 (q, J = 4.4 Hz, 1H), 7.74-7.68 (m, 1H), 4.20-4.10 (m, 4H), 1.27 (t, J = 7.1 Hz, 6H); ESI MS (m / z): 333.05 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.79 (d, J = 0.5 Hz, 1H), 9.39 (d, J = 2.4 Hz, 1H), 8.73 (dd, J = 4.8, 1.3 Hz, 1H), 8.56 (dq, J = 8.3, 1.4 Hz, 146 1H), 8.39 (qd, J = 4.6, 1.0 Hz, 1H), 7.76 (q, J = 4.4 Hz, 1H), 7.74-7.68 (m, 1H), 4.20-4.10 (m, 4H), 1.27 (t, J = 7.1 Hz, 6H); ESI MS (m / z): 419.2 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.82 (s, 1H), 9.32 (s, 1H), 8.78 (d, J = 2.2 Hz, 1H), 8.60 (dt, J = 9.9, 2.4 Hz, 1H), 8.40 (qd, J = 4.6, 0.9 Hz, 147 1H), 7.77 (q, J = 4.4 Hz, 1H), 4.19-4.11 (m, 4H), 1.27 (t, J = 7.1 Hz, 6H); ESI MS (m / z): 350.9 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.37 (d, J = 2.4 Hz, 1H), 9.34 (s, 1H), 8.83 (d, J = 5.6 Hz, 1H), 8.68 (dd, J = 4.6, 1.2 Hz, 1H), 8.54-8.52 (m, 1H), 8.34 (s, 1H), 8.23 (d, J = 4.2 Hz, 1H), 7.95-7.90 (m, 2H), 7.81 148 (dd, J = 9.3, 1.7 Hz, 1H), 7.67 (q, J = 4.3 Hz, 1H), 2.03-1.95 (m, 4H), 1.64-1.48 (m, 2H), 1.37-1.30 (m, 2H), 0.91 (t, J = 7.3 Hz, 6H); ESI MS (m / z): 405.15 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.58 (s, 2H), 9.40 (d, J = 0.7 Hz, 1H), 9.29 (s, 1H), 8.35 (s, 1H), 8.07 (d, J = 6.1 Hz, 1H), 7.92 (d, J = 149 9.3 Hz, 1H), 7.84-7.81 (m, 2H), 2.62 (s, 3H), 1.71 (s, 3H), 1.68 (s, 3H); ESI MS (m / z): 364 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.37 (d, J = 2.2 Hz, 1H), 9.32 (d, J = 1.0 Hz, 1H), 9.14 (t, J = 2.1 Hz, 1H), 8.84 (dd, J = 5.3, 1.8 Hz, 1H), 8.67 (dd, J = 4.8, 1.3 Hz, 1H), 8.53 (dq, J = 8.4, 1.3 Hz, 1H), 8.40 (dt, 150 J = 10.8, 2.1 Hz, 1H), 8.23 (q, J = 0.8 Hz, 1H), 7.90 (d, J = 9.0 Hz, 1H), 7.78 (dd, J = 9.2, 1.8 Hz, 1H), 7.67 (ddd, J = 8.3, 4.8, 0.6 Hz, 1H), 2.12-1.99 (m, 4H), 1.56-1.46 (m, 2H), 1.42-1.32 (m, 2H), 0.93 (t, J = 7.2 Hz, 6H); ESI MS (m / z): 404.85 [M+1]. PI External 1H-NMR (400 MHz, Chloroform-d) δ 9.20 (d, J = 2.4 Hz, 1H), 8.70 (dd, J = 4.9, 1.5 Hz, 1H), 8.53 (d, J = 0.7 Hz, 1H), 8.31-8.27 (m, 2H), 151 7.87-7.84 (m, 1H), 7.72-7.67 (m, 1H), 7.54-7.50 (m, 1H), 7.37 (dd, J = 8.1, 1.5 Hz, 2H), 7.03 (d, J = 8.1 Hz, 2H), 2.27 (s, 3H), 1.39-1.29 (m, 1H), 1.07-0.79 (m, 4H); ESI MS (m / z): 405.95 [M+1]. 1H-NMR (400 MHz, Chloroform-d) δ 9.21 (d, J = 2.2 Hz, 1H), 8.71 (dd, J = 4.6, 1.5 Hz, 1H), 8.60 (d, J = 0.7 Hz, 1H), 8.41 (dt, J = 15.9, 1.1 Hz, 1H), 8.30 (dq, J = 8.3, 1.4 Hz, 1H), 7.87-7.83 (m, 1H), 7.62- 152 7.57 (m, 1H), 7.53 (ddd, J = 8.3, 4.9, 0.7 Hz, 1H), 5.84-5.74 (m, 2H), 5.15-5.06 (m, 4H), 4.21-4.04 (m, 4H), 2.46 (qt, J = 6.8, 1.3 Hz, 4H); ESI MS (m / z): 383.95 [M+1]. 1H-NMR (400 MHz, Chloroform-d) δ 9.19 (d, J = 2.2 Hz, 1H), 8.70 (dd, J = 4.9, 1.5 Hz, 1H), 8.49 (d, J = 0.7 Hz, 1H), 8.28-8.24 (m, 2H), 7.81 (dd, J = 9.0, 2.7 Hz, 1H), 7.60 (td, J = 9.2, 1.3 Hz, 1H), 7.51 (dd, 153 J = 8.4, 4.8 Hz, 1H), 7.27 (s, 1H), 7.25 (d, J = 1.5 Hz, 1H), 6.95 (d, J = 8.1 Hz, 2H), 2.21 (m, 4H), 2.06-2.00 (m, 2H), 1.89-1.79 (m, 2H), 1.10 (t, J = 7.3 Hz, 3H), 0.93-0.88 (m, 3H); ESI MS (m / z): 436 [M+1]. 1H-NMR (400 MHz, Chloroform-d) δ 9.22 (d, J = 2.2 Hz, 1H), 8.71 (dd, J = 4.6, 1.5 Hz, 1H), 8.59 (d, J = 1.0 Hz, 1H), 8.40 (dt, J = 13.2, 1.1 Hz, 1H), 8.29 (dq, J = 8.3, 1.4 Hz, 1H), 7.89-7.86 (m, 1H), 7.52 154 (ddd, J = 8.3, 4.8, 0.6 Hz, 1H), 7.41 (td, J = 9.0, 1.3 Hz, 1H), 2.09-1.91 (m, 2H), 1.76 (d, J = 12.5 Hz, 3H), 1.16 (dt, J = 17.4, 7.6 Hz, 3H); ESI MS (m / z): 285.9 [M+1]. 1H-NMR (400 MHz, Chloroform-d) δ 9.21 (d, J = 2.2 Hz, 1H), 8.71 (dd, J = 4.9, 1.5 Hz, 1H), 8.60 (d, J = 1.0 Hz, 1H), 8.42 (dt, J = 13.4, 1.1 Hz, 1H), 8.29 (dq, J = 8.3, 1.4 Hz, 1H), 7.88-7.85 (m, 1H), 7.55- 155 7.50 (m, 2H), 5.82-5.73 (m, 1H), 5.14-5.07 (m, 2H), 4.13-4.07 (m, 1H), 3.88-3.82 (m, 1H), 2.46-2.41 (m, 2H), 2.04-1.90 (m, 2H), 1.14 (dt, J = 19.1, 7.7 Hz, 3H); ESI MS (m / z): 341.95 [M+1]. 1H-NMR (400 MHz, CHLOROFORM-D) δ 9.20 (d, J = 2.4 Hz, 1H), 8.70 (dd, J = 4.7, 1.4 Hz, 1H), 8.52 (s, 1H), 8.32-8.26 (m, 2H), 7.83 (dd, J = 8.9, 2.8 Hz, 1H), 7.61 (td, J = 9.2, 1.2 Hz, 1H), 7.52 (dd, J = 156 8.3, 4.9 Hz, 1H), 7.32 (dd, J = 7.9, 1.2 Hz, 2H), 6.99 (d, J = 8.3 Hz, 2H), 2.44-2.34 (m, 1H), 2.23 (s, 3H), 1.42-1.33 (m, 3H), 1.18 (dd, J = 19.0, 7.3 Hz, 3H); ESI MS (m / z): 408.05 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.41 (s, 2H), 9.37 (d, J = 2.4 Hz, 1H), 8.87 (s, 1H), 8.69 (d, J = 4.9 Hz, 1H), 8.54 (t, J = 5.3 Hz, 2H), 157 8.25 (dd, J = 9.0, 1.7 Hz, 1H), 7.91 (d, J = 9.3 Hz, 1H), 7.67 (dd, J = 8.3, 4.6 Hz, 1H), 1.77 (d, J = 13.9 Hz, 6H); ESI MS (m / z): 349.8 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.42-9.40 (m, 2H), 9.37 (d, J = 2.4 Hz, 1H), 8.87 (s, 1H), 8.69 (dd, J = 4.6, 1.5 Hz, 1H), 8.55-8.50 (m, 158 2H), 8.24 (dd, J = 9.3, 1.7 Hz, 1H), 7.91 (d, J = 9.3 Hz, 1H), 7.67 (dd, J = 8.7, 5.0 Hz, 1H), 2.11-2.00 (m, 4H), 1.04 (t, J = 7.7 Hz, 3H), 0.99 (t, J = 7.7 Hz, 3H); ESI MS (m / z): 377.95 [M+1]. PI External 1H-NMR (400 MHz, DMSO-d6) δ 9.84 (s, 1H), 9.60 (s, 2H), 9.34 (s, 1H), 8.42 (ddd, J = 8.9, 4.9, 0.9 Hz, 1H), 7.78 (q, J = 4.4 Hz, 1H), 4.19- 159 4.12 (m, 4H), 1.27 (t, J = 7.0 Hz, 6H); ESI MS (m / z): 334.05 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.40 (d, J = 0.7 Hz, 1H), 9.24 (s, 1H), 8.74 (d, J = 2.4 Hz, 1H), 8.52 (dt, J = 9.9, 2.3 Hz, 1H), 8.20 (d, J 160 = 15.9 Hz, 1H), 7.88 (dd, J = 9.0, 3.4 Hz, 1H), 7.64-7.58 (m, 1H), 7.30 (dd, J = 8.2, 1.8 Hz, 4H), 7.14 (d, J = 8.1 Hz, 4H), 2.25 (s, 6H); ESI MS (m / z): 505.8 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.40 (d, J = 0.7 Hz, 1H), 9.25 (s, 1H), 8.73 (d, J = 2.7 Hz, 1H), 8.53 (dt, J = 9.9, 2.3 Hz, 1H), 8.21 (d, J = 13.9 Hz, 1H), 7.86 (dd, J = 9.0, 2.7 Hz, 1H), 7.63-7.58 (m, 1H), 7.26 161 (d, J = 6.8 Hz, 2H), 7.09 (d, J = 7.8 Hz, 2H), 2.34-2.27 (m, 2H), 2.23 (s, 3H), 1.05 (dt, J = 19.9, 7.6 Hz, 3H); ESI MS (m / z): 412.15 [M+1]. 1H-NMR (400 MHz, CHLOROFORM-D) δ 9.04 (d, J = 2.0 Hz, 1H), 8.61 (d, J = 0.7 Hz, 1H), 8.57 (d, J = 2.7 Hz, 1H), 8.40 (dt, J = 15.9, 1.1 Hz, 1H), 8.13 (dt, J = 8.9, 2.4 Hz, 1H), 7.83 (dq, J = 9.0, 1.0 Hz, 162 1H), 7.63-7.57 (m, 1H), 5.84-5.74 (m, 2H), 5.14 (q, J = 1.6 Hz, 1H), 5.10-5.09 (m, 2H), 5.07 (q, J = 1.4 Hz, 1H), 4.21-4.13 (m, 2H), 4.12- 4.05 (m, 2H), 2.46 (qt, J = 6.7, 1.3 Hz, 4H); ESI MS (m / z): 401.95 [M+1]. 1H-NMR (400 MHz, CHLOROFORM-D) δ 9.20 (d, J = 2.2 Hz, 1H), 8.70 (dd, J = 4.6, 1.5 Hz, 1H), 8.53 (d, J = 1.0 Hz, 1H), 8.33-8.26 (m, 2H), 7.84 (dq, J = 9.0, 0.9 Hz, 1H), 7.60-7.55 (m, 1H), 7.52 (ddd, J = 163 8.3, 4.9, 0.7 Hz, 1H), 7.33 (dd, J = 8.1, 1.5 Hz, 2H), 7.02 (t, J = 8.6 Hz, 2H), 2.31-2.11 (m, 5H), 1.80-1.62 (m, 2H), 0.99 (td, J = 7.3, 1.5 Hz, 3H); ESI MS (m / z): 408.2 [M+1]. 1H-NMR (400 MHz, CHLOROFORM-D) δ 9.21 (d, J = 2.4 Hz, 1H), 8.71 (dd, J = 4.9, 1.5 Hz, 1H), 8.58 (d, J = 0.7 Hz, 1H), 8.40 (d, J = 13.2 Hz, 1H), 8.29 (dq, J = 8.3, 1.4 Hz, 1H), 7.87 (dt, J = 9.0, 1.0 Hz, 164 1H), 7.54-7.50 (m, 1H), 7.40 (td, J = 8.9, 1.3 Hz, 1H), 2.07-1.87 (m, 2H), 1.75 (d, J = 12.5 Hz, 3H), 1.70-1.67 (m, 1H), 1.60-1.49 (m, 1H), 1.01 (dd, J = 7.7, 7.0 Hz, 3H); ESI MS (m / z): 299.9 [M+1]. 1H-NMR (400 MHz, CHLOROFORM-D) δ 9.21 (d, J = 2.2 Hz, 1H), 8.71 (dd, J = 4.6, 1.5 Hz, 1H), 8.60 (d, J = 1.0 Hz, 1H), 8.42 (dt, J = 13.4, 1.2 Hz, 1H), 8.29 (dq, J = 8.3, 1.4 Hz, 1H), 7.88-7.85 (m, 1H), 165 7.55-7.50 (m, 2H), 5.83-5.73 (m, 1H), 5.14-5.06 (m, 2H), 4.14-4.06 (m, 1H), 3.86-3.78 (m, 1H), 2.42 (qt, J = 6.7, 1.3 Hz, 2H), 2.02-1.84 (m, 2H), 1.70-1.61 (m, 2H), 0.99 (td, J = 7.3, 1.3 Hz, 3H); ESI MS (m / z): 356.05 [M+1]. 1H-NMR (400 MHz, CHLOROFORM-D) δ 9.05 (d, J = 1.8 Hz, 1H), 8.61 (d, J = 0.9 Hz, 1H), 8.57 (d, J = 2.4 Hz, 1H), 8.41-8.38 (m, 1H), 166 8.13 (dt, J = 9.0, 2.4 Hz, 1H), 7.86 (dq, J = 10.1, 1.0 Hz, 1H), 7.41 (td, J = 8.9, 1.3 Hz, 1H), 2.09-1.91 (m, 2H), 1.76 (d, J = 12.5 Hz, 3H), 1.16 (dt, J = 17.4, 7.6 Hz, 3H); ESI MS (m / z): 304 [M+1]. PI External 1H-NMR (400 MHz, DMSO-d6) δ 9.58 (s, 2H), 9.47 (s, 1H), 9.42 (s, 1H), 9.29 (s, 1H), 8.89 (s, 1H), 8.56 (d, J = 5.6 Hz, 1H), 8.26 (d, J = 167 8.8 Hz, 1H), 7.92 (d, J = 9.0 Hz, 1H), 1.78 (d, J = 13.7 Hz, 6H); ESI MS (m / z): 350.9 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.58 (s, 2H), 9.46 (d, J = 0.7 Hz, 1H), 9.43 (d, J = 1.0 Hz, 1H), 9.30 (s, 1H), 8.90 (s, 1H), 8.53 (dd, J = 168 5.9, 1.5 Hz, 1H), 8.26 (dd, J = 9.3, 1.7 Hz, 1H), 7.92 (d, J = 9.3 Hz, 1H), 2.13-1.99 (m, 4H), 1.02 (dt, J = 17.1, 7.7 Hz, 6H); ESI MS (m / z): 378.9 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.36 (d, J = 2.4 Hz, 1H), 9.29 (d, J = 0.7 Hz, 1H), 8.67 (dd, J = 4.6, 1.5 Hz, 1H), 8.60 (d, J = 4.9 Hz, 1H), 8.52 (dq, J = 8.3, 1.4 Hz, 1H), 7.85 (d, J = 9.0 Hz, 1H), 7.81 (t, J = 1.2 169 Hz, 1H), 7.66 (q, J = 4.2 Hz, 1H), 7.44 (dd, J = 4.9, 2.0 Hz, 1H), 7.35 (dd, J = 8.9, 1.6 Hz, 1H), 2.64 (d, J = 11.7 Hz, 3H), 1.77 (d, J = 13.4 Hz, 6H); ESI MS (m / z): 363.05 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.35 (d, J = 2.2 Hz, 1H), 9.28 (d, J = 1.0 Hz, 1H), 8.67 (dd, J = 4.8, 1.3 Hz, 1H), 8.61 (d, J = 4.6 Hz, 1H), 8.52 (dq, J = 8.3, 1.4 Hz, 1H), 7.85-7.81 (m, 2H), 7.66 (ddd, J = 8.3, 170 4.8, 0.6 Hz, 1H), 7.42 (dd, J = 4.8, 1.8 Hz, 1H), 7.35 (dd, J = 8.8, 1.7 Hz, 1H), 2.63 (s, 3H), 2.18-2.05 (m, 2H), 2.04-1.92 (m, 2H), 1.03 (dt, J = 16.7, 7.7 Hz, 6H); ESI MS (m / z): 391.3 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.35 (d, J = 2.4 Hz, 1H), 9.27 (d, J = 0.7 Hz, 1H), 8.67 (dd, J = 4.6, 1.2 Hz, 1H), 8.61 (d, J = 4.6 Hz, 1H), 8.51 (dq, J = 8.4, 1.3 Hz, 1H), 7.85-7.81 (m, 2H), 7.66 (dd, J = 8.3, 4.9 171 Hz, 1H), 7.41 (dd, J = 4.6, 1.7 Hz, 1H), 7.34 (dd, J = 9.0, 1.7 Hz, 1H), 2.63 (s, 3H), 2.16-2.05 (m, 2H), 2.01-1.91 (m, 2H), 1.59-1.38 (m, 4H), 0.95 (t, J = 7.3 Hz, 6H); ESI MS (m / z): 419.4 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.34 (d, J = 1.0 Hz, 1H), 9.29 (s, 1H), 8.71 (d, J = 2.4 Hz, 1H), 8.60 (d, J = 4.6 Hz, 1H), 8.55 (dt, J = 172 9.9, 2.3 Hz, 1H), 7.86-7.82 (m, 2H), 7.45 (dd, J = 4.8, 1.8 Hz, 1H), 7.37 (dd, J = 8.8, 1.7 Hz, 1H), 2.63 (s, 3H), 1.77 (d, J = 13.4 Hz, 6H) ESI MS (m / z): 380.8 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.33 (d, J = 0.7 Hz, 1H), 9.29 (s, 1H), 8.71 (d, J = 2.4 Hz, 1H), 8.61 (d, J = 4.6 Hz, 1H), 8.55 (dt, J = 9.9, 2.3 Hz, 1H), 7.85-7.83 (m, 2H), 7.43 (dd, J = 4.8, 1.8 Hz, 1H), 173 7.37 (dd, J = 9.2, 1.3 Hz, 1H), 2.62 (s, 3H), 2.16-2.05 (m, 2H), 2.03- 1.94 (m, 2H), 1.03 (dt, J = 16.8, 7.6 Hz, 6H); ESI MS (m / z): 409.15 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.33 (s, 1H), 9.29 (s, 1H), 8.71 (d, J = 2.4 Hz, 1H), 8.61 (d, J = 4.6 Hz, 1H), 8.55 (dt, J = 9.9, 2.3 Hz, 1H), 7.83 (d, J = 9.3 Hz, 2H), 7.41 (dd, J = 4.8, 1.8 Hz, 1H), 7.36 (dd, J = 174 8.9, 1.8 Hz, 1H), 2.62 (s, 3H), 2.16-2.05 (m, 2H), 2.01-1.90 (m, 2H), 1.61-1.43 (m, 4H), 0.95 (t, J = 7.2 Hz, 6H); ESI MS (m / z): 437.25 [M+1]. PI External 1H-NMR (400 MHz, DMSO-d6) δ 9.57 (s, 2H), 9.35 (s, 1H), 9.28 (s, 1H), 8.61 (d, J = 4.9 Hz, 1H), 7.86 (d, J = 9.8 Hz, 2H), 7.45 (dd, J = 175 4.9, 2.0 Hz, 1H), 7.38 (dd, J = 8.8, 1.7 Hz, 1H), 2.63 (s, 3H), 1.77 (d, J = 13.2 Hz, 6H); ESI MS (m / z): 363.95 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.57 (s, 2H), 9.35 (d, J = 1.0 Hz, 1H), 9.28 (s, 1H), 8.62 (d, J = 4.9 Hz, 1H), 7.87-7.85 (m, 2H), 7.43 176 (dd, J = 4.8, 1.8 Hz, 1H), 7.38 (dd, J = 9.0, 1.5 Hz, 1H), 2.62 (s, 3H), 2.18-2.05 (m, 2H), 2.05-1.92 (m, 2H), 1.03 (dt, J = 16.8, 7.7 Hz, 6H); ESI MS (m / z): 392.2 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.57 (s, 2H), 9.34 (d, J = 1.0 Hz, 1H), 9.28 (s, 1H), 8.61 (d, J = 4.9 Hz, 1H), 7.87-7.84 (m, 2H), 7.42 177 (dd, J = 4.6, 1.7 Hz, 1H), 7.37 (dd, J = 9.3, 1.5 Hz, 1H), 2.62 (s, 3H), 2.16-2.05 (m, 2H), 2.01-1.92 (m, 2H), 1.58-1.45 (m, 4H), 0.95 (t, J = 7.1 Hz, 6H); ESI MS (m / z): 420.05 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.73 (d, J = 0.7 Hz, 1H), 9.39 (d, J = 2.4 Hz, 1H), 8.92 (dd, J = 5.1, 0.7 Hz, 1H), 8.74-8.71 (m, 2H), 8.54 (dq, J = 8.4, 1.3 Hz, 1H), 8.43 (dd, J = 9.2, 0.9 Hz, 1H), 8.25 (td, J = 178 3.5, 1.7 Hz, 1H), 8.17 (d, J = 9.3 Hz, 1H), 7.70 (dd, J = 8.3, 4.6 Hz, 1H), 2.06-1.91 (m, 4H), 1.60-1.48 (m, 2H), 1.38-1.26 (m, 2H), 0.90 (t, J = 7.3 Hz, 6H); ESI MS (m / z): 406.15 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.74 (d, J = 0.7 Hz, 1H), 9.39 (d, J = 2.4 Hz, 1H), 8.93-8.92 (m, 1H), 8.74-8.71 (m, 2H), 8.55 (dq, J = 8.3, 179 1.4 Hz, 1H), 8.45-8.41 (m, 1H), 8.27 (td, J = 3.5, 1.7 Hz, 1H), 8.21- 8.17 (m, 1H), 7.70 (dd, J = 8.3, 4.6 Hz, 1H), 2.07-1.94 (m, 4H), 0.98 (dt, J = 16.9, 7.7 Hz, 6H); ESI MS (m / z): 377.95 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.68 (d, J = 0.7 Hz, 1H), 9.41 (d, J = 2.7 Hz, 1H), 8.71 (dd, J = 4.6, 1.5 Hz, 1H), 8.60-8.55 (m, 2H), 8.49 (d, J = 9.3 Hz, 1H), 8.40 (dd, J = 9.3, 0.7 Hz, 1H), 8.16 (td, J = 7.7, 3.2 180 Hz, 1H), 8.01 (ddd, J = 7.5, 4.9, 1.1 Hz, 1H), 7.71-7.67 (m, 1H), 2.12- 2.04 (m, 4H), 1.02 (dt, J = 16.7, 7.7 Hz, 6H); ESI MS (m / z): 378.2 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.59 (d, J = 5.4 Hz, 2H), 9.46 (d, J = 1.0 Hz, 1H), 9.42 (s, 1H), 9.30 (d, J = 2.7 Hz, 1H), 8.90 (s, 1H), 8.52 181 (dd, J = 5.9, 1.5 Hz, 1H), 8.26 (dd, J = 9.3, 1.7 Hz, 1H), 7.92 (d, J = 9.3 Hz, 1H), 2.08-1.97 (m, 4H), 1.60-1.52 (m, 2H), 1.44-1.34 (m, 2H), 0.93 (t, J = 7.3 Hz, 6H); ESI MS (m / z): 407.05 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.59-9.56 (m, 2H), 9.44 (d, J = 1.0 Hz, 1H), 9.40 (s, 2H), 9.29 (s, 1H), 8.38 (d, J = 1.5 Hz, 1H), 7.95 (d, J 182 = 9.0 Hz, 1H), 7.87 (dd, J = 9.0, 1.7 Hz, 1H), 1.83-1.77 (m, 6H); ESI MS (m / z): 350.7 [M+1]. 1H-NMR (400 MHz, CHLOROFORM-D) δ 9.21 (d, J = 2.7 Hz, 1H), 8.71 (dd, J = 4.8, 1.3 Hz, 1H), 8.59 (d, J = 1.0 Hz, 1H), 8.47 (dt, J = 13.9, 1.2 Hz, 1H), 8.29 (dq, J = 8.3, 1.4 Hz, 1H), 7.86 (dt, J = 9.0, 1.2 183 Hz, 1H), 7.73-7.70 (m, 1H), 7.59 (qd, J = 3.5, 1.0 Hz, 1H), 7.54-7.47 (m, 2H), 7.22-7.20 (m, 1H), 2.42-2.27 (m, 2H), 1.26 (dt, J = 18.3, 7.6 Hz, 3H); ESI MS (m / z): 353.7 [M+1]. PI External 1H-NMR (400 MHz, CHLOROFORM-D) δ 9.21 (d, J = 2.4 Hz, 1H), 8.71 (dd, J = 4.8, 1.3 Hz, 1H), 8.58 (d, J = 1.0 Hz, 1H), 8.42 (dt, J = 13.5, 1.1 Hz, 1H), 8.29 (dq, J = 8.3, 1.4 Hz, 1H), 7.89 (dq, J = 7.1, 1.3 184 Hz, 1H), 7.85 (dt, J = 9.0, 1.1 Hz, 1H), 7.52 (dd, J = 7.9, 4.5 Hz, 1H), 7.49-7.43 (m, 2H), 7.34-7.32 (m, 1H), 2.37-2.25 (m, 2H), 1.23 (dt, J = 17.9, 7.6 Hz, 3H); ESI MS (m / z): 353.85 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.59 (s, 2H), 9.44-9.43 (m, 1H), 9.40 (s, 2H), 9.29 (s, 1H), 8.40 (s, 1H), 7.95 (d, J = 9.3 Hz, 1H), 7.87 (dd, J 185 = 9.0, 1.7 Hz, 1H), 2.16-1.98 (m, 4H), 1.59-1.47 (m, 4H), 0.97 (t, J = 7.2 Hz, 6H); ESI MS (m / z): 406.95 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.38 (d, J = 2.4 Hz, 1H), 9.36 (s, 1H), 9.06 (s, 1H), 8.68 (dd, J = 4.6, 1.2 Hz, 1H), 8.55-8.52 (m, 1H), 186 8.33 (s, 1H), 8.29 (dq, J = 11.4, 1.9 Hz, 1H), 7.90 (d, J = 9.2 Hz, 1H), 7.82 (dd, J = 9.0, 1.7 Hz, 1H), 7.66 (q, J = 4.3 Hz, 1H), 1.82 (d, J = 13.8 Hz, 6H); ESI MS (m / z): 366.95 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.68 (d, J = 0.9 Hz, 1H), 9.41 (d, J = 2.8 Hz, 1H), 8.70 (dd, J = 4.7, 1.4 Hz, 1H), 8.58-8.55 (m, 2H), 8.48 (d, J = 9.2 Hz, 1H), 8.41 (dd, J = 9.2, 0.9 Hz, 1H), 8.15 (td, J = 7.8, 3.4 187 Hz, 1H), 8.01 (ddd, J = 7.4, 4.8, 1.0 Hz, 1H), 7.71-7.67 (m, 1H), 2.10- 2.01 (m, 4H), 1.62-1.51 (m, 2H), 1.44-1.32 (m, 2H), 0.93-0.83 (m, 6H); ESI MS (m / z): 406.05 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.38 (d, J = 2.4 Hz, 1H), 9.35 (d, J = 0.6 Hz, 1H), 9.06 (s, 1H), 8.67 (dd, J = 4.7, 1.4 Hz, 1H), 8.53 (dq, J = 8.3, 1.4 Hz, 1H), 8.34 (s, 1H), 8.26 (dq, J = 11.4, 1.9 Hz, 1H), 7.89 188 (d, J = 9.2 Hz, 1H), 7.83 (dd, J = 9.2, 1.5 Hz, 1H), 7.66 (q, J = 4.3 Hz, 1H), 2.17-1.96 (m, 4H), 1.59-1.45 (m, 4H), 0.97 (dd, J = 7.5, 6.9 Hz, 6H); ESI MS (m / z): 423.25 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.64 (s, 1H), 9.40 (d, J = 2.8 Hz, 1H), 8.71 (dd, J = 4.6, 1.2 Hz, 1H), 8.58-8.55 (m, 1H), 8.38 (d, J = 8.9 189 Hz, 1H), 8.06 (q, J = 3.8 Hz, 1H), 7.92 (dd, J = 7.6, 5.2 Hz, 1H), 7.71- 7.65 (m, 2H), 2.65 (d, J = 8.3 Hz, 3H), 1.70 (d, J = 13.8 Hz, 6H) ESI MS (m / z): 364 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.65 (d, J = 0.7 Hz, 1H), 9.40 (d, J = 2.2 Hz, 1H), 9.28 (s, 1H), 8.71 (dd, J = 4.8, 1.3 Hz, 1H), 8.56 (dq, J 190 = 8.5, 1.3 Hz, 1H), 8.44 (d, J = 2.7 Hz, 1H), 8.41 (dd, J = 9.3, 1.0 Hz, 1H), 8.13 (d, J = 9.3 Hz, 1H), 7.69 (q, J = 4.4 Hz, 1H), 2.78 (s, 3H), 1.76 (d, J = 13.2 Hz, 6H); ESI MS (m / z): 364.15 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.64 (d, J = 1.0 Hz, 1H), 9.40 (d, J = 2.7 Hz, 1H), 9.29 (d, J = 1.7 Hz, 1H), 8.71 (dd, J = 4.6, 1.5 Hz, 1H), 8.56 (dq, J = 8.3, 1.4 Hz, 1H), 8.42-8.39 (m, 2H), 8.13 (d, J = 9.3 Hz, 191 1H), 7.69 (dd, J = 8.3, 4.6 Hz, 1H), 2.77 (s, 3H), 2.14-1.91 (m, 4H), 1.61-1.49 (m, 2H), 1.45-1.34 (m, 2H), 0.93 (t, J = 7.3 Hz, 6H); ESI MS (m / z): 420.05 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.34 (d, J = 17.1 Hz, 2H), 8.67 (d, J 192 = 4.2 Hz, 1H), 8.52 (d, J = 6.6 Hz, 1H), 8.30 (s, 1H), 8.04 (d, J = 5.1 Hz, 1H), 7.90 (d, J = 9.0 Hz, 1H), 7.79 (d, J = 13.9 Hz, 2H), 7.67 (d, J PI External = 7.8 Hz, 1H), 2.61 (s, 3H), 1.96 (d, J = 9.0 Hz, 4H), 1.56 (s, 2H), 1.37 (s, 2H), 0.90 (d, J = 6.8 Hz, 6H); ESI MS (m / z): 419.1 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.36 (d, J = 2.4 Hz, 1H), 9.32 (s, 1H), 8.68 (dd, J = 4.8, 1.3 Hz, 1H), 8.52 (dq, J = 8.4, 1.3 Hz, 1H), 8.31 193 (s, 1H), 8.04 (d, J = 5.6 Hz, 1H), 7.90 (d, J = 9.3 Hz, 1H), 7.82-7.78 (m, 2H), 7.66 (dd, J = 8.1, 4.6 Hz, 1H), 2.61 (s, 3H), 2.02-1.93 (m, 4H), 0.99 (dt, J = 16.5, 7.8 Hz, 6H); ESI MS (m / z): 391 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.36 (d, J = 0.7 Hz, 1H), 9.30 (s, 1H), 8.71 (d, J = 2.4 Hz, 1H), 8.56 (dt, J = 9.9, 2.3 Hz, 1H), 8.31 (s, 194 1H), 8.04-8.03 (m, 1H), 7.89 (d, J = 9.3 Hz, 1H), 7.82-7.79 (m, 2H), 2.61 (s, 3H), 2.04-1.91 (m, 4H), 0.99 (dt, J = 16.7, 7.7 Hz, 6H); ESI MS (m / z): 409.15 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.58 (s, 2H), 9.39 (d, J = 1.0 Hz, 1H), 9.29 (s, 1H), 8.35 (s, 1H), 8.04 (dd, J = 5.7, 1.6 Hz, 1H), 7.92 (d, 195 J = 9.0 Hz, 1H), 7.81 (dd, J = 9.0, 1.7 Hz, 2H), 2.61 (s, 3H), 2.03-1.93 (m, 4H), 1.01 (t, J = 7.7 Hz, 3H), 0.97 (t, J = 7.6 Hz, 3H); ESI MS (m / z): 392.05 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.37 (s, 1H), 9.30 (s, 1H), 8.71 (d, J = 2.4 Hz, 1H), 8.57 (dt, J = 10.0, 2.3 Hz, 1H), 8.32 (s, 1H), 8.06 (d, J 196 = 6.4 Hz, 1H), 7.90 (d, J = 9.0 Hz, 1H), 7.83-7.80 (m, 2H), 2.62 (s, 3H), 1.70 (d, J = 13.4 Hz, 6H); ESI MS (m / z): 381.25 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.39 (d, J = 0.7 Hz, 1H), 9.31 (d, J = 2.2 Hz, 1H), 8.69 (dd, J = 4.6, 1.5 Hz, 1H), 8.48 (dq, J = 8.5, 1.3 Hz, 1H), 8.33 (d, J = 15.4 Hz, 1H), 8.11 (td, J = 4.6, 1.0 Hz, 1H), 7.90 (dd, 197 J = 9.0, 2.9 Hz, 1H), 7.73-7.65 (m, 3H), 7.34 (dd, J = 8.1, 1.5 Hz, 2H), 7.31-7.28 (m, 1H), 7.10 (d, J = 8.1 Hz, 2H), 2.21 (s, 3H) ESI MS (m / z): 447.95 [M+1]. 1H-NMR (400 MHz, CHLOROFORM-D) δ 9.19 (d, J = 2.4 Hz, 1H), 8.71 (dd, J = 4.6, 1.5 Hz, 1H), 8.51 (s, 1H), 8.29-8.24 (m, 2H), 7.83 198 (dd, J = 9.2, 3.5 Hz, 1H), 7.74-7.69 (m, 1H), 7.53-7.47 (m, 5H), 7.31 (td, J = 7.2, 1.5 Hz, 2H), 7.27 (d, J = 1.7 Hz, 2H), 7.24 (d, J = 7.1 Hz, 2H); ESI MS (m / z): 460.1 [M+1]. 1H-NMR (400 MHz, CHLOROFORM-D) δ 9.19 (d, J = 2.7 Hz, 1H), 8.71 (dd, J = 4.6, 1.5 Hz, 1H), 8.51 (s, 1H), 8.29-8.24 (m, 2H), 7.84 199 (dd, J = 9.0, 3.7 Hz, 1H), 7.79-7.73 (m, 1H), 7.53-7.48 (m, 3H), 7.23- 7.17 (m, 4H), 7.08-7.04 (m, 2H), 2.37 (s, 6H); ESI MS (m / z): 488.1 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.58 (s, 2H), 9.39 (d, J = 1.0 Hz, 1H), 9.29 (s, 1H), 8.34 (s, 1H), 8.01-8.00 (m, 1H), 7.92 (d, J = 9.0 Hz, 200 1H), 7.83 (s, 1H), 7.80 (dd, J = 9.3, 1.7 Hz, 1H), 2.61 (s, 3H), 2.41 (td, J = 7.2, 3.3 Hz, 2H), 1.13 (q, J = 7.3 Hz, 6H), 0.99 (dd, J = 15.4, 7.1 Hz, 6H); ESI MS (m / z): 436.85 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.37 (d, J = 1.0 Hz, 1H), 9.30 (s, 1H), 8.72 (d, J = 2.4 Hz, 1H), 8.56 (dt, J = 9.9, 2.3 Hz, 1H), 8.31 (s, 201 1H), 8.00 (d, J = 5.4 Hz, 1H), 7.90 (d, J = 9.3 Hz, 1H), 7.83 (s, 1H), 7.79 (dd, J = 9.0, 1.7 Hz, 1H), 2.61 (s, 3H), 2.45-2.39 (m, 2H), 1.13 (q, PI External J = 7.3 Hz, 6H), 0.99 (dd, J = 15.4, 7.1 Hz, 6H); ESI MS (m / z): 419.95 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.36 (d, J = 2.7 Hz, 1H), 9.32 (d, J = 1.0 Hz, 1H), 8.68 (dd, J = 4.6, 1.5 Hz, 1H), 8.52 (dq, J = 8.4, 1.3 Hz, 1H), 8.30 (s, 1H), 8.00 (d, J = 3.9 Hz, 1H), 7.90 (d, J = 9.0 Hz, 1H), 202 7.82 (s, 1H), 7.78 (dd, J = 9.0, 1.7 Hz, 1H), 7.67 (dd, J = 8.1, 4.4 Hz, 1H), 2.61 (s, 3H), 2.45-2.39 (m, 2H), 1.13 (q, J = 7.3 Hz, 6H), 0.99 (dd, J = 15.4, 7.1 Hz, 6H); ESI MS (m / z): 419 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.58 (s, 2H), 9.39 (d, J = 1.0 Hz, 1H), 9.29 (s, 1H), 8.34 (s, 1H), 8.04 (d, J = 5.6 Hz, 1H), 7.92 (d, J = 203 9.3 Hz, 1H), 7.81 (dd, J = 9.2, 1.6 Hz, 2H), 2.61 (s, 3H), 2.00-1.93 (m, 4H), 1.57-1.50 (m, 2H), 1.39-1.32 (m, 2H), 0.91 (t, J = 7.3 Hz, 6H); ESI MS (m / z): 419.95 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.43 (s, 2H), 9.35 (ddd, J = 7.1, 2.6, 0.9 Hz, 1H), 9.27 (s, 1H), 7.66 (d, J = 0.7 Hz, 1H), 7.47 (dd, J = 7.0, 204 2.8 Hz, 1H), 2.46 (q, J = 3.4 Hz, 2H), 1.15 (dd, J = 15.3, 7.2 Hz, 6H), 1.01 (dd, J = 15.9, 7.1 Hz, 6H); ESI MS (m / z): 329.95 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.37 (d, J = 2.2 Hz, 1H), 9.32 (d, J = 0.7 Hz, 1H), 9.15 (t, J = 2.1 Hz, 1H), 8.81 (dd, J = 4.4, 1.7 Hz, 1H), 8.67 (dd, J = 4.6, 1.5 Hz, 1H), 8.53 (dq, J = 8.3, 1.4 Hz, 1H), 8.33 (dt, 205 J = 9.6, 2.1 Hz, 1H), 8.21 (d, J = 1.5 Hz, 1H), 7.90 (d, J = 9.0 Hz, 1H), 7.76 (dd, J = 9.0, 1.7 Hz, 1H), 7.68-7.65 (m, 1H), 2.57-2.52 (m, 2H), 1.11 (dd, J = 15.2, 7.1 Hz, 6H), 0.97 (dd, J = 16.0, 7.2 Hz, 6H); ESI MS (m / z): 405.05 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.58 (s, 2H), 9.46 (s, 1H), 9.43 (s, 1H), 9.30 (s, 1H), 8.89 (s, 1H), 8.49-8.48 (m, 1H), 8.25 (dd, J = 9.2, 206 1.6 Hz, 1H), 7.92 (d, J = 9.3 Hz, 1H), 2.46 (d, J = 7.1 Hz, 2H), 1.17 (dd, J = 15.3, 7.2 Hz, 6H), 1.01 (dd, J = 15.9, 7.1 Hz, 6H); ESI MS (m / z): 407.05 [M+1]. 1H-NMR (400 MHz, CHLOROFORM-D) δ 9.20 (d, J = 2.0 Hz, 1H), 8.71 (dd, J = 4.6, 1.5 Hz, 1H), 8.60 (d, J = 0.7 Hz, 1H), 8.43 (dt, J = 207 15.2, 1.2 Hz, 1H), 8.29 (dq, J = 8.3, 1.3 Hz, 1H), 7.86 (dt, J = 9.0, 1.2 Hz, 1H), 7.78 (td, J = 4.5, 1.0 Hz, 2H), 7.61-7.56 (m, 3H), 7.52 (ddd, J = 8.3, 4.7, 0.7 Hz, 1H), 7.24-7.21 (m, 2H); ESI MS (m / z): 408.2 [M+1]. 1H-NMR (400 MHz, CHLOROFORM-D) δ 9.21 (d, J = 2.1 Hz, 1H), 8.71 (dd, J = 4.6, 1.2 Hz, 1H), 8.60 (s, 1H), 8.45 (d, J = 14.4 Hz, 1H), 208 8.31-8.28 (m, 1H), 7.87-7.85 (m, 1H), 7.72 (t, J = 3.8 Hz, 1H), 7.59- 7.56 (m, 1H), 7.54-7.48 (m, 2H), 7.22-7.19 (m, 1H), 2.13 (d, J = 13.4 Hz, 3H); ESI MS (m / z): 340 [M+1]. 1H-NMR (400 MHz, CHLOROFORM-D) δ 9.20 (d, J = 2.4 Hz, 1H), 8.71 (d, J = 4.3 Hz, 1H), 8.59 (s, 1H), 8.47 (d, J = 13.8 Hz, 1H), 8.28 (d, J = 8.3 Hz, 1H), 7.86 (d, J = 8.9 Hz, 1H), 7.71 (t, J = 4.3 Hz, 1H), 209 7.58 (q, J = 3.5 Hz, 1H), 7.54-7.48 (m, 2H), 7.20 (d, J = 3.4 Hz, 1H), 2.41-2.25 (m, 2H), 1.82-1.67 (m, 2H), 1.05 (t, J = 7.3 Hz, 3H); ESI MS (m / z): 368.1 [M+1]. PI External 1H-NMR (400 MHz, DMSO-d6) δ 9.46 (d, J = 0.7 Hz, 1H), 9.25 (s, 1H), 8.73 (d, J = 2.2 Hz, 1H), 8.52 (dt, J = 9.9, 2.3 Hz, 1H), 8.26 (dt, J 210 = 15.1, 1.1 Hz, 1H), 8.14-8.12 (m, 2H), 7.89 (dt, J = 9.0, 1.2 Hz, 1H), 7.58-7.52 (m, 3H), 7.33-7.31 (m, 2H); ESI MS (m / z): 408.35 [M+1]. 1H-NMR (400 MHz, CHLOROFORM-D) δ 9.20 (d, J = 2.4 Hz, 1H), 8.71 (dd, J = 4.9, 1.5 Hz, 1H), 8.58 (s, 1H), 8.33 (d, J = 14.7 Hz, 1H), 211 8.29 (dq, J = 8.3, 1.4 Hz, 1H), 7.86-7.80 (m, 3H), 7.54-7.47 (m, 4H), 7.33-7.31 (m, 2H); ESI MS (m / z): 408.35 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.61 (d, J = 1.0 Hz, 1H), 9.40 (d, J = 2.4 Hz, 1H), 8.71 (dd, J = 4.8, 1.3 Hz, 1H), 8.56 (dq, J = 8.4, 1.3 Hz, 1H), 8.37 (dd, J = 9.0, 1.0 Hz, 1H), 8.07 (dd, J = 7.7, 3.1 Hz, 1H), 7.88 212 (dd, J = 7.7, 4.5 Hz, 1H), 7.70-7.68 (m, 2H), 2.64 (s, 3H), 2.44-2.40 (m, 2H), 1.13 (q, J = 7.3 Hz, 6H), 1.01 (dd, J = 15.4, 7.1 Hz, 6H) ESI MS (m / z): 420.1 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.62 (d, J = 0.7 Hz, 1H), 9.40 (d, J = 2.4 Hz, 1H), 8.71 (dd, J = 4.8, 1.3 Hz, 1H), 8.56 (dq, J = 8.4, 1.3 Hz, 213 1H), 8.38-8.36 (m, 1H), 8.07 (dd, J = 7.7, 3.1 Hz, 1H), 7.91 (dd, J = 7.5, 4.8 Hz, 1H), 7.71-7.67 (m, 2H), 2.65 (d, J = 9.8 Hz, 3H), 2.04-1.94 (m, 4H), 1.00 (dt, J = 16.7, 7.7 Hz, 6H); ESI MS (m / z): 392.1 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.58 (s, 2H), 9.40 (s, 1H), 9.29 (s, 1H), 8.84 (d, J = 4.9 Hz, 1H), 8.37 (s, 1H), 8.21-8.20 (m, 1H), 7.96- 214 7.92 (m, 2H), 7.82 (dd, J = 9.3, 1.7 Hz, 1H), 2.46-2.40 (m, 2H), 1.14 (q, J = 7.3 Hz, 6H), 0.98 (dd, J = 15.6, 7.1 Hz, 6H); ESI MS (m / z): 406.05 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.39 (s, 1H), 9.30 (s, 1H), 8.71 (d, J = 2.7 Hz, 1H), 8.59 (s, 1H), 8.55 (dt, J = 9.9, 2.3 Hz, 1H), 8.24-8.20 215 (m, 2H), 8.07 (td, J = 7.8, 3.7 Hz, 1H), 7.90-7.86 (m, 2H), 1.75 (d, J = 13.7 Hz, 6H); ESI MS (m / z): 366.95 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.40 (s, 1H), 9.30 (s, 1H), 8.71 (d, J = 2.7 Hz, 1H), 8.58 (s, 1H), 8.55 (dt, J = 10.0, 2.3 Hz, 1H), 8.23 (d, J 216 = 9.3 Hz, 1H), 8.19 (dd, J = 9.2, 1.6 Hz, 1H), 8.07 (td, J = 7.8, 3.3 Hz, 1H), 7.89-7.86 (m, 2H), 2.09-2.01 (m, 4H), 1.01 (dt, J = 16.6, 7.7 Hz, 6H); ESI MS (m / z): 395.65 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.41 (s, 1H), 9.30 (s, 1H), 8.71 (d, J = 2.4 Hz, 1H), 8.55 (dt, J = 10.1, 2.4 Hz, 2H), 8.24 (d, J = 9.0 Hz, 1H), 217 8.16 (dd, J = 9.2, 1.6 Hz, 1H), 8.07 (td, J = 7.8, 3.1 Hz, 1H), 7.89-7.84 (m, 2H), 2.53 (q, J = 3.6 Hz, 2H), 1.14 (q, J = 7.3 Hz, 6H), 1.02 (dd, J = 15.4, 7.1 Hz, 6H); ESI MS (m / z): 423.8 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.43 (s, 1H), 9.26 (s, 1H), 8.72 (d, J = 2.4 Hz, 1H), 8.53 (dt, J = 9.9, 2.3 Hz, 1H), 8.34 (d, J = 13.4 Hz, 1H), 218 8.00 (t, J = 3.7 Hz, 1H), 7.85 (d, J = 9.0 Hz, 1H), 7.70-7.68 (m, 1H), 7.60 (td, J = 9.3, 1.2 Hz, 1H), 7.29-7.27 (m, 1H), 2.46-2.40 (m, 2H), 1.05 (dt, J = 18.3, 7.5 Hz, 3H); ESI MS (m / z): 372.15 [M+1]. PI External 1H-NMR (400 MHz, DMSO-d6) δ 9.41 (d, J = 0.7 Hz, 1H), 9.26 (s, 1H), 8.72 (d, J = 2.4 Hz, 1H), 8.52 (dt, J = 9.9, 2.4 Hz, 1H), 8.31-8.28 (m, 1H), 8.14 (dq, J = 6.9, 1.3 Hz, 1H), 7.83 (dt, J = 9.0, 1.0 Hz, 1H), 219 7.75-7.73 (m, 1H), 7.58 (td, J = 9.1, 1.3 Hz, 1H), 7.42-7.39 (m, 1H), 2.41-2.31 (m, 2H), 1.02 (dt, J = 17.6, 7.6 Hz, 3H); ESI MS (m / z): 372.4 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.36 (d, J = 0.7 Hz, 1H), 9.31 (s, 1H), 9.15 (t, J = 2.2 Hz, 1H), 8.84 (dd, J = 5.1, 1.7 Hz, 1H), 8.71 (d, J = 2.2 Hz, 1H), 8.57 (dt, J = 9.9, 2.3 Hz, 1H), 8.40 (dt, J = 10.7, 2.1 Hz, 220 1H), 8.24 (s, 1H), 7.90 (d, J = 9.0 Hz, 1H), 7.80 (dd, J = 9.0, 1.7 Hz, 1H), 2.12-2.02 (m, 4H), 0.99 (dt, J = 17.0, 7.6 Hz, 6H); ESI MS (m / z): 395.2 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.58 (s, 2H), 9.38 (d, J = 1.0 Hz, 1H), 9.28 (s, 1H), 9.16 (t, J = 2.1 Hz, 1H), 8.81 (q, J = 2.0 Hz, 1H), 221 8.35-8.32 (m, 1H), 8.25 (s, 1H), 7.92 (d, J = 9.0 Hz, 1H), 7.78 (dd, J = 9.0, 1.7 Hz, 1H), 2.56-2.52 (m, 2H), 1.12 (q, J = 7.3 Hz, 6H), 0.97 (dd, J = 16.1, 7.1 Hz, 6H); ESI MS (m / z): 406.45 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.35 (d, J = 1.0 Hz, 1H), 9.33 (d, J = 2.2 Hz, 1H), 8.68 (dd, J = 4.8, 1.3 Hz, 1H), 8.49 (dq, J = 8.5, 1.3 Hz, 222 1H), 8.25 (d, J = 12.5 Hz, 1H), 7.85-7.82 (m, 1H), 7.68-7.65 (m, 1H), 7.58-7.53 (m, 1H), 2.00-1.89 (m, 4H), 1.32-1.21 (m, 2H), 1.05-0.89 (m, 6H); ESI MS (m / z): 314.25 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.36 (d, J = 1.0 Hz, 1H), 9.31 (s, 1H), 9.14 (t, J = 2.2 Hz, 1H), 8.90 (dd, J = 5.9, 1.7 Hz, 1H), 8.71 (d, J 223 = 2.4 Hz, 1H), 8.57 (dt, J = 9.9, 2.3 Hz, 1H), 8.45 (dt, J = 11.7, 2.1 Hz, 1H), 8.24 (s, 1H), 7.90 (d, J = 9.0 Hz, 1H), 7.81 (dd, J = 9.0, 1.7 Hz, 1H), 1.79 (d, J = 13.7 Hz, 6H); ESI MS (m / z): 367.15 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.57 (s, 2H), 9.43 (d, J = 1.0 Hz, 1H), 9.28 (s, 1H), 8.59 (d, J = 1.0 Hz, 1H), 8.25-8.23 (m, 1H), 8.17 (dd, J = 9.3, 1.7 Hz, 1H), 8.07 (td, J = 7.8, 3.2 Hz, 1H), 7.89 (d, J = 9.3 224 Hz, 1H), 7.85 (ddd, J = 7.3, 4.6, 1.0 Hz, 1H), 2.56-2.52 (m, 2H), 1.14 (q, J = 7.3 Hz, 6H), 1.02 (dd, J = 15.4, 7.1 Hz, 6H); ESI MS (m / z): 406.5 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.57 (s, 2H), 9.34 (d, J = 1.0 Hz, 1H), 9.28 (s, 1H), 7.91 (d, J = 1.5 Hz, 1H), 7.89-7.81 (m, 3H), 7.47 225 (dd, J = 8.9, 1.6 Hz, 1H), 2.54 (s, 3H), 2.44-2.39 (m, 2H), 1.13 (q, J = 7.3 Hz, 6H), 1.01 (dd, J = 15.4, 7.1 Hz, 6H); ESI MS (m / z): 420.35 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.70 (d, J = 1.0 Hz, 1H), 9.39 (d, J = 2.2 Hz, 1H), 8.72 (dd, J = 4.6, 1.5 Hz, 1H), 8.56-8.52 (m, 2H), 8.42 226 (dd, J = 9.0, 1.0 Hz, 1H), 8.17-8.14 (m, 2H), 7.70 (ddd, J = 8.4, 4.8, 0.7 Hz, 1H), 2.67 (d, J = 7.6 Hz, 3H), 1.71 (dd, J = 13.6, 6.2 Hz, 6H); ESI MS (m / z): 364.25 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.37 (d, J = 1.0 Hz, 1H), 9.34 (d, J 227 = 2.2 Hz, 1H), 8.68 (dd, J = 4.6, 1.5 Hz, 1H), 8.50 (dq, J = 8.4, 1.3 Hz, 1H), 8.27 (dt, J = 13.0, 1.1 Hz, 1H), 7.85 (dt, J = 8.8, 1.0 Hz, 1H), 7.68- PI External 7.63 (m, 2H), 1.71 (d, J = 13.0 Hz, 3H), 1.29-1.19 (m, 1H), 0.88-0.59 (m, 4H); ESI MS (m / z): 298.15 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.73 (d, J = 1.0 Hz, 1H), 9.39 (d, J = 2.4 Hz, 1H), 8.72 (dd, J = 4.6, 1.5 Hz, 1H), 8.56-8.51 (m, 2H), 8.42 228 (dd, J = 9.2, 0.9 Hz, 1H), 8.15 (t, J = 4.6 Hz, 2H), 7.72-7.68 (m, 1H), 2.65 (s, 3H), 2.45-2.39 (m, 2H), 1.12 (q, J = 7.3 Hz, 6H), 0.99 (dd, J = 15.4, 7.1 Hz, 6H); ESI MS (m / z): 420.3 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.68 (d, J = 4.4 Hz, 1H), 9.50 (d, J = 2.4 Hz, 1H), 9.39 (d, J = 2.7 Hz, 1H), 9.00 (d, J = 5.4 Hz, 1H), 8.86- 229 8.83 (m, 1H), 8.71 (d, J = 4.4 Hz, 1H), 8.55 (d, J = 5.6 Hz, 1H), 8.42 (t, J = 4.6 Hz, 1H), 8.19-8.16 (m, 1H), 7.69 (dd, J = 8.3, 4.6 Hz, 1H), 1.80 (dd, J = 13.6, 5.0 Hz, 6H); ESI MS (m / z): 349.9 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.69 (d, J = 0.7 Hz, 1H), 9.51 (t, J = 2.1 Hz, 1H), 9.39 (d, J = 2.2 Hz, 1H), 8.94 (dd, J = 5.0, 1.8 Hz, 1H), 8.83 (dt, J = 10.8, 2.1 Hz, 1H), 8.71 (dd, J = 4.6, 1.2 Hz, 1H), 8.55 (dq, 230 J = 8.3, 1.4 Hz, 1H), 8.42 (dd, J = 9.2, 0.9 Hz, 1H), 8.17 (d, J = 9.0 Hz, 1H), 7.71-7.68 (m, 1H), 2.13-2.02 (m, 4H), 0.99 (dt, J = 17.1, 7.7 Hz, 6H); ESI MS (m / z): 377.9 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.71 (d, J = 4.4 Hz, 1H), 9.39 (d, J = 2.4 Hz, 1H), 8.72 (d, J = 4.6 Hz, 1H), 8.54 (s, 2H), 8.42 (d, J = 9.0 231 Hz, 1H), 8.16 (d, J = 3.9 Hz, 2H), 7.70 (dd, J = 8.3, 4.6 Hz, 1H), 2.66 (d, J = 4.4 Hz, 3H), 2.01-1.95 (m, 4H), 1.02-0.94 (m, 6H); ESI MS (m / z): 392 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.40 (d, J = 0.7 Hz, 1H), 9.25 (s, 1H), 8.73 (d, J = 2.4 Hz, 1H), 8.53 (dt, J = 9.8, 2.3 Hz, 1H), 8.22 (d, J = 14.4 Hz, 1H), 7.87 (dd, J = 9.0, 2.7 Hz, 1H), 7.71-7.66 (m, 1H), 7.30- 232 7.28 (m, 2H), 7.09 (d, J = 7.8 Hz, 2H), 2.23 (s, 3H), 1.73-1.65 (m, 1H), 0.94-0.90 (m, 1H), 0.84-0.74 (m, 2H), 0.67 (dd, J = 15.8, 6.0 Hz, 1H); ESI MS (m / z): 423.95 [M+1]. 1H-NMR (400 MHz, CHLOROFORM-D) δ 9.22 (s, 1H), 8.71 (s, 1H), 8.54 (s, 1H), 8.33-8.25 (m, 2H), 7.85 (d, J = 9.0 Hz, 1H), 7.68 (t, J = 233 9.5 Hz, 1H), 7.57-7.53 (m, 2H), 7.21-7.16 (m, 2H), 7.07-7.03 (m, 1H), 2.43 (s, 3H), 1.41-1.31 (m, 1H), 1.06-0.82 (m, 4H); ESI MS (m / z): 406 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.36 (d, J = 1.0 Hz, 1H), 9.34 (d, J = 2.2 Hz, 1H), 8.68 (dd, J = 4.6, 1.5 Hz, 1H), 8.50 (dq, J = 8.3, 1.4 Hz, 234 1H), 8.30-8.26 (m, 1H), 7.86 (dt, J = 8.9, 1.0 Hz, 1H), 7.71-7.65 (m, 2H), 1.34-1.26 (m, 2H), 0.90-0.71 (m, 6H), 0.66-0.59 (m, 2H); ESI MS (m / z): 323.95 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.71 (d, J = 0.7 Hz, 1H), 9.51 (t, J = 2.1 Hz, 1H), 9.39 (d, J = 2.2 Hz, 1H), 8.91 (q, J = 2.0 Hz, 1H), 8.80 (dt, J = 9.8, 2.1 Hz, 1H), 8.71 (dd, J = 4.8, 1.3 Hz, 1H), 8.55 (dq, J = 235 8.3, 1.4 Hz, 1H), 8.42 (dd, J = 9.2, 0.9 Hz, 1H), 8.17 (d, J = 9.3 Hz, 1H), 7.69 (ddd, J = 8.4, 4.7, 0.7 Hz, 1H), 2.56-2.51 (m, 2H), 1.12 (dd, J = 15.0, 7.0 Hz, 6H), 0.97 (dd, J = 16.0, 7.2 Hz, 6H); ESI MS (m / z): 406.05 [M+1]. PI External 1H-NMR (400 MHz, DMSO-d6) δ 9.58 (s, 2H), 9.38 (d, J = 1.0 Hz, 1H), 9.28 (s, 1H), 9.00 (d, J = 2.2 Hz, 1H), 8.30 (s, 1H), 8.09 (s, 1H), 236 7.90 (d, J = 9.3 Hz, 1H), 7.83 (dd, J = 9.3, 1.7 Hz, 1H), 2.74 (s, 3H), 2.52 (d, J = 7.1 Hz, 1H), 2.45 (s, 1H), 1.14 (q, J = 7.3 Hz, 6H), 0.98 (dd, J = 15.4, 7.1 Hz, 6H); ESI MS (m / z): 420.1 [M+1]. 1H-NMR (400 MHz, DMSO-d6) δ 9.39 (d, J = 0.7 Hz, 1H), 9.25 (s, 1H), 8.73 (d, J = 2.4 Hz, 1H), 8.52 (dt, ...

Claims

PI External CLAIMS:

1. A compound of formula (I),Formula (I) 5 wherein, A1 represents C or N; Q is selected from 8- or 9- membered fused heterobicyclic ring system selected from Q-a to Q-t10andthe expression “*” indicates the point of attachment to substituted pyridine or pyrimidine ring; Z is selected from a direct bond, O, N, a substituted or unsubstituted 5-6 membered heterocyclic ring or a substituted or unsubstituted 6-10 membered aryl ring; wherein said heterocyclic ring and aryl ring can be substituted by one to three substituents independently selected fromPI External halogen, cyano, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-haloalkyl, C3-C8-cycloalkyl, C1-C6-alkoxy, -NH(C1-C6-alkyl), -N(C1-C6-alkyl)2, or -S(O)0-2C1-C6-alkyl; G represents O or S; R1and R2are independently selected from the group consisting of hydrogen, halogen, cyano, 5 C1-C4-alkyl, and C1-C4-haloalkyl; R3is selected from the group consisting of hydrogen, halogen, cyano, C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6-cycloalkyl, C1-C6-alkoxy, and C1-C6haloalkyl; R4is selected from the group consisting of C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6haloalkyl, C1-C6-alkoxy, C2-C6 haloalkenyl, C3-C8 cycloalkyl, C3-C8 cycloalkyl-C1-C6 alkyl, 10 C2-C6 heterocyclyl, phenyl, phenoxy, phenylthio, and -NRcRd; Rcis selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, and C3-C8 cycloalkyl; Rdis selected from the group consisting of hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C2-C6 haloalkenyl, C3-C8 cycloalkyl, C3-C6-cycloalkyl-C1-C4- 15 alkyl; or Rcand Rdsubstituents together with the atom to which they are attached or together with further atoms selected from the group consisting of C, N, O, C(=O), C(=S), and S(O)0-2 may form a 3- to 6-membered ring, which may optionally be substituted by one or more substituents selected from the group consisting of halogen, CN, and C1-C6 20 alkyl; R5is selected from the group consisting of C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6-alkoxy, C3-C8 cycloalkyl, C3-C8 cycloalkyl-C1-C6 alkyl, C2-C6 alkenyl, C2-C6 haloalkenyl, phenyl, phenoxy, phenylthio, benzyl, and C2-C6 heterocyclyl; or R4and R5substituents together with the atom to which they are attached or together with 25 further atoms selected from the group consisting of C, N, O, C(=O), C(=S), and S(O)0-2 may form a 3- to 6-membered ring, which may optionally be substituted by one or more substituents selected from the group consisting of halogen, CN, and C1-C6 alkyl; wherein each aliphatic group of R1, R2, R4and, R5may be optionally substituted with one or more groups of Ra; and cyclic groups of R1, R2, R4, and R5may optionally be substituted with 30 one or more groups of Rb, wherein, Rais selected from the group consisting of halogen, cyano, C1-C6alkyl, C1-C6haloalkyl, C3-C8cycloalkyl, C1-C6alkoxy, C3-C8cycloalkyloxy, C1-C6alkylthio, phenyl, and C2-C6heterocyclyl; Rbis selected from the group consisting of halogen, cyano, C1-C6alkyl, C2-C6alkenyl,35 C2-C6alkynyl, C1-C6haloalkyl, C2-C6haloalkenyl, C3-C8cycloalkyl, C1-C6alkylthio, C1- C6haloalkylthio, C1-C6alkoxy, and C1-C6haloalkoxy; or salts, stereo-isomers, tautomers, polymorphs, metal complexes or N-oxides thereof.PI External 2. The compound of formula (I) or its salts, stereo-isomers, tautomers, polymorphs, metal complexes or N-oxides thereof according to claim 1, wherein Z is direct bond; or a substituted or unsubstituted 5-6 membered heterocyclic ring which is selected from pyridinyl, pyrimidinyl, pyrazynyl, pyrazolyl, thiazolyl or oxazolyl; or a substituted or unsubstituted phenyl ring 5 wherein said heterocyclic ring and phenyl ring can be substituted by one to two substituents independently selected from halogen, cyano, C1-C4-alkyl, C1-C4-haloalkyl, C3-C6-cycloalkyl, or C1-C4-alkoxy.

3. The compound of formula (I) or salts, stereo-isomers, tautomers, polymorphs, metal complexes or N-oxides thereof according to claim 1 wherein, 10 Q is selected from:.

4. The compound of formula (I) or salts, stereo-isomers, tautomers, polymorphs, metal complexes or N-oxides thereof according to claim 1 wherein, R1and R2are independently selected from the group consisting of hydrogen, halogen, cyano, 15 C1-C6 alkyl, C1-C6 haloalkyl; R3is selected from the group consisting of hydrogen, halogen, cyano, C1-C6 alkyl, C1-C6-alkoxy and C1-C6 haloalkyl; R4is selected from the group consisting of C1-C6 alkyl, C1-C6 haloalkyl, C1-C6-alkoxy, C3-C8 cycloalkyl, C2-C6 heterocyclyl and C3-C8 cycloalkyl-C1-C6 alkyl; 20 R5is selected from the group consisting of C1-C6alkyl, C1-C6haloalkyl, C1-C6-alkoxy, C3-C8cycloalkyl, C3-C8cycloalkyl-C1-C6alkyl, C2-C6alkenyl, C2-C6haloalkenyl, phenyl, phenoxy, phenylthio, benzyl, and C2-C6 heterocyclyl; R4and R5substituents together with the atom to which they are attached or together with further atoms selected from the group consisting of C, N, O, C(=O), C(=S), and S(O)0-225 may form a 3- to 6-membered ring, which may optionally be substituted by one or more substituents selected from the group consisting of halogen, CN, and C1-C6alkyl; Q is selected from:PI ExternalZ is a direct bond or a substituted or unsubstituted 5-6 membered aromatic heterocyclic ring selected from pyridinyl, pyrimidinyl, pyrazynyl, pyrazolyl, thiazolyl or oxazolyl wherein said heterocyclic ring can be substituted by one to two substituents independently selected from 5 halogen, cyano, C1-C4-alkyl, C1-C4-haloalkyl, C3-C6-cycloalkyl, or C1-C4-alkoxy.

5. A method for the preparation of compound of formula (I) or salts, stereo-isomers, tautomers, polymorphs, metal complexes or N-oxides thereof according to claim 1 wherein said method comprises the step of: reacting a compound of formula (A-2) with compound of formula (D-1) in the presence of 10 suitable reagents to obtain compound of formula (I), according to the scheme below:; wherein, LG represents halogen, tosylate, triflate or mesylate; A1, Q, Z, G, R3, R4and R5are same as defined in claim 1.

6. A composition comprising the compound of formula (I), or salts, stereo-isomers, tautomers, 15 polymorphs, metal complexes or N-oxides thereof according to claim 1 and at least one additional component selected from the group consisting of surfactants and auxiliaries.

7. The composition according to claim 6, wherein the said composition additionally comprises at least one biological active compatible compound selected from fungicides, insecticides, nematicides, acaricides, biopesticides, herbicides, plant growth regulators, biostimulants, 20 antibiotics, fertilizers or nutrients.

8. The composition according to claim 6, wherein the said compound of formula (I) is present in an amount ranging from 0.1 % to 99 % by weight with respect to the total weight of the composition.

9. A combination comprising a biologically effective amount of the compound of formula (I) 25 according to claim 1 and at least one additional biological active compatible compound selectedPI External from fungicides, insecticides, nematicides, acaricides, biopesticides, herbicides, plant growth regulators, biostimulants, antibiotics, fertilizers and nutrients.

10. A method for combating insects and mite pests comprising contacting the insects and mite pests, their habitat, breeding ground, food supply, plant, seed, soil, area, material or 5 environment in which the insect and mite pests are growing or may grow, or the materials, plants, seeds, soils, surfaces or spaces to be protected from a pest attack or an infestation with a biologically effective amount of a compound of formula (I), or salts, stereo-isomers, tautomers, polymorphs, metal complexes, N-oxides thereof according to claim 1, composition thereof according to claim 6 or combination thereof according to claim 9. 10 11. A method for protecting crops from an attack or infestation by insects and mite pests comprises contacting the crop with the compound of formula (I), or salts, stereo-isomers, tautomers, polymorphs, metal complexes, N-oxides thereof according to claim 1, composition thereof according to claim 6 or combination thereof according to claim 9.

12. The method according to claim 10 or 11, wherein the said method comprises applying effective 15 dosages of the compound of formula (I) in amounts ranging from 1 gai to 5000 gai per hectare in agricultural or horticultural crops.

13. A method for the protection of seeds, plants and plant parts from soil insects and of the seedlings roots and shoots from soil and foliar insects comprising contacting the seeds before sowing and / or after pre-germination with the compound of formula (I), or salts, stereo-isomers, 20 tautomers, polymorphs, metal complexes, N-oxides thereof according to claim 1, composition thereof according to claim 6 or combination thereof according to claim 9.

14. Use of a compound of formula (I) or salts, stereo-isomers, tautomers, polymorphs, metal complexes, N-oxides thereof according to claim 1, composition thereof according to claim 6 or combination thereof according to claim 9, for combating insects and mite pests in agricultural 25 crops, horticultural crops, household and vector control and parasites on animals.

15. The use of a compound of formula (I) according to claim 14, wherein the said agricultural crops are cereals, corn, sorghum, bajra, rice, soybean, oil seeds and other leguminous plants, fruits and fruit trees, grapes, nuts and nut trees, citrus and citrus trees, any horticultural plants, cucurbitaceae, oleaginous plants, tobacco, coffee, tea, cacao, sugar beet, sugar cane, cotton, 30 potato, tomato, onions, peppers, other vegetables and ornamentals.

16. A seed comprising a compound of formula (I) or salts, stereo-isomers, tautomers, polymorphs, metal complexes, N-oxides thereof according to claim 1, composition thereof according to claim 6 or combination thereof according to claim 9, wherein the amount of the compound of formula (I) in the said seed is ranging from 0.0001 % to 1 % by weight. 35

Images